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Stroke is an important disease in the Western Society both in medical and socio-economic 
terms with an estimated incidence of 30.000 patients per year in the Netherlands [1]. One 
third of these stroke patients dies within the first year, while 41% experiences long-term 
disabilities [2]. In approximately 70 to 80% of the stroke survivors, upper-extremity motor 
function is impaired and in almost one third of these patients motor impairments are severe 
[2, 3]. Among those with severe impairments, two-thirds do not regain the functional use of 
the affected arm or hand [3-5], resulting in difficulty with arm or hand positioning in space, 
grasp, self-care, and other activities of daily living. Nevertheless, nearly 25% of these 
patients will regain partial motor recovery, and 5-20% even complete motor recovery of the 
upper limb [2, 4]. 
Although stroke is the leading cause of long-term disability in Western society, it is a 
condition for which there is no universally accepted, evidence based, rehabilitation approach. 
The general objective of rehabilitation is to enable individual patients to regain the highest 
possible degree of physical and psychological performance [6]. In this perspective, treatment 
goals should depend on the expected level of disability, as well as on the potential for motor 
recovery of stroke patients. In stroke patients with a potential for motor recovery it is 
important to focus on the restoration of motor function, preferably as early as possible [7, 8]. 
In these patients, repeated failures to use the paretic arm and hand in the acute and sub-
acute phases after stroke can lead to negative reinforcement, the so-called ‘learned non-use’ 
[7], complicating the rehabilitation process later on. Moreover, in patients with the potential 
for motor recovery, there is evidence for the efficacy of specific targeted treatments, such as 
constrained induced movement therapy [9, 10]. On the other hand, focusing on the 
restoration of motor function in stroke patients without a potential for motor recovery will lead 
to frustration and disappointment among both patients and therapists. It also delays the shift 
of therapy focus towards learning compensation strategies. As a result, the functional 
outcome after rehabilitation may be suboptimal. To optimize stroke rehabilitation through 
appropriate goal setting and implementation of resources, clinicians are challenged at an 
early stage post-stroke to reliably and accurately predict the degree of disability the patient 
will ultimately experience [4, 11]. Such prediction requires fundamental knowledge of the 
essential determinants of functional recovery.  
Several clinical and socio-demographic variables have been identified as determinants of 
functional recovery from stroke, including age, previous stroke, sitting balance, urinary 
incontinence, severity of paresis, initial disability, and the presence of social support [12]. 
Although functional recovery from stroke depends on behavioral modification as well, 
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allowing patients to accomplish the same objective by different strategies, motor function can 
be considered as a vital determinant of functional ability [13]. Accurate, early prediction of 
motor recovery seems particularly relevant in severe stroke patients, because the 
appropriate rehabilitation strategy depends on the probability of motor recovery and the 
chance of developing complications secondary to paralysis. For instance, patients with 
residual arm and hand function at the time of stroke onset are very likely to show some motor 
recovery, which warrants a treatment strategy promoting such recovery [10]. 
In patients with severe, middle cerebral artery strokes, the initial grade of paresis and the 
early patterns of motor recovery are the most important clinical determinants of functional 
recovery of the upper extremity [4, 14]. In patients with an initial flaccid hemiplegic arm who 
achieved at least 19 points on the upper-extremity subscore of the Fugl-Meyer motor 
assessment (FMA) at the end of the fourth week post onset, Kwakkel et al. [4] found a 
probability of 94% for regaining dexterity at 6 months after stroke. In the more acute phase, 
1-week post onset, however, the predictive value of clinical assessment was substantially 
lower; a probability of only 74% for regaining dexterity at 6 months after stroke was found in 
those patients who reached some voluntary movement over the hip, knee, or foot (FMA 
lower-extremity subscore >10 points).  
The rather low predictive value of clinical assessment in the acute phase might be due to the 
difficulty of clinical assessment of motor functions in the first weeks after stroke, particularly 
in patients suffering from concurrent cognitive deficits such as aphasia, apraxia, or 
sensorimotor neglect. These patients may lack the ability to move the arm and its segments 
selectively, whereas clinical scores such as the FMA rely on the patients’ ability to voluntarily 
and selectively move their extremities. Therefore, early motor assessment may be biased by 
severe cognitive deficits. Particularly in these patients, neurophysiological assessment might 
be of additional value to clinical assessment.  
Spasticity 
Spasticity is a characteristic feature of the upper motor neuron syndrome in the post-acute 
and chronic phases of stroke. Spasticity develops in 20-40% of all stroke survivors, usually 
within 3 month after stroke [15-19]. It is defined as a velocity-dependent increase in muscle 
resistance against passive lengthening due to a supra-spinal disinhibition of both tonic and 
phasic stretch reflexes [20]. However, the spastic movement disorder is also characterised 
by efferent symptoms such as loss of selective muscle control and force, delayed and 
disrupted muscle synergies (e.g., co-contractions), or remote involuntary (associated) muscle 
activity during active movements, as well as massive flexion or extension reactions to touch, 
pain, and passive muscle stretch. In the upper extremity, spasticity may cause great difficulty 
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with arm positioning, grasping, self-care and other activities of daily living, in particular when 
spastic antagonists counteract selective voluntary muscle activity [19, 21-23]. In the long-
term, untreated spasticity may lead to secondary complications such as changes in the 
visco-elastic properties of the musculo-tendinous apparatus, the development of 
contractures, and pain, which may further impede the functional use of the affected limb [16, 
24].  
Until now, anti-spastic treatments are usually instituted after spasticity has developed. Early 
and more pro-active treatment of spasticity with focal techniques (e.g., muscle injections with 
Botulinum toxin type A) applied in patients with a good potential for motor recovery, may 
result in a better functional outcome than currently achieved through the late application in 
unselected stroke survivors. The functional results of such treatments may inherently be 
improved by preventing secondary complications, learned disuse, and possibly adjusting 
reorganisation processes in the brain [9, 25]. However, not only stroke patients with a good 
potential for motor recovery may benefit from a pro-active treatment approach to prevent 
disabling spasticity. Even for patients with severe stroke it may be advantageous. In this 
subgroup, dexterity scores are anticipated to change only marginally and benefits can only 
be achieved with regard to “passive” skills in activities such as dressing, bathing and 
grooming, as well as with regard to limb positioning, cosmetics, and comfort [26-29]. 
This claim of possible therapeutic relevance requires further intervention studies. 
Furthermore, the clinical relevance of early identification of patients at risk of developing 
spasticity should be acknowledged considering the impact of spasticity on upper-extremity 
function and, subsequent also on quality of life after stroke [30]. Accurate, early prediction of 
spasticity is therefore considered relevant for developing a more proactive and efficient 
treatment approach than that is currently adopted in neurorehabilitation.  
Transcranial Magnetic Stimulation 
Transcranial Magnetic Stimulation (TMS) of the human motor cortex is a non-invasive 
neurophysiological technique, which provides objective and quantitative information on the 
integrity and responsiveness of the corticomotoneuron and corticospinal tract [31, 32]. TMS 
activates the cortical motor neurons and their dendritic connections presynaptically by 
activation of interneurons (precortico-motoneuronal cells) projecting onto the cortical motor 
neuron pool. The cortical motor neuron discharges and, subsequently, corticospinal volleys 
are mediated via fast-conducting corticospinal connections. These connections within the 
corticospinal tract have direct, monosynaptic, terminations on the spinal alpha motor neurons 
that innervate the muscles of the hand and control independent and selective (fine 
manipulatory) finger movements. As a consequence, TMS is particularly effective in the 
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activation of distal hand muscles [33-35] in which a short-latency motor evoked potential 
(MEP), as an excitatory effect, can be recorded by surface electromyography (EMG) [32]. In 
tonically pre-activated muscles, TMS of the primary motor cortex induces a transitory 
suppression of the EMG-activity after the short-latency MEP, the silent period (SP), as an 





The predictive value of the presence of a MEP with regard to motor recovery in patients with 
severe, middle cerebral artery stroke and an initial upper-extremity paralysis has been 
established previously [36, 37]. These studies consistently showed high specificity of the 
presence of a MEP (nearly 100%) in those patients who will show motor recovery. In 
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contrast, sensitivity was lower and more variable (62-94%), indicating that not all patients 
who will show motor recovery can be identified by the presence of an early MEP. In this 
perspective, the SP has been proposed as an additional parameter (to MEP) for predicting 
hand motor recovery. It has been suggested that the degree of shortening of the SP during 
the sub-acute phase after stroke correlates with the amount of hand function recovery [38-
40]. There is also a possibility that the SP may be of value in predicting the development of 
post-stroke spasticity [40-42]. However, only few, well designed, TMS-studies on the 
prognostic of the SP with regard to both post-stroke motor recovery and spasticity have been 
performed with rather inconsistent results [38-41].  
In the case of severe post-stroke cognitive deficits, the additional value of neurophysiological 
assessment (including TMS) to clinical assessment is anticipated to be substantial with 
regard to early prediction of both motor recovery and spasticity. However, the routine clinical 
application of TMS to predict motor recovery or the development of spasticity in individual 
stroke patients is still controversial [43]. There is some concern about the practical, clinical 
consequences of TMS in terms of improved prognostication in stroke patients [43]. At 
present, there is no consensus on the preferred methodology, because the precise technique 
and TMS characteristics used have not been standardized. Moreover, “evidence” is often 
based on cross-sectional studies that do not account for the non-linear nature of stroke 
recovery, which makes it difficult to validly generalize this information to longitudinal recovery 
processes. Because the results of relatively few well-designed prognostic studies are 
available to be integrated in stroke rehabilitation programs, a gap still remains between 
prognostic research and rehabilitation practices. In this perspective, there is a need for valid 
data on the predictive value of both MEP and SP for both motor and functional recovery from 
stroke (including the development of spasticity) to better substantiate the place that 
neurophysiological assessment deserves in making a functional prognosis in individual 
patients. 
 
Objective of this thesis 
This PhD-thesis should be viewed against the gradually increasing acceptance that 
neurorehabilitation is in need for studies that can bridge the gap between “fundamental” and 
“clinical” research, particularly in the fields of basic and clinically applied neurophysiology. 
The pathophysiological processes underlying motor recovery after stroke and the 
development of spasticity are not well understood. It seems essential to enhance our 
knowledge of (cortical) reorganization processes to ultimately improve the effects of various 
treatment approaches on motor recovery in stroke patients. In this study, both clinical 
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examinations and neurophysiological techniques will be used to investigate the importance of 
the integrity of the corticospinal pathways for upper-extremity functioning. 
This thesis focuses primarily on long-term hand motor recovery of the hemiplegic upper 
extremity in a homogeneous group of stroke survivors with a severe, supratentorial, ischemic 
stroke. The aim of this thesis is to investigate the predictive value of TMS characteristics for 
functional prognostication of the upper extremity in patients with a severe, middle cerebral 
artery stroke. More specifically, the additional value of MEP and SP will be compared to 
clinical examination with regard to both recovery of hand motor function and the development 
of spasticity in these severe stroke patients. 
 
Outline of this thesis 
This thesis is organized in 4 sections. Besides this introductory chapter, the first part 
(“Introduction”), provides an important rationale for studying post-stroke motor recovery and 
the development of spasticity. Chapter 2 contains a systematic review of the literature 
focusing on the treatment of upper-extremity spasticity in stroke patients by focal neuronal or 
neuromuscular blockade. 
The second part (“Prognostic studies”) focuses on the prediction of long-term hand motor 
recovery (Chapters 3 and 4) and the development of spasticity (Chapters 5 and 6) in the 
upper extremity in severe stroke patients. It contains a review addressing the question 
whether the SP can be of additional value (compared to MEP) with regard to post-stroke 
hand motor recovery (Chapter 3), as well as three cohort studies performed in a 
homogeneous group of stroke survivors with a supratentorial, middle cerebral artery stroke. 
The first cohort study (Chapter 4) focuses on the added value of the presence of a MEP to 
early clinical assessment with regard to predicting long-term hand motor function. In the 
second cohort study (Chapter 5), the incidence and time course of spasticity is reported, as 
well as the predictive value of clinical assessment with regard to the development of post-
stroke spasticity. In the last cohort study (Chapter 6), the prognostic value of 
neuroradiological and neurophysiological parameters with regard to the development of 
upper-extremity spasticity is addressed.  
The third part (“Neurophysiological studies”) starts with an investigation of secondary 
changes in the peripheral nervous system as a consequence of stroke (Chapter 7), followed 
by some important methodological considerations concerning TMS. Chapter 8 focuses on 
the question whether TMS characteristics differ between proximal and distal upper-extremity 
muscles in healthy subjects.  
Chapter 1 
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The last part (“Conclusion”) is the general discussion (Chapter 9), which elaborates on the 
reported findings of the above-mentioned studies in a more comprehensive manner. It also 
addresses the most important limitations of the studies included. Last but not least, 







































































































Treatment of upper-extremity spasticity in stroke patients 
by focal neuronal or neuromuscular blockade:  
a systematic review of the literature 
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Objective: The primary aim of this study was to reveal the clinical effects of focal neuronal 
and neuromuscular blockade in post-stroke upper-limb spasticity. 
Methods: Systematic review of studies published from January 1966 until October 2000 on 
the clinical effects of focal neuronal and neuromuscular blockade in post-stroke upper-limb 
spasticity. Twelve studies were included and evaluated on 13 methodological criteria.  
Results: Ten studies on Botulinum toxin type A (BTX-A) treatment were found (of which 4 
RCTs and 6 uncontrolled observational studies), as well as one uncontrolled observational 
study on phenol blockade of the subscapular muscle and one on alcohol blockade of the 
musculocutaneous nerve. The homogeneity of the patient groups with regard to diagnosis 
and their comparability with regard to functional prognosis and other sources of bias were 
generally unsatisfactory. Only two RCTs met the predetermined criteria of minimal validity.  
Conclusions: There is evidence of effectiveness of BTX-A treatment on reducing muscle tone 
and improving passive range of motion at all arm-hand levels in chronic stroke patients for 
approximately 3 to 4 months. Effectiveness of BTX-A treatment on improving functional 
abilities could not be convincingly demonstrated, although two subgroups were identified that 
might specifically benefit at a functional level: 1) patients with mild spasticity and a potential 
for voluntary extensor activity, and 2) patients with severe spasticity suffering from problems 
with positioning and taking care of the affected arm and hand.  
 
Introduction 
Spasticity is a characteristic component of the upper motor neuron syndrome that 
complicates the rehabilitation process of many stroke patients. It is usually defined as a 
velocity-dependent increase in muscle resistance against passive lengthening due to a 
supraspinal disinhibition of both tonic and phasic stretch reflexes [1]. However, spasticity is 
also characterised by delayed and disrupted muscle synergies (e.g., co-contractions) or 
remote involuntary (associated) muscle activity during active movements, as well as by 
massive flexion or extension reactions to touch or pain stimuli [2, 3]. Spasticity can interfere 
with the functional use of the affected body parts, in particular when spastic antagonists 
counteract selective voluntary muscle activity. In the long term, untreated spasticity may lead 
to secondary complications such as muscle stiffness, contractures, and pain. In the upper 
extremity of stroke patients, spasticity most frequently emerges in a predominant flexion 
pattern. It may cause great difficulty with arm or hand positioning in space, grasping, self-
care, and many other activities of daily living (ADL) [4, 5]. 
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The management of spasticity remains a major challenge in rehabilitation medicine. The 
available treatment options include various physical methods (e.g., muscle lengthening, 
splinting, electrostimulation), systemic use of spasmolytic drugs, soft-tissue surgery (e.g., 
muscle-tendon lengthening or transposition, tenotomy, neurectomy), as well as several 
invasive procedures for focal neuronal or neuromuscular blockade [4-13]. The ideal 
treatment strategy would be to achieve a long-lasting relief of disabling hypertonia in selected 
groups of muscle fibres without causing impairment of sensation, deterioration of motor skills, 
or other local or systemic side-effects [14]. Because spasticity is a variable phenomenon in 
time and apparent only in certain muscle groups, the application of low-threshold and 
“reversible” focal treatment techniques seems to be the preferable first option. Besides 
peripheral and intramuscular neurolysis (e.g., with phenol), intramuscular administration of 
Botulinum toxin type A (BTX-A) is increasingly applied in stroke patients. 
Phenol has two different actions on nerve tissue. The first, immediate and reversible effect is 
a local anaesthetic nerve conduction blockade [15, 16]. The second, long-term effect is 
demyelination and axonal degeneration by denaturation of proteins [17-21]. Through the 
same mechanism, phenol causes atrophy within muscle tissue [22, 23]. Although phenol 
blocks act non-selectively across nerve fibres, the extent of the blocks may depend on the 
injection technique (e.g., perineural or intraneural) and the phenol concentration used. The 
reported duration of neurolytic blocks with phenol varies between 6 weeks and 6 months, 
depending on the technique, as well as on the time required for remyelisation and axonal 
regeneration. Dysaesthesia and neuralgia are among the most frequently reported side-
effects of neurolytic blocks [21, 24-40]. 
Recently, neuromuscular blockade with BTX-A has been introduced as an alternative to focal 
neurolysis in the management of spasticity [41-43]. BTX-A weakens the activation of spastic 
muscles by selectively blocking the release of acetylcholine at the neuromuscular junction of 
both extrafusal and intrafusal muscle fibres. Its effect seems to be to some extent dose-
dependent and usually lasts 2 to 4 months [44-49]. An important advantage of motor-point 
blockade over neurolysis is the absence of sensory disturbances. 
At present, there is no consensus about the preferred strategy, precise method of 
administration, and optimal dosage in the focal treatment of upper-limb spasticity following 
stroke. Valid comparisons of studies concerning the efficacy of different methods for focal 
neuronal or neuromuscular blockade in stroke are complicated because of differences in 
selected patients, treatment goals, and functional evaluations. The goal of this study was to 
provide preliminary clinical guidelines and suggestions for future research through 





Material for the review was selected from a systematic search in the databases of Medline 
(January 1966-October 2000), Current Contents (January 1996-October 2000), Cinahl 
(January 1982- October 2000), and the Cochrane Library. This search was conducted using 
the following combinations of search terms: spasticity, chemical neurolysis, intramuscular 
neurolysis, chemical denervation, neuromuscular blockade, nerve block, motor point block, 
phenol, alcohol / ethanol, Botulinum toxin, thermo-coagulation, cryotherapy, and neurotomy / 
neurectomy. Identifying relevant references from the retrieved articles extended the search. 
Only studies concerning the treatment of upper-extremity spasticity by focal neuronal or 
neuromuscular blockade in adult stroke patients and published in the English, German, 
French, or Dutch languages were considered. After the primary search, the papers were 
subjected to a preliminary screening based on the following exclusion criteria: (1) studies not 
primarily addressing aspects of clinical efficacy, (2) reviews, (3) comments or letters to the 
editor, (4) preliminary reports or abstracts, (5) heterogeneous patient samples in which the 
stroke patients could not be identified, (6) sample sizes smaller than 10 patients, (7) papers 
not available in medical libraries in the Netherlands. Ultimately, the remaining studies were 
selected for detailed methodological evaluation. 
Methodological evaluation 
Both internal validity (V) and data extraction (D) were assessed. We established adapted V 
and D criteria based on a system that was originally developed for evaluating randomised 
controlled trials (RCTs) [50]. Adaptation of these criteria was necessary to be able to 
evaluate other study designs than RCTs. Each criterion was scored according to three levels: 
sufficient (+) (all subcriteria fulfilled), moderate (+/-) (all but one subcriterion fulfilled), or 
insufficient (-) (other). When a specific criterion was not applicable, it was scored as such (0). 
Criteria V5, D3, D5, and D6 had no subcriteria. Hence, these were scored only with sufficient 
(+) or insufficient (-). All selected studies were independently assessed by 3 referees (AK, 
AG, BB). In the case of disagreement between referees, consensus was established in 
second instance. 
Internal validity 
V1: The homogeneity of the study sample with regard to stroke and spasticity was tested. (1) 
A diagnosis of stroke by clinical standards was accepted, preferably confirmed by CT or MRI 
scanning. (2) Spasticity, being a velocity-dependent increase in muscle resistance on 
passive stretching, should clearly be distinguished from other types of hypertonia, muscle 
stiffness, and contracture. 
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V2: Control of bias related to functional prognosis before exposure to the therapeutic 
intervention was judged for the controlled trials. Based on the literature, three such potential 
confounders were identified: (1) the severity of stroke judged by its sensorimotor and 
cognitive consequences, (2) the chances of neurological recovery based on the time after 
stroke [51, 52], and (3) co-morbidity with a possible effect on the outcome of the therapeutic 
event (e.g., concomitant rheumatic or neuromuscular disease). As for the observational 
studies, the homogeneity of the (sub)group(s) with respect to these factors was judged. 
Furthermore, a minimal time interval after stroke of 6 months was considered appropriate to 
assume a relatively stable clinical situation [51, 52]. 
V3: This criterion tested whether there had been sufficient control for potential confounding 
during the study. More specifically, (1) paramedical co-interventions (e.g., physiotherapy) 
and (2) concurrent use of medication (e.g., spasmolytic drugs) should have been reported 
and taken into account. As for the observational studies, all co-interventions should have 
been kept stable during the follow-up period. 
V4: Adequacy of technical aspects of the therapeutic intervention was assessed. Studies 
should have indicated: (1) concentration and volume of substance applied, (2) whether a 
fixed or individualised treatment algorithm was used, and (3) how target muscles were 
localised. Only injections guided by internal electrical stimulation or electromyography were 
considered appropriate [53-55]. 
V5: The selected study design was evaluated in relation to the study aim. Randomised 
controlled trials were accepted as was any other design with the ability to control for 
confounding, for instance, a cohort study making within-subjects comparisons of 
experimental and control interventions allowing sufficient wash-out periods. 
V6: The (1) reliability, validity, and responsiveness of the selected outcome measures were 
assessed in relation to the study aim [56]. Also, (2) blinding of the outcome assessor was 
considered an absolute prerequisite for unbiased observations. 
Data extraction 
D1: This criterion tested (1) whether the inclusion and exclusion criteria were sufficiently 
reported, as well as (2) whether the base population was identified from which the study 
sample was selected. 
D2: It was judged whether treatment effects were adequately reported in terms of (1) 
statistical (e.g., F- and p-values or confidence intervals) and (2) quantitative measures (e.g., 
absolute or relative differences). 
D3: The length of the total follow-up period was assessed. 
D4: This criterion tested the numbers of patients lost to follow up. 
D5: It was determined whether intention-to-treat analysis was done in the case of any loss to 
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follow up, non-compliance, or unplanned crossovers. 
D6: Description of adverse effects was assessed. 
D7: The total number of included stroke patients at baseline was determined. 
Criteria of minimal validity 
Based on the scores for all criteria mentioned above, those studies were identified that were 
able to meet the following minimal criteria of validity: (1) no negative scores on the internal 
validity items, and (2) at least half of the items scored positive (+). These studies were 
primarily used for establishing clinical evidence. All other studies were considered to yield 
merely secondary evidence. 
 
Results 
The primary search yielded 116 papers, including preliminary reports and abstracts. After the 
preliminary assessment, 12 studies were included for detailed methodological evaluation [57-
68]. Ten studies focused on the treatment of upper-limb spasticity with BTX-A [57-66], one 
focused on alcohol neurolysis [67], and one study dealt with phenol neuromuscular blockade 
[68]. No studies were found concerning the treatment of upper-limb spasticity with 
neuromuscular blockade using thermocoagulation or cryotherapy. Studies addressing 
neurectomy consisted of combined treatment procedures including soft-tissue surgery. For 
this reason these studies were excluded from further evaluation. The BTX-A treatment 
studies included 4 RCTs and 6 uncontrolled observational studies. Both the study on alcohol 
neurolysis and the one dealing with phenol nerve blockade were observational studies. The 
results of the assessment of both V- and D-criteria for all 12 studies are given in Table 1. 
Here, the RCTs will first be critically reviewed in more detail, whereas some of the 
methodological issues related to the observational studies will only be globally highlighted. 
Randomised controlled trials 
Three trials [57-59] studied the efficacy (and safety) of different dosages of BTX-A in the 
reduction of upper-limb spasticity in stroke patients using a randomised, triple-blind (patient, 
physician, and outcome-assessor), placebo-controlled design. Both Simpson et al. [57] and 
Bakheit et al. [58] presented multi-centred studies. Only Smith et al. [59] included two 
patients with head injury. Although Smith et al. [59] claimed to have excluded patients with 
fixed contractures, the reported results on joints range of motion (ROM) suggested the 
existence of contractures in their study sample. No study explicitly differentiated between 
spasticity and other types of increased muscle tone. The control for the influence of 
sensorimotor and cognitive functioning on outcome was considered insufficient in all three  

























































































































































































































































































































































































































































































































































































































































































































































































































studies. In the study of Bakheit et al. [58], the control for the influence of spontaneous 
recovery was also considered moderate, because patients were allowed to enter the study 
already 3 months after their stroke, whereas the other RCTs used minimal post-stroke 
intervals of 9 [57] and 12 months [59]. As for co-morbidity, only Simpson et al. [57] explicitly 
excluded other neuromuscular diseases. Ongoing spasticity treatments (e.g., medication, 
physiotherapy) were maintained during the trial by Simpson et al. [57], but could differ 
between patients. Bakheit et al. [58] did not allow de novo treatment with spasmolytic drugs, 
whereas Smith et al. [59] did not control for any type of concurrent intervention. Bakheit et al. 
[58] determined the injection sites only by using anatomical landmarks. Smith et al. [59] used 
a partially individualised treatment algorithm, which was insufficiently specified. Moreover, no 
specifications of the localisation technique or of injected volumes were given. 
In none of the three RCTs mentioned above, the base populations from which the study 
samples had been selected were clearly identified. Both Simpson et al. [57] and Smith et al. 
[59] primarily analysed within-group changes from baseline for different aspects of spasticity, 
where the preferable analysis should have consisted of between-group comparisons of 
changes from baseline. No statistical corrections were made for multiple testing of similar 
hypotheses. Although Bakheit et al. [58] mentioned a follow-up period of 16 weeks, the main 
analysis was performed using changes from baseline at 4 weeks after the intervention. 
Simpson et al. [57] lost 2 patients to follow up without specifying the precise reasons for drop 
out, or the group to which these patients had been allocated. Although Smith et al. [59] had 
no dropouts, 4 patients (of which 3 stroke patients) crossed over who had been originally 
allocated to placebo treatment.  
These patients were re-randomised to one specific dosage of BTX-A. As a result, there was 
a source of selection bias for which the analysis was not adjusted. Considering the small 
sample sizes in the four parallel groups, there should be a major concern about lack of 
statistical power in the studies by Simpson et al. [57] and Smith et al. [59]. 
Hesse et al. [60] conducted a randomised, triple-blind, placebo-controlled trial on the efficacy 
of combining BTX-A with electrical stimulation (ES) in the reduction of upper-limb spasticity in 
stroke patients compared to single treatments using a four-arm parallel design (BTX-A + ES, 
BTX-A, placebo + ES, placebo). All patients received additional treatment consisting of 
physiotherapy and home exercises. There was no explicit differentiation between spasticity 
and other types of increased muscle tone. The possible influence of sensorimotor and 
cognitive functioning, and the influence of co-morbidity on outcome were not controlled for. 
As for the data analysis, the primary outcome measures at 2, 6, and 12 weeks were 
averaged and the mean post-injection value was used to determine the treatment effect on 
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different aspects of spasticity. As a result, no adjustments were made for the (small) 
differences in outcome measures at baseline. Moreover, by averaging effects over time, 
relatively small and temporary effects may have been obscured by false negative statistical 
tests (type II error) especially in view of the small group sizes (n=6) and the correction of 
alpha (chance of type I error) to 1%. 
Observational studies 
No study explicitly differentiated spasticity from other types of increased muscle tone. In 
(almost) all observational studies the study samples were heterogeneous with regard to 
patient characteristics related to diagnosis, severity of stroke, chance of neurological 
recovery, and co-morbidity. Only few studies controlled for ongoing spasticity treatments [61, 
64-67]. Small sample sizes were common and in some studies [63, 64, 66] loss to follow up 
was unacceptable (> 33%). Therefore, no detailed methodological evaluation of the 
observational studies will be given. Instead, the reader is referred to Table 1. 
 
Discussion 
Although focal neuronal and neuromuscular blocks are increasingly used in clinical practice 
for the treatment of post-stroke upper-limb spasticity, the number and quality of the traced 
publications investigating the efficacy of these treatments is as yet limited. Four randomised 
controlled trials were identified [57-60], whereas other studies reported uncontrolled 
observations [61-68]. Of all selected studies, only two met the predetermined criteria of 
minimal validity [57, 60]. These studies will be primarily used for discussing clinical 
effectiveness. Nevertheless, the outcomes of several other studies will still be considered 
because they may yield secondary (supportive) evidence of effectiveness and safety, and 
provide important perspectives for further research. The treatment goals and outcome 
measures of each selected study are given in Table 2. The applied treatment protocols and 
main clinical outcomes are summarised in Table 3. 
Alcohol or phenol 
Kong et al. [67] reported a case series on the effectiveness of neurolysis of the 
musculocutaneous nerve with alcohol on post-stroke elbow flexion spasticity. Although 
patients with fixed elbow flexion contractures were included, significant improvements in tone 
and PROM were found with effects lasting up to 6 months. Hecht [68] reported a case series 
of patients with therapy resistant shoulder pain due to spasticity. Patients were given a 
motorpoint block of the subscapularis muscle with phenol and the immediate post-injection 
effects were determined. Although immediate improvements in PROM were seen, the 
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authors did not use an adequate measure for determining shoulder pain (patient observation 
during passive shoulder examination). In both studies the most common reported side effect 
was a transient soreness over the injection side. In the study on alcohol neurolysis [67], three 
patients (15%) suffered from temporary dysesthetic pain, which could be reasonably treated 
with amitriptyline or non-steroidal anti-inflammatory drugs. The only conclusion one can draw 
based upon these uncontrolled studies is that phenol or alcohol may be used as a potential 
agent for reducing spasticity and improving PROM in the upper extremity of stroke patients 
by neuronal or neuromuscular blockade, but that controlled comparative studies (e.g., with 
BTX-A) are urgently needed. Particular attention should be paid to comparing side effects 
and cost-effectiveness. This conclusion seems to be supported by the literature on the 
treatment of post-stroke spasticity with phenol or alcohol in general [24-40, 70-73]. 
Botulinum toxin 
The efficacy of BTX-A treatment on tone and PROM was demonstrated by the RCT 
performed by Simpson et al. [57] and supported by other studies [58, 59, 61-66]. In addition, 
Hesse et al. [60] found evidence of a synergistic effect of ES combined with BTX-A 
treatment. In particular, the combined treatment of BTX-A and ES seemed superior with 
regard to the facilitation of hand hygiene and spasticity reduction. This synergism might be 
explained by a stimulating effect of ES on the uptake of BTX-A in the terminal nerve 
branches. Therefore, the degree of motor activity may be an important factor for the potency 
of BTX-A. Although Hesse et al. [60] did not find a statistically significant reduction in 
spasticity in the BTX-A only group compared to the placebo group, an average reduction of 
0.5 Ashworth score at 6 weeks was still seen, which may not have been reached statistical 
significance due to the small group size (n=6) (see results). 
Dosage and duration of effects. Although a clear dose-response relationship could not be 
demonstrated, a tendency for a dose-related improvement of the Ashworth score and PROM 
was seen in the studies of Simpson et al. [57], Smith et al. [59], and Bakheit et al. [58]. Their 
results suggest a critical dosage of BTX-A to achieve a clinically significant tone reduction. 
The reported doses were globally 200 MU Botox® (600 to 1000 MU Dysport®) for the biceps, 
100 MU Botox® (400 to 500 MU Dysport®) in total for the wrist flexors, and 100 MU Botox® 
(300 MU Dysport®) in total for the finger flexors. These dosages seem to correspond with the 
suggested maximal dose of the dosing guidelines for adult onset spasticity by the Spasticity 
Study Group [69]. 
The duration of the reported effects varied between 10 weeks and 4 months [57-66]. The first 
effects of treatment became apparent not earlier than 2 to 3 days after injection [63], and the 
peak effects were reported between 2 to 6 weeks after injection [62, 65]. The efficacy of 
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repeated BTX-A injections was specifically studied by Lagalla et al. [61]. All patients 
exhibited a tone reduction (mean reduction in MAS 1 point) and PROM increase (mean 
increase at the elbow: 5 degrees, at the wrist: 19 degrees) after the first injection, which 
effects remained constant across repeated injections. Although the dose injected over time 
did not change, the intervals between injections became significantly longer, which may 
possibly be related to a decreasing capacity for terminal neuronal sprouting. 
It is not possible to further specify the optimal dose of BTX-A for the treatment of post-stroke 
upper-limb spasticity from the studies included in this review, because the magnitude and 
duration of the spasmolytic effects are theoretically influenced by the presence of other forms 
of hypertonia or muscle stiffness, as well as by loss of muscle length (and thus by 
concomitant therapy directed at these muscle characteristics), for which influences no study 
adequately controlled. In addition, the products and dosages of BTX-A differed considerably 
between studies (Table 3). 
Safety. In all selected studies, only minor side effects were seen, such as transient skin rash 
[58], soreness, and pain at the injection sides [57, 61, 62, 66]. Incidentally, flu-like symptoms 
were reported [58, 59, 65] and in one study bladder instability was observed in one patient 
after BTX-A treatment [57]. The most serious reported side effect seems to be an excessive 
muscle weakness due to an overdose of BTX-A. This seems of particular functional 
importance for the finger flexors. Bakheit et al. [58] found a critical dosage for preserving 
active movement of the finger flexors at 300 MU Dysport®. This finding was supported by 
Rodriquez et al. [64], who reported a critical dosage of 100 MU Botox® for preserving active 
finger flexion. Hence BTX-A treatment seems to be a safe treatment for upper-extremity 
spasticity as long as these critical dosages are appreciated. 
Functional abilities. Despite the reported improvements in tone and PROM of BTX-A 
treatment a clear impact on functional abilities could not be convincingly demonstrated. Also, 
the overall reported effect on global disability scores was minimal. Nevertheless, patients in 
the study of Smith et al. [59] reported that the arm felt looser and appeared more relaxed 
particularly during walking after BTX-A injection into the biceps brachii and brachialis 
muscles. Subjectively, beneficial findings in gait quality and balance were reported by some 
ambulatory patients. Sampaio et al. [65] reported improvement in functional ability of the 
affected arm as assessed by the Frenchay Arm Test (FAT benefit of 1 point) in patients who 
were able to perform only minimal voluntary movements of the upper limb before treatment. 
Lagalla et al. [61] reported a FAT benefit of 2 points in a similar subgroup of 8 patients 
(29%). Although Reiter et al. [62] did not find a beneficial effect on the median FAT in the 
total treatment group, subgroup analysis gave a more discriminative picture. One subgroup 
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(4/17) with relatively mild spasticity and voluntary motor activity of the extensor muscles 
showed an increase (5%) in median FAT score after BTX-A treatment. No changes in a 
global disability measure (FIM) were seen, which can be explained by a ceiling effect and 
lack of responsiveness of this measure to functional improvement of a single arm. A second 
subgroup (4/17) consisted of paralytic patients with relatively severe spasticity, in which BTX-
A treatment resulted in PROM increase, better passive positioning of and care for the 
affected limb (e.g., easier fitting of splints). 
 
Conclusion 
This review emphasizes the importance of adequate patient and goal selection when treating 
upper-extremity spasticity in chronic stroke patients. Since most authors used a standardised 
treatment protocol, the muscles selected for treatment may not have been the most optimal 
targets adapted to the needs of individual patients. A more individualised approach based on 
the distribution of spasticity, as well as on a patient’s personal needs might give a better 
indication of the potential functional benefits of BTX-A in treating upper-extremity spasticity 
following stroke. Indeed, the results of Hesse et al. [60] suggest that individualised goal 
attainment scales may be essential to identify relevant functional changes. To identify 
relevant functional changes, it is of utmost importance that adequate measures to quantify 
functional outcome in all stages of recovery will be developed. Moreover, larger controlled 
studies are needed to compare the effectiveness of different and / or combined treatment 
approaches to reduce focal spasticity in stroke patients. In particular, adequate clinical trials 
are needed to compare the efficacy of BTX-A neuromuscular blockade versus phenol nerve 
blockade in upper-limb spasticity. The application of neurolytic techniques (chemical or 
thermal) to some of the (predominantly) motor branches of the upper arm seems to be a 
promising area of further research. Special attention should be paid to comparisons of the 
(duration of) functional benefits, essential co-treatment and aftercare, the (duration and 
severity of) side-effects, as well as cost-effectiveness. Another important issue for further 
research is the identification of prognostic factors in patients at risk of developing disabling 
upper-limb spasticity and the early institution of anti-spastic treatments before secondary 
complications have been developed. Two subgroups may be identified that might specifically 
benefit at a functional level: (1) patients with mild spasticity and a potential for voluntary 
extensor activity at the wrist or fingers, and (2) patients with severe spasticity suffering from 
problems with positioning and taking-care of the affected arm and hand. 
 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































How salient is the Silent Period?  
The role of the silent period in the prognosis of upper-
extremity motor recovery after severe stroke 
 
Annette A van Kuijk, Jaco W Pasman, Alexander CH Geurts, and Henk T Hendricks 
 
 




Objective: The primary aim of this study was to reveal the additional value of the silent period 
(SP) to the motor evoked potential (MEP) with regard to the prediction of motor recovery in 
acute stroke patients with an initially severe paresis or paralysis of the upper extremity. 
Methods: Narrative review of the literature and a case series focusing on the additional value 
of the SP to the MEP for predicting post-stroke hand motor recovery. Results: Studies that 
have analyzed the SP for predicting post-stroke motor recovery have rather inconsistent 
results and suffer from heterogeneity in technical methods, methodology, and patient 
characteristics. In most studies prolonged SPs have been found immediately after stroke, 
whereas in the (sub)acute phases thereafter, different patterns of SP duration have been 
found. Post-stroke reduced SPs and contraction-induced inhibitory phenomena have been 
associated with spasticity. However, in the majority of the patients with a severe, middle 
cerebral artery stroke the voluntary contraction of the hand muscles was so severely 
impaired that no SP could be recorded.  
Conclusions: In acute stroke patients with an initial severe paresis or paralysis, the SP 
seems to have no additional value to MEP for predicting post-stroke hand motor recovery. 
Although the relation between the SP, recovery-related intracortical phenomena, and 
spasticity remains as yet unclear, the SP has been proposed as a prognostic factor for post-
stroke spasticity.  
 
Introduction 
Motor impairments of the upper extremity are among the most common and therapeutically 
challenging sequellae of stroke. In stroke patients with initially severe motor impairments, the 
prognosis with respect to motor recovery and subsequent functional recovery is usually poor 
[1-4]. Most patients will end up with a non-functional arm [5-10], although some patients may 
show partial or even complete motor recovery [1-4]. Early prediction of motor recovery based 
on clinical and radiographic findings in severe stroke patients is, however, very difficult, 
particularly when patients suffer from aphasia, apraxia, or sensorimotor neglect. In these 
patients neurophysiologic assessment may be of additional value in providing objective, 
reliable, and quantitative data on the integrity of the corticospinal pathways [11-12]. 
Transcranial magnetic stimulation (TMS) of the motor cortex is a non-invasive 
neurophysiological technique in which motor potentials are evoked by magnetical stimulation 
of the motor cortex. TMS activates the cortical motor neurons and their dendritic connections 
presynaptically [11, 13-15] by activation of interneurons (precortico-motoneuronal cells) 
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projecting onto the cortical motor neuron pool. The cortical motor neuron discharges and, 
subsequently, corticospinal volleys are mediated via fast-conducting corticospinal 
connections [11, 13, 15, 16]. These connections within the corticospinal tract have direct, 
monosynaptic, terminations on spinal alpha motor neurons that innervate, for example, the 
intrinsic muscles of the hand and control independent and selective (fine manipulatory) finger 
movements. As a consequence, TMS is particularly effective in the activation of distal hand 
muscles [17-21]. 
In stroke patients with initially severe paresis or paralysis of the upper extremity, the 
observed specificity of motor evoked potentials (MEPs) was consistently high (nearly 100%), 
indicating that all MEP-positive patients will show some degree of motor recovery [22, 23]. In 
contrast, the sensitivity of MEP in severe stroke patients is lower (62-94%) [22, 23]. In this 
perspective, the silent period (SP) has been proposed as an additional factor to the MEP for 
predicting motor recovery [24-26]. 
This article is primarily a literature review focusing on whether the SP can be of additional 
prognostic value to MEP with regard to post-stroke hand motor recovery. It also integrates a 
case series on the prognostic value of the SP in a homogeneous sample of acute stroke 
patients with initial paralysis of the upper extremity.  
 
Silent period 
In tonically (pre)activated muscles, TMS of the primary motor cortex induces a short-latency 
MEP in the electromyogram as an excitatory effect followed by a transitory suppression of 
electromyographic (EMG) activity, the SP, as an inhibitory effect [11, 17, 19, 20, 27-37]. At 
subthreshold stimulus intensities (SI) and in single motor unit registrations, however, the SP 
can occur even without a preceding MEP [17, 18 36, 38-40]. In healthy volunteers, the MEP 
and the SP share a number of features. In both MEP and SP, optimal responses can be 
obtained when the primary motor cortex is stimulated, and the responses are more 
pronounced in distal hand muscles than in proximal arm muscles [17, 19, 20, 41]. 
Furthermore, the threshold for eliciting both MEP and SP in the biceps brachii and abductor 
digiti minimi muscles at the dominant side in healthy volunteers is lower than the threshold at 
the non-dominant side [42-44]. This physiological hemispheric threshold asymmetry is 
different for subjects of different ages. In elderly subjects (aged 61 to 82 years), the threshold 
asymmetries are less pronounced than in younger subjects, probably because of less 
functional dominance [42]. Although the stimulation thresholds at one body side in one 
particular individual are almost identical for both MEP and SP [31, 36, 45], with increasing SI 
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the amplitude of the MEP reaches a plateau [17, 20, 29, 31], whereas a near linear increase 
in the SP duration can be observed [17, 19, 20, 27, 28, 30, 31, 35, 37, 39, 46-49]. At 
constant SI, no correlation was found between the amplitude of the MEP and the SP duration 
among different individuals [37, 48, 49]. 
TMS performed during voluntary muscle contraction evokes MEPs with shorter latency and 
higher amplitude than when the muscle is at rest [25, 26, 29, 50]. It has been assumed that 
this facilitation phenomenon is due to recruitment of a larger number of active corticospinal 
neurons [51, 52]. In contrast to the MEP, there is no correlation between the SP duration and 
the level of tonic muscle preactivation in healthy volunteers [17, 19, 20, 25, 26, 30, 33, 34, 
37, 40, 47- 49, 53-56]. The inhibitory mechanisms involved in the initiation and maintenance 
of the SP are normally uninfluenced by the recruitment of a larger number of active 
corticospinal neurons [25, 26]. Based on these different characteristics of the MEP and the 
SP, the SP is regarded as a phenomenon that is physiologically distinct from the MEP [17, 
19, 35, 36, 45, 48, 49, 53].  
Although the exact mechanisms for the TMS-induced SP are poorly understood, both spinal 
and supraspinal factors appear to be involved. During the early part of the SP, up to 
approximately 50 ms, a marked decrease in spinal alpha motor neuron excitability has been 
found with concomitant inhibition of the H-reflex [17, 19, 20, 27, 28, 30, 40, 48, 55, 57, 58]. 
Inhibition of the H-reflex during this early part, however, was submaximal [20, 39], which 
suggests that both spinal inhibitory phenomena and supraspinal inhibitory pathways 
descending from the motor cortex may interact. During the late part of the SP (>50 ms), the 
spinal alpha motor neuron excitability returns to normal, so that supraspinal inhibition is 
thought to be responsible for the continuing suppression of EMG-activity [28, 31, 39, 49, 59]. 
This supraspinal inhibition has been attributed to intracortical inhibitory interneurons [17, 19, 
20, 28, 35, 37, 57].  
In healthy volunteers, studies concerning the quantification of the SP revealed a high inter-
individual variability of its duration. The SP duration reaches its minimal variability and 
maximal length after cortical stimulation with maximal stimulator output (1.5 to 2.4 Tesla) and 
when facilitated by a slight tonic contraction of the test muscle (20 to 30% of maximum 
voluntary contraction) [17]. Even with such maximal stimulator output, the SP duration in a 
hand muscle of healthy volunteers may range between 100 and 300 ms [17, 19, 20, 24-26, 
28, 40, 49, 54, 60-65]. Despite this high inter-individual variability (100 to 300 ms), a low 
intra-individual variability with a high inter-side symmetry (mean inter-side differences <10 
ms, range 0 to 26 ms) of the SP duration has been reported [20, 24]. 
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Silent period in stroke patients 
In stroke patients, the SP has been proposed as a prognostic factor for motor and functional 
recovery besides the MEP. These studies that have analyzed the SP have provided rather 
inconsistent results (Table 1). Comparison of the results from these studies is difficult owing 
to variability in their technical methods, methodology, and patient characteristics. The lack of 
uniformity with regard to the definition of the SP and the subsequent use of different onsets 
and offsets for the SP (Table 2) may easily have influenced the observed SP duration [34]. If 
manual methods are used to assess the SP duration, inter-rater inconsistencies will further 
add to its variability [66]. Indeed, using a visually guided manual method, both Nilsson et al. 
[67] and Garvey et al. [68] found an inter-observer variability of the SP duration of as much 
as 20 to 22 ms. Also, different SI have been used to elicit the SP in stroke patients, which 
may partially account for the variability in the SP duration found in stroke patients.  
Clinical heterogeneity may be another factor contributing to the inconsistencies in the 
literature. In previous TMS studies, stroke patients have been included with lesions located in 
different arterial territories, with different degrees of motor deficits, and at different times after 
stroke (Table 2). Von Giessen et al. [69] found a relation between stroke localization and the 
SP duration. In their study, shortened or even absent SPs were found despite the presence 
of a clear MEP response in stroke patients with infarctions located in the primary motor 
cortex. In addition, Schnitzler and Benecke [65] reported two patients with acute focal 
ischemic lesions of the primary motor cortex, who despite the presence of clear MEP 
responses, showed complete loss of the SP. These results suggest that in focal lesions of 
the primary motor cortex selective damage of cortical inhibitory interneurons and subsequent 
shortening or even complete loss of the SP may occur. In contrast, in acute strokes with 
lesions outside but anatomically projecting to the primary motor cortex, only prolonged or 
normal SPs have been found [62, 63, 69-71]. Afferents from the primary sensory cortex and 
from the premotor and supplementary motor areas bilaterally project to the primary motor 
cortex through cortico-cortical or transcallosal connections (Figure 1). Apart from these 
cortical connections, the thalamus projects to the primary motor cortex through thalamo-
cortical connections [72]. These cortical and sub-cortical projections can modulate both 
inhibitory and excitatory interneurons within the primary motor cortex [62]. Lesions within 
these projections might, therefore, result in a partial deafferentiation of the primary motor 
cortex and a subsequent change in the balance between excitatory and inhibitory influences 
on the intracortical motor neurons. The prolonged SPs may result from a decreased 
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The duration of the period after stroke may also be a relevant factor in determining the SP 
duration. In the post-acute phase after stroke, a decrease in the SP duration has been found 
in parallel with clinical improvement [62], whereas normalization and shortening of the SP 
have been reported in the chronic phases [49, 56, 62, 70, 73]. Cruz-Martinez et al. [73] 
performed TMS in 10 chronic stroke patients (6 months to 4 years after stroke) and in 10 
healthy volunteers. In the four patients without spastic hands, the mean absolute SP did not 
differ from the SP found in their unaffected hands. Shortened SPs were observed mainly in 
patients with spastic hands (n=6), and the amount of shortening was associated with the 
degree of spasticity as assessed by the Ashworth scale. The authors hypothesized that in 
the course of the development of spasticity, cortical inhibition decreases and the SP 
subsequently shortens. However, the authors did not provide any information about the 
methods of their TMS, nor about infarct localization. Moreover, they gave no specifications of 
the motor, cognitive, and functional problems in their stroke sample. 
 
Lastly, the degree of motor deficit may also be of influence on the reported SP after stroke, 
because the level of voluntary contraction used to elicit a SP may easily be affected by the 
degree of paresis. Although in healthy volunteers the inhibitory mechanisms involved in the 
SP are not clearly influenced by the recruitment of a larger amount of active corticospinal 
neurons, in the acute stage of stroke, a contraction-induced reduction in the SP duration has 
been observed. Catano et al. [25] performed TMS in 49 acute stroke patients (less than 5 to 
10 days after stroke) with a focal ischemic lesion in the territory of the middle cerebral artery 
and partial motor deficit of the first dorsal inter-osseous muscle. Whether the cortical lesions 
involved the primary motor cortex was not delineated. To elicit a SP, patients were instructed 
to sustain a steady voluntary isometric contraction (VIC) of 10% and 100% of maximal 
strength, respectively. At 10% VIC, the mean absolute SP was prolonged in all stroke 
patients compared with the SP in healthy volunteers. At 100% VIC, two different patterns in 
SP duration were observed; in 34 patients the SP was stable and not influenced by the 
increased muscle contraction (pattern 1), whereas in 15 patients the SP decreased with 
increasing muscle contraction (pattern 2). The differences in mean absolute SPs between 
stroke patients with pattern 1 responses and those with pattern 2 responses at 100% VIC 
were significant. Ninety days after stroke, the same pattern of responses was still found. 
Moreover, pattern 2 responses were associated with poorer functional outcomes and 
increased Ashworth scores at day 90, whereas pattern 1 responses were associated with 
relatively good functional outcomes. The authors extended their study with 24 acute stroke 
patients (4 to 9 days after stroke) with a middle cerebral artery infarction and partial motor 




Again, whether the cortical lesions involved the primary motor cortex was not delineated. 
Two more levels of muscle contraction force were added, i.e., the weakest contraction 
necessary to induce recordable EMG-activity (VICmin) and 50 % VIC. At VICmin, the mean 
absolute SP did not differ between stroke patients and healthy volunteers, whereas at the 
other levels of background contraction the same response patterns were found as in the first 
study. In five acute stroke patients and all patients with long-standing spasticity, the mean 
absolute SP duration decreased with increasing muscle contraction, whereas in the other 15 
acute stroke patients and in healthy volunteers the SP remained stable and uninfluenced by 
the increased muscle contraction. Again, the differences in mean absolute SP duration 
between stroke patients with pattern 2 responses and both patients and healthy volunteers 
with pattern 1 responses were significant. The authors stated that in acute stroke patients 
with initially moderate to mild paresis, the relative inefficacy of the inhibitory mechanisms as 
indicated by a contraction-induced reduction in SP could be a negative prognostic factor for 
motor and functional recovery. 
 
Case series 
In a period of 1.5 years, we studied 40 acute stroke patients with initial paralysis of the upper 
extremity (stage I according to Brunnstrom within 7 days after stroke), admitted to the 
department of neurology at the Radboud University Nijmegen, Medical Centre. The diagnosis 
of stroke was made clinically on admission and confirmed by computed tomography (CT) 
scanning. In each patient a CT scan was performed twice; first on admission and second at 1 
week after stroke. Patients with poor prognosis for survival (loss of consciousness, severe 
CT abnormalities, and severe co-morbidity), and patients with preexisting impairments of the 
upper extremity of any type were excluded. Patients with a history of craniotomy, epilepsy, 
cardiac prosthetic valve, pacemaker implantation, or severe polyneuropathies were excluded 
as well. The local ethical committee approved the study protocol and written informed 
consent was obtained from all patients before study entry.  
Each patient received a standard medical treatment according to the guidelines of the Dutch 
Society of Neurology, including a multidisciplinary team approach. From post-stroke day 1, 
each patient received physiotherapy treatment to maintain optimal range of (joint) motion and 
to regulate muscle tone of the upper extremity; however, no specific therapy was initiated to 
improve motor recovery. 
 
 
Silent period in post-stroke motor recovery 
 45
Neurophysiologic assessment 
In each patient TMS of the motor cortex was performed twice, first within 1 week (mean 6.8, 
median 7 days) after stroke (t1), and second after 3 weeks (mean 27.8, median 25) post 
stroke (t2) by the same researcher. Patients were positioned comfortably in a supine 
position. TMS was performed through a 90-mm circular coil placed in a tangential plane 
above the vertex and powered by a Magstim 200 magnetic stimulator. The SI was set at 
maximum stimulator output ( = 2.0 Tesla). To obtain a preferential activation of each 
hemisphere, a clockwise inducing current flow was used for the right hemisphere and a 
counter-clockwise current for the left hemisphere. MEPs and SPs were recorded at t1 and t2 
from the abductor digiti minimi (ADM) muscle on the affected and the unaffected side. The 
ADM was regarded as representative of distal motor functions of the upper extremity. EMG 
recordings were made using an Oxford Synergy electromyograph with filter settings of 20 Hz 
and 3 kHz (amplifier range 100 mV, recording sensitivity of 0.5 mV / bit). A 500-ms post-
stimulus period was analyzed. The MEPs were recorded when facilitated by a slight 
voluntary muscle contraction (20% of max VIC of the unaffected side). If the patient could not 
perform a contraction of the contralateral muscle (i.e., the muscle under investigation), he or 
she was told to activate the corresponding muscle on the healthy side [29]. The patients 
were asked to maintain the constant isometric contraction during the TMS performance. 
Because our patients lacked the ability to apply different degrees of voluntary contraction in 
the acute phase after stroke, the phenomenon of contraction-induced reduction in SP could 
not be assessed.  
At least two responses were obtained to assess the reproducibility of the responses. The 
presence of a MEP was defined as a reproducible response with minimal peak-to-peak 
amplitude of 200 microVolts. The SP length was measured from MEP onset until the return 
of uninterrupted voluntary EMG-activity. The ADM responses were studied separately for 
both the affected and the unaffected side. Responses with the highest MEP amplitude and 
the shortest SP were used for analysis. Data from the unaffected side were compared with 
normative data and used as controls.  
Outcome assessment 
The motor functions were assessed using the separate hand motor score within the upper-
limb subset of the Brunnstrom / Fugl-Meyer Motor Assessment (FMA) [74-76] on admission, 
at both the first (t1) and the second (t2) MEP registration, and at 26 weeks after stroke. The 
hand motor score concerns the seven original hand items of the FMA with a maximum score 
of 14 points. Clinical follow-up was performed by a physiatrist, who was not aware of the 




In this study, the electrophysiological data from the ADM MEP were used and correlated with 
hand motor deficits as assessed by the FMA. The differences of the MEP amplitudes and SP 
durations between the first and second MEP investigation were assessed and correlated with 
the FMA hand score. 
Results 
Only the SP results will be discussed; the MEP results have been presented elsewhere [77]. 
In only 5 out of 40 patients, a SP could be elicited at t2 (Table 3). This small number of 
patients is probably due to the patient selection. In stroke patients, the amount of voluntary 
contraction varies with the degree of paresis. The voluntary contraction of the hand muscles 
in the majority of our patients was so severely impaired that no SP could be recorded [60]. 
The occurrence of a SP in our patients was always accompanied by the presence of motor 
recovery sufficient to voluntarily move the hand (FMA hand score > 3). In concordance with 
former studies on the SP in acute stroke patients [24-26, 54, 60-64, 71], SPs were prolonged 
(4 patients), reduced (1 patient), or normal (1 patient), and if any difference was found, 
increased inter-side differences were also found (Table 3). The mean absolute SP duration 
at the affected side was 349.4 (range 237 to 487) ms versus 199.2 (range 126.5 to 243.5) ms 
at the unaffected side. The mean absolute inter-side difference in SP duration was 150.2 
(range 5 to 283) ms.  
All of our patients had massive ischemic strokes located in the territory of the middle cerebral 
artery with involvement of both cortical and subcortical areas. In four of the five patients with 
a SP on the affected side at t2 the primary motor cortex was involved in the infarct area. In 
the acute post-stroke phase (t1), two of these four patients showed decreased or absent SP, 
whereas all four patients showed prolonged SPs in the sub-acute phase (t2). In two patients, 
one patient with a SP at t2 and involvement of the primary motor cortex, and in one patient 
with a SP at t2 without involvement of the primary motor cortex, SP data at t1 were missing. 
Although these limited data seem to support the primary versus non-primary motor cortex 
dichotomy by Von Giessen et al. [69] and Schnitzler and Benecke [65], they should be 
interpreted very carefully. In contrast to these authors, most of our patients had severe 
strokes involving both the primary and non-primary motor cortices.  
All patients with a SP present at t2 showed full recovery of hand motor function at the 26-
week motor assessment. These patients, however, could also be identified by the presence 
of a MEP response at t2. The SP could not identify patients with only partial recovery of hand 
motor function at the 26-week motor assessment, whereas the presence of a MEP response 
at t2 could identify these patients. Three patients showed partial recovery of hand motor 
function during follow-up, without a SP in the affected ADM both at t1 and t2. In one patient, 
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the SP could not be determined at t2 despite a present MEP response (amplitude 1.5 
amplitude ratio1= 0.1). This patient did not show any motor recovery at t1 or t2, but had a 
near full hand motor recovery (FMA 12) at 6 months after stroke. In 2 additional patients the 
SP could not be elicited at t2 despite a MEP response (MEP amplitude = 0.2 with amplitude 
ratio1= 0.04 and MEP amplitude = 1.1 with amplitude ratio1 = 0.16, respectively). Both 
patients showed recovery of hand motor function at 6 months after stroke (FMA 4). They 
could flex and extend their fingers in gross synergies with only minimal dexterity. Therefore, 
the SP in our patients (i.e., patients with initial complete paralysis of the upper extremity) 
seems to have no additional prognostic value to MEP with regard to hand motor recovery. 
These results are in agreement with Nardone and Tezzon [64]. In their study on acute stroke 
patients with variable degrees of upper-extremity paresis, changes in the inhibitory motor 
cortical circuits proved to be of little prognostic value, whereas early reductions in intrinsic 
excitatory properties, i.e., increased motor threshold intensity to TMS at rest, were 
associated with poor motor recovery.  
 
Discussion 
In stroke patients, the SP has been proposed as a possible prognostic factor for motor 
recovery. However, only few TMS studies have been performed on the role of the SP in 
motor recovery after stroke with rather inconsistent results. Comparison of these results is 
difficult because of the variability in the methodology, technical methods, and patient 
characteristics. In most studies prolonged SPs have been found immediately after stroke. In 
the first hours immediately after stroke, there might be a generalized decrease in intracortical 
inhibition in order to optimize the intracortical excitatory processes, thus, supporting motor 
output (MEP). As a consequence, intra-cortical inhibition of the inhibitory interneurons that 
mediate the SP also decreases, resulting in prolonged SPs. In some lesions of the primary 
motor cortex, however, the inhibitory interneurons mediating the SP may become selectively 
damaged, leading to a decreased or even lost SP [65]. In the (sub)acute phases thereafter, 
different patterns of SP duration have been found, i.e., normal, prolonged, as well as 
shortened SPs. These different patterns are also thought to be related to stroke localization; 
however, contraction-induced reduction phenomena and recovery-related intracortical 
phenomena may also be responsible for the different SP durations found. 
                                                            
1 Amplitude ratio= MEP amplitudes relative to the maximal M-response recorded from the ADM 
muscle on the affected side 
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Although in acute stroke patients the SP might be of value to identify clinically silent or minor 
strokes [69], in acute stroke patients with initial paralysis or severe paresis the SP seems to 
have no additional prognostic value for post-stroke motor recovery when compared with 
TMS-induced excitatory phenomena (increased motor thresholds and decreased amplitudes) 
[22, 64, 70, 77]. Therefore, in the acute phase of severe stroke, merely the evaluation of 
motor cortex excitability provides prognostic information about both the likelihood and the 
extent of motor recovery [23, 64, 70, 77].  
Nevertheless, in acute stroke patients with initially moderate to mild paresis and in chronic 
stroke patients with long-standing (more than 3 months) spasticity, Catano et al. [25, 26] 
observed a contraction-induced reduction in SP. The authors stated that the relative 
inefficacy of the inhibitory mechanisms as indicated by a contraction-induced reduction in SP 
could be a negative prognostic factor in post-stroke motor recovery and a positive prognostic 
factor in the development of spasticity. Uozumi et al. [49] and Cruz-Martinez et al. [73] also 
found a possible association between the SP and the development of spasticity. The authors 
observed shortened SPs mainly in chronic stroke patients with spastic hands [49, 73], and 
the amount of shortening was associated with the degree of spasticity as assessed by the 
Ashworth scale [73]. Both authors hypothesized that in the course of the development of 
spasticity, cortical inhibition decreases and the SP subsequently shortens.  
Yet, from a neurophysiologic point of view, the proposed relationship between TMS-induced 
SP and spasticity is not evident. TMS primarily assesses the corticomotoneuron and 
corticospinal tract. These corticospinal pathways are generally believed not to be responsible 
for spasticity [78]. Selective damage to the corticomotoneuron or the corticospinal tract does 
not result in spasticity but in hypotonia and loss of fine, manipulatory hand movements. 
Spasticity is generally thought to result from concomitant damage to para-pyramidal motor 
pathways, such as the reticulospinal tract [78]. Damage to these para-pyramidal motor 
pathways results in a loss of the cortical drive to several inhibitory centers in the brainstem, 
resulting in disinhibition of spinal and bulbar reflexes [78, 79]. Although the para-pyramidal 
motor pathways cannot be directly assessed, they might be indirectly assessed by the TMS. 
Loss of cortical drive to the inhibitory centers in the brainstem may be due to lesions within 
areas projecting to the primary motor cortex (Figure 1). Indeed, the primary sensory area, 
supplementary motor area, premotor area, basal ganglia, thalamus, and cerebellum all 
provide important modulatory inputs to the primary motor cortex. Lesions within these areas 
might, therefore, result in a partial deafferentiation of the primary motor cortex and lead to a 
subsequent change in the balance between excitatory and inhibitory influences on the 
intracortical motor neurons that project to both the reticulospinal tract and to the corticospinal 
tract.  
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Conclusion 
The exact relation between TMS-induced, contraction-induced reduction phenomena and 
recovery-related intracortical phenomena and spasticity remains unclear. More research is 
needed to identify the prognostic value of the SP in relation to post-stroke spasticity. 
Furthermore, to identify relevant prognostic changes in SP, a standardized approach to elicit, 
define, and measure the SP should be developed first. 
The SP duration reaches its minimal variability and maximal length after cortical stimulation 
using maximal stimulator output and when facilitated by a slight tonic contraction of the test 
muscle (20 to 30% of maximal voluntary contraction) [17]. We therefore, recommend the use 
of at least this SI and level of muscle pre-activation. A proper recommendation of the 
definition of the SP is more difficult. Although the time-interval between the end of the M-
wave and the first burst of uninterrupted EMG-activity is the most proper definition of the SP, 
it is also the most difficult method to visually assess. Both the end of the M-wave and the first 
burst of uninterrupted EMG-activity are inconsistent and difficult to interpret in the EMG-
tracings. The time of stimulus delivery and even MEP onset used as the onset marker, may 
be easier to interpret. However, both include also the MEP-duration that could affect the 
duration of the SP. It seems worthwhile to study SP onset and offset markers to determine 
which is the most valid, precise, and applicable method. The development of graphical 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Predicting hand motor recovery in severe stroke; 
The role of motor evoked potentials in relation to early 
clinical assessment 
 










Objective: The primary aim of this study was to compare the predictive value of motor evoked 
potentials (MEPs) and early clinical assessment with regard to long-term hand motor 
recovery in severe stroke patients. 
Methods: Inception cohort of 39 stroke patients with an acute, ischemic, supratentorial stroke 
and an initial upper-extremity paralysis admitted to an academic hospital. Hand motor 
function recovery was defined at 26 weeks post stroke as a Fugl-Meyer motor assessment 
(FMA) hand score >3 points. The following prognostic factors were compared at week 1 and 
week 3 post stroke: motor functions as assessed by the FMA upper-extremity and lower-
extremity subscores, and the presence of a MEP in the abductor digiti minimi (ADM) and 
biceps brachii (BB) muscle. 
Results: Both the presence of an ADM-MEP and any motor recovery in the FMA upper-
extremity subscore showed a positive predictive value of 1.00 at week 1 and 3. The FMA 
lower-extremity subscore showed the best negative predictive value (0.90; 95%-CI 0.78-1.00 
at week 1, and 0.95; 95%-CI 0.87-1.00 at week 3). 
Conclusions: In stroke patients with an initial paralysis of the upper extremity the presence or 
absence of a MEP has similar predictive value compared to early clinical assessment with 
regard to long-term hand motor recovery.  
 
Introduction 
Nearly one third of all stroke survivors initially shows severe motor impairments in the upper 
extremity [1-3]. Although 30-66% of these severe patients will regain no motor function of the 
upper extremity at all, 25% will show partial motor recovery and 5-20% will even regain full 
motor function of the upper extremity [2-5]. Because both motor recovery and the 
development of complications such as shoulder subluxation, spasticity [6], and contractures 
already take place very early after stroke onset, the preferred time window for the institution 
of rehabilitation strategies is shifting from the subacute phase (6 weeks to 6 months) into the 
acute phase (within the first 6 weeks) after stroke.  
In patients with a potential for motor recovery it is important to focus on the restoration of 
motor function as early as possible [7]. In these patients, repeated failures to use the paretic 
arm and hand in the acute and subacute phases after stroke can lead to negative 
reinforcement, the so-called ‘learned non-use’, complicating the rehabilitation process later 
on [7]. On the other hand, focusing on the restoration of motor function in stroke patients 
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without a potential for motor recovery will lead to frustration and disappointment in both 
patients and therapists, and delays a shift of therapy focus towards learning compensation 
strategies. To proactively apply appropriate rehabilitation strategies in individual patients, it is 
important to differentiate those with a potential for motor recovery from those without such 
potential as early as possible and with a high degree of accuracy. 
The initial grade of paresis and the early patterns of motor improvement are well known 
clinical predictors of functional recovery [2, 3]. At the end of week 4 after stroke, Kwakkel et 
al. [3] found a probability of 94% for regaining dexterity at 6 months after stroke in patients 
with an initially flaccid arm who had achieved at least 19 points on the upper-extremity 
subscore of the Fugl-Meyer motor assessment (FMA). However, at 1 week after stroke the 
predictive value of clinical assessment was substantially lower. A probability of only 74% for 
regaining dexterity at 6 months after stroke was found in those patients who had reached 
some voluntary movement over the hip, knee, and/or foot. Moreover, clinical assessment of 
motor functions can sometimes be difficult, particularly in patients suffering from concomitant 
cognitive deficits, such as aphasia, apraxia, or sensorimotor neglect. Hence, in the first week 
post stroke and in patients with cognitive deficits, neurophysiological assessment might add 
to the predictive value of early clinical assessment with regard to upper-extremity motor 
recovery.  
Indeed, transcranial magnetic stimulation (TMS) has been proven successful in the 
prediction of motor recovery of the upper extremity in patients within the first 3 weeks after 
stroke [8, 9]. It offers an objective evaluation of the integrity of the corticospinal pathways, 
responsible for the primary motor functions. In stroke patients with an initial paralysis of the 
upper extremity, the specificity of the presence of a motor evoked potential (MEP) in the 
abductor digiti minimi muscle (ADM) for hand motor recovery has consistently been shown to 
be high (nearly 100%) [8, 9], indicating that at 3 weeks after stroke all MEP-positive patients 
will show some degree of hand motor recovery at 6 months after stroke. However, the 
sensitivity of the MEP in these patients was lower and more variable (62-94%) [8], indicating 
that not all patients who will show hand motor recovery can be identified by the presence of 
an early MEP. Therefore, the clinical value of TMS in terms of improved prognostication in 
stroke patients is still debated.  
There are no studies available, however, that have made a direct comparison between early 
clinical assessment and TMS with regard to predicting long-term hand motor recovery in 
stroke patients with an initial paralysis. Moreover, studies focusing on the predictive value of 
either clinical assessment or TMS are difficult to compare due to the variability in patient 
characteristics and time-post stroke. The primary aim of this study was, therefore, to 
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compare the predictive value of clinical assessment and motor evoked potentials at one and 
at three weeks after stroke with regard to long-term hand motor recovery in a homogeneous 
group of patients with severe stroke. 
 
Materials and Methods 
Patients 
Patients with a first-ever, ischemic, supratentorial stroke and admitted to the Department of 
Neurology at the Radboud University Nijmegen, Medical Centre during a 3,5 years’ period 
(2002-2006) were eligible. The diagnosis of stroke was made clinically by a neurologist 
according to the World Health Organisation clinical criteria [10] and confirmed by CT scan. In 
each patient, a CT scan of the brain was made twice: at first on the day of admission and, 
second, at 1 week after stroke to delineate the structural lesion. 
Only patients presenting with no voluntary muscle activity and no muscle tone at the elbow, 
wrist, or finger flexors (Brunnstrom stage I [11]) on the day of admission were included within 
the first 7 days after stroke. Patients with a poor prognosis for survival (loss of 
consciousness, severe CT abnormalities, and severe co-morbidity), as well as patients with 
severe pre-existing impairments of the upper extremity of any type (e.g., rheumatic 
deformities, contractures) were excluded. Patients with a history of craniotomy, epilepsy, 
cardiac prosthetic valve or pacemaker implantation, or severe polyneuropathy were excluded 
as well. The local ethics committee approved the study protocol and written informed consent 
was obtained from all patients before study entry. 
All patients received a ‘best medical treatment’ according to the guidelines of the 
Netherlands Society of Neurology, ensuring that each patient was given physiotherapy to 
maintain optimal passive and active range of motion of all upper-extremity joints from the first 
day after stroke. However, for the first 3 weeks after stroke, no specific therapy was initiated 
specifically aimed at facilitation of hand function recovery. Thereafter, patients were 
discharged to their private homes, rehabilitation centres, or nursing homes, dependent on 
their functional status, implicating that the total amount of rehabilitation given was not 
controlled. 
Neurophysiological assessment 
TMS of the motor cortex was performed twice in each patient; at first, at 1 week after stroke 
(t1) and, secondly, at 3 weeks after stroke (t2) by the same experienced clinical 
neurophysiologist (JP). This clinical neurophysiologist was blinded with regard to the results 
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of the clinical assessments. Patients were positioned comfortably in a supine position. TMS 
was performed through a 90 mm circular coil placed in a tangential plane above the vertex 
and powered by a Magstim 200 magnetic stimulator. The stimulus intensity was set at 
maximum stimulator output (100% = 2.0 Tesla) to ensure maximum stimulation of the MEP 
[12]. To obtain a preferential activation of each hemisphere, a clockwise inducing current flow 
was used for the right hemisphere and a counter-clockwise current for the left hemisphere. 
MEPs were recorded at week 1 (t1) and at week 3 (t2) post stroke from the biceps brachii 
muscle (BB) and the ADM on both the paretic and non-paretic sides. These muscles were 
regarded as representatives of proximal and distal motor functions of the upper extremity. 
Because it has been suggested that early, proximal movements of the arm are predictors for 
upper-extremity motor recovery [13], we performed a BB MEP as well. Two self-adhesive 
recording surface electrodes were placed on the ADM and BB on both the paretic and non-
paretic side. The active electrode was placed on the muscle belly and the reference 
electrode was placed on the tendon approximately 3 cm distal from the position of the active 
electrode. Recordings were made using an Oxford Synergy electromyograph with filter 
settings of 20 Hz and 3 kHz (amplifier range 100 mVolts and recording sensitivity of 0.5 
mVolts / bit). A 500-ms post-stimulus period was analysed in search for a MEP response.  
The MEPs were preferably recorded when facilitated by a slight voluntary muscle 
contraction. If the patients could not perform a contraction of the affected hand or arm 
muscle, they were asked to activate the corresponding muscle on the non-paretic side [14, 
15]. The patients were instructed to maintain the constant isometric contraction during the 
TMS performance. Although muscle preactivation facilitates enlargement of the MEP 
amplitudes, preactivation is not a prerequisite to elicit a MEP-response. Three responses 
were obtained to assess the reproducibility. The presence of a MEP was defined as the 
presence of at least two responses out of three with a minimal peak-to-peak amplitude of 200 
microVolts.  
Clinical assessment 
Within the first 24 hours after stroke the treating neurologist assessed all patients with regard 
to initial motor functions, muscle tone, and level of consciousness (Mini-Mental State 
Examination [16]). Thereafter, an experienced rehabilitation physician who was not aware of 
the MEP results performed the clinical assessments. The motor functions of the upper 
extremity were assessed at week 1 (t1), 2, 3 (t2), 6, and 12, and at 26 weeks (t3) after stroke 
using the motor part of the upper-limb subset of the FMA [11]. Motor functions of the lower 
extremity were assessed on admission, at week 1 (t1), and at week 3 (t2) using the motor 
part of the lower-limb subset of the FMA [11]. This cumulative numerical scale is based on 
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the sequential motor recovery stages that can be observed in hemiparetic patients and is 
scored under standardised test conditions. For the upper extremity, we defined a separate 
arm and hand motor score within the FMA. The arm score included motor functions of the 
shoulder, elbow, and forearm, with a maximum score of 30 points, whereas the hand score 
concerned the 7 original hand items with a maximum of 14 points.  
Data Analysis 
In the prediction model, the FMA hand subset was used as the primary outcome. Because 
particularly achieving voluntary extension of the wrist and fingers is critical for regaining 
dexterity [17], the optimal dichotomization point was, based on the literature [3, 18], set at ≤ 3 
versus > 3 points.  
As potential prognostic factors were tested at week 1 (t1) and at week 3 (t2): 
1) the presence of an ADM-MEP, 2) the presence of either a BB-MEP or ADM-MEP, and 3) 
the presence of any motor recovery of the upper extremity. In addition, we tested the 
presence of any voluntary movements of the affected lower extremity at week 1 (t1), and a 
FMA lower extremity subscore of at least 10 points at week 3 (t2). This latter dichotomization 
point was also based on existing data in severe stroke patients with an initially flaccid arm 
[3]. 
In second instance, we investigated whether the combination of early clinical assessment 
and the presence of a MEP offered a better prediction of long-term hand motor recovery than 
that offered by any single determinant. 
To investigate the possible association between hand motor recovery at 26 weeks (t3) after 
stroke and the selected prognostic factors, both a positive (PPV) and negative predictive 
value (NPV) were calculated for each factor with corresponding 95% confidence intervals.  
 
Results 
Forty-four patients with an initial paralysis of the upper-extremity were screened for inclusion 
in this study. Five patients did not met the inclusion criteria because of poor prognosis for 
survival, none refused to participate in this study. Of the initially included 39 patients, 4 
patients (2 men and 2 women) died during the first 3 weeks after stroke. These patients were 
excluded from the analysis. Thus, 35 patients, 18 male and 17 female patients, completed 
the study. Their mean age was 59.8 years (standard deviation 15 years; range 20-86 years). 
All patients had extensive lesions located in the territory of the middle cerebral artery. The 
patient characteristics are described in Table 1. 
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Table 1. Characteristics of the 35 patients 
      number 
       
Gender     Female   18 
    Male   17 
       
Stroke history     First ever   35 
       
Lesion side     Left   20 
    Right   15 





       
Mean age, years (range; SD)     58 (20‐86; 15)   













       
Aphasia    present  22 
    absent 13 
       
Hemi‐inattention    present 20 
    absent 15 




Upper-extremity Motor Recovery  
In 21 patients (60%) the upper extremity did not show any motor recovery throughout the 26-
week follow-up period, whereas in 14 patients (40%) upper-extremity motor recovery was 
present at 26 weeks after stroke. These patients are depicted in Figure 1. At 6 months post 
stroke, 6 patients (17%) achieved complete motor recovery of the upper extremity (FMA= 
44), whereas 8 patients (23%) showed partial motor recovery of various degrees. At one 
week post stroke (t1), motor recovery was present in 4 patients (10%) of which 2 progressed 
to complete recovery at the 26 weeks. At 3 weeks post stroke (t2), motor recovery was 
present in 9 patients (26%) of which 5 patients eventually reached complete motor recovery. 
Two patients with partial motor recovery showed only gross motor functions of the arm, not of 
the hand, implicating that 12 patients (34%) achieved hand motor recovery at 26 weeks post 
stroke. In all these patients, hand motor recovery was always accompanied by arm motor 
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Motor Evoked Potentials 
Five patients refused the second MEP assessment. Three patients reported discomfort during 
the first TMS assessment as the primary reason, whereas 2 patients where too ill to attend the 
second TMS assessment (both suffered from pneumonia). These patients did not differ from the 
other participants with regard to their neuroradiological or clinical assessment. Two of these 
patients showed hand motor recovery at 6 months. Therefore, the neurophysiological data set 
was complete for 30 patients. In 17 patients, no MEP response could be elicited after maximal 
stimulation of the affected hemisphere, neither at week 1 (t1), nor at week 3 (t2). A MEP of the 
ADM or BB muscle was obtained in 10 patients (34%) at week 1 (t1) and in 13 patients (43%) at 
week 3 (t2) post stroke.  
Prediction of hand motor recovery 
Table 2 shows the contingency tables and the PPVs and NPVs for each prognostic factor. PPVs 
varied from 0.62 to 1.00 and NPVs from 0.74 to 0.95. 
At t1, both the FMA upper-extremity subscore and the presence of an ADM-MEP showed PPVs 
of 1.00. Both factors identified 4 patients who regained hand motor function at t3. However, only 
2 of these patients were identified by both the FMA upper-extremity subscore and the ADM-
MEP. The highest NPVs were found for the FMA lower-extremity subscore (0.90, 95%-CI 0.78-
1.00) and the presence of any MEP (BB and /or ADM) (0.80, 95%-CI 0.64-0.96). At t2, the NPVs 
increased with the highest values for the FMA lower-extremity subscore of at least 10 points 
(0.95, 95%-CI 0.87-1.00) and the presence of any MEP (BB and/or ADM) (0.94, 95%-CI 0.83-
1.00). Again, the highest PPVs were found for the upper-extremity subscore and the presence of 
an ADM-MEP (PPV 1).  
In addition, table 3 shows the PPVs and NPVs for the selected combinations of the potential 
prognostic factors. At t1, the presence of a FMA upper-extremity subscore or a positive ADM-
MEP identified 2 additional patients (6 instead of 4) with hand motor recovery at t3, whereas at 
t2 this combination of factors identified 1 additional patient (10 instead of 9). As a result the 
NPVs slightly increased from 0.74 to 0.79 at t2 and from 0.88 to 0.91 at t2. Only when the FMA 
upper-extremity subscore was combined with any MEP (BB and / or ADM) a NPV of 1.00 was 
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Discussion 
To our knowledge, this is the first study that made a direct comparison between early clinical 
assessment and TMS with regard to predicting hand motor recovery after stroke. A well-
selected, homogeneous, sample of patients with an initial paralysis of the upper extremity 
caused by a first-ever, ischemic, supratentorial stroke was included, because particularly in 
this subgroup early prediction of motor recovery is considered both clinically relevant and 
difficult at the same time. As a consequence, the results of this study are applicable only to 
the severely affected stroke survivors with an initial paralysis of the upper extremity. At six 
months after the initial stroke, 12 patients (34%) developed some hand function as assessed 
by the FMA hand subscore. Six of these patients (17%) even regained complete hand motor 
function. These figures are consistent with those reported in the literature on motor recovery 
after severe stroke [3, 5]. 
Thirty-four percent of the patients had a positive MEP response in either proximal or distal 
upper-extremity muscles at the first TMS assessment, which increased to 43% at the second 
assessment. Most muscles that generated motor evoked potentials at week 1 showed motor 
recovery at 6 months after stroke. The presence of an ADM-MEP was able to accurately 
identify hand motor recovery at 6 months post stroke in patients with an initial upper-
extremity paralysis (PPV = 1). Indeed, all patients with a MEP response in the ADM muscle 
at either week 1 (t1) or week 3 (t2) showed hand function recovery at 6 months after stroke, 
whereas for the BB muscle a positive MEP response did not result in any hand motor 
recovery at 6 months in 3 patients at week 1 and in 5 patients at week 3. In all 3 patients at 
week 1 post stroke and in 4 patients at week 3, a positive MEP-response in the BB muscle 
did not result in any recovery of arm motor function at 6 months as well. 
This discrepancy between positive predictive values of ADM and BB may be due to 
differences in the physiology of motor control between proximal and distal upper-extremity 
muscles [19, 20]. In contrast to proximal muscles, the motoneurons that innervate the 
intrinsic muscles of the hand and govern independent and fractionated (fine manipulatory) 
finger movements, receive direct, monosynaptic inputs from the corticospinal tract [21-23]. 
Therefore, the integrity of the corticospinal pathway is considered a prerequisite for normal 
hand function rather than for arm function.  
However, the selected neurophysiological parameters did not yield better predictive values 
compared to clinical assessment. At week 1 after stroke, both early hand motor recovery and 
the presence of an ADM-MEP showed a good positive predictive value (PPV = 1) with regard 
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Early leg motor recovery had a lower predictive value (PPV = 0.71). This pattern of results 
differs to some extent from the results reported by Kwakkel et al. [3]. Yet, Kwakkel et al. [3] 
did not include the presence of hand motor recovery at 1 week in their prediction model. 
Prediction of hand function at 6 months after stroke in their study was best identified by leg 
motor recovery in the first week after stroke with a probability of 74%. This discrepancy with 
the results of the present study may be due to the different populations of severe stroke 
patients studied. In the study of Kwakkel et al. [3], only 76 % of the patients had a paralysis 
of the upper extremity at onset, whereas in our study all patients had an initial paralysis. 
Although both early hand motor recovery and the presence of an ADM-MEP were highly 
predictive with regard to hand motor function at 6 months after stroke, only 4 and 6 out of 12 
patients with hand function at 6 months were identified at week 1 and week 3 respectively, 
implicating a rather poor NPV for both prognostic factors. By combining these factors a few 
more recovering patients could be identified, but the NPV just slightly increased. Only when 
the FMA upper-extremity subscore was combined with any MEP of the BB or the ADM a 
NPV of 1.00 was reached at 3 weeks after stroke. Compared to the NPV of the FMA lower-
extremity subscore at 3 weeks post stroke (NPV = 0.95), this difference is small and 
attributable to merely 1 false-negative patient for the leg score. 
In severe stroke patients with a potential for motor recovery it is generally important to focus 
rehabilitation efforts on the restoration of motor function. In this perspective, one wants to 
treat as many of these patients as early as possible after stroke, accepting the chance of 
treating some patients without potential for motor recovery unsuccessfully. From this point of 
view, false-negative classifications must be prevented and prediction of hand motor recovery 
can best be based on early motor recovery of the leg, which has a good NPV at 1 week 
(0.90) and at 3 weeks (0.95) post stroke. Only the combination of an absent upper-extremity 
FMA subscore and an absent MEP in BB and ADM at 3 weeks post stroke may provide more 
certainty (NPV = 1.00). However, if one considers vigorous treatment strategies that impose 
an unacceptable burden on non-responders, one should strive for as few false-positives as 
well. From this perspective, a positive leg motor score is certainly informative, but one might 
want to rely on a positive upper extremity-motor score or a positive ADM-MEP for excluding 
false positives. 
Our results show that, apparently, critical residual sparing of corticospinal connections 
cannot be detected by TMS in all cases during the acute and sub-acute phases post stroke. 
This might be due to insufficient cortical stimulation of functionally depressed, but 
undamaged corticomotoneurons. Another explanation is that restoration of motor function 
may be due to cortical reorganization involving brain systems that cannot be recruited by 
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TMS, because these are not directly connected to the corticospinal pathways [24]. In these 
cases, adding neuroimaging studies to TMS may provide valuable additional information 
about the residual function of the cortical sensorimotor system [25]. 
Our TMS protocol was restricted to TMS assessment at 100% stimulator output. Several 
authors have reported that at this stimulus intensity, maximum values of the MEP amplitude 
with minimal variability can be obtained [12, 26]. In this study, we were merely interested in 
the question whether the intactness of the corticospinal tract is predictive of hand motor 
function recovery. For this purpose, both TMS characteristics (presence or absence of a 
MEP) and hand function (FMA hand score > 3) have been dichotomized. Thus, we were able 
to minimize the time taken and effort needed to perform TMS measures in the patients 
suffering from severe stroke. 
Another limitation of our study is the still relatively small number of patients included, which 
affects the accuracy of the estimated PPVs and NPVs. Many more patients would be needed 
to reduce the estimated confidence intervals. Yet, we deliberately restricted the inclusion to 
patients with an initial paralysis. This subgroup of severely affected stroke patients comprises 
only 19-30% of the stroke population at large, and has a high risk of post-stroke death (62%) 
and a relatively small chance of motor recovery [2-5]. As a result, the inclusion rate and the 
incidence of motor recovery were relatively low. However, as we argued in the introduction, 
accurate prediction of hand motor recovery is particularly relevant in these severe patients, 
because the appropriate rehabilitation strategy depends on the probability of motor recovery 
and the chance of developing complications secondary to paralysis or spasticity. Patients 
with residual arm and hand function at the time of stroke onset will always show some motor 
recovery, which warrants a treatment strategy promoting such recovery [27].  
 
Conclusion 
In stroke patients with an initial paralysis of the upper extremity the presence or absence of a 
MEP seems to have no additional predictive value compared to early clinical assessment 
with regard to long-term hand motor recovery. Based on the FMA, accurate prediction of 
long-term hand function recovery can be made 3 weeks after stroke using the upper-
extremity subscore to predict motor recovery and the lower-extremity subscore to predict the 
absence of recovery. In individual patients that are difficult to examine, for instance due to 
severe cognitive deficits or loss of consciousness, TMS may still provide more reliable results 
than clinical examination. In the future, stimulus-response curves of the MEP amplitude 
might be used to assess corticospinal function in patients with mild to moderate strokes. By 
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combining such TMS techniques with modern imaging techniques, we may be able to 












































































Are clinical characteristics associated with upper-extremity 
hypertonia in severe ischemic supratentorial stroke? 
 








Objective: The primary aim of this study was to identify clinical risk factors, in addition to 
muscle weakness, for upper-extremity hypertonia in patients with severe, ischemic, 
supratentorial stroke. The secondary goal was to investigate the time course of upper-
extremity hypertonia in these patients during the first 26 weeks after stroke. 
Methods: Inception cohort of forty-three consecutive patients with an acute ischemic 
supratentorial stroke and an initial upper-extremity paralysis. Primary outcome: Hypertonia 
assessed by the Ashworth scale at week 26 after stoke. Potential risks factors: Motor 
functions assessed by the upper-extremity subscore of the Fugl-Meyer motor assessment, 
Barthel Index at week 1, consciousness, sensory disturbances, apraxia, neglect, and 
hyperreflexia. Secondary outcome: time course of upper-extremity hypertonia by assessing 
its prevalence at 6 consecutive moments after stroke during a follow-up period of 26 weeks. 
Results: Twenty-five patients (63%) developed hypertonia during the follow-up period of 26 
weeks. During this period, the prevalence of hypertonia followed a rather dynamic course, 
with cases of early, transient, and late hypertonia. Univariate analyses yielded none of the 
selected clinical characteristics as significantly associated with hypertonia.  
Conclusions: Despite the high incidence of hypertonia (63%) observed, none of the selected 
clinical characteristics could be identified as a risk factor for hypertonia.  
 
Introduction 
Spasticity is a characteristic component of the upper motor neuron syndrome in the post-
acute and chronic phases of stroke. Spasticity develops in about 20 to 40% of all stroke 
survivors, usually within 3 months after stroke [1-5]. In the upper extremity, spasticity may 
cause difficulty with basic arm and hand abilities, such as reaching and grasping, as well as 
with many more complex activities of daily living (ADL) [6-8]. In the acute and post-acute 
phases after stroke, recurrent negative reinforcement in attempts to use the affected arm can 
lead to so-called ‘learned non-use’, in particular when spastic antagonists counteract 
selective voluntary muscle activity [9]. Moreover, in the long-term, untreated spasticity can 
lead to secondary complications, such as changes in the visco-elastic properties of the 
musculo-tendinous apparatus (stiffness), loss of muscle length (contractures), and pain, 
which may further impede the functional use of the upper extremity [3, 10]. 
The precise relationship between spasticity elicited by passive tendon or muscle stretch and 
the active movement capacity, however, remains unclear. As a consequence, it is not clear 
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whether reduction of spasticity will always improve active motor functions and dexterity. A 
systematic review of the treatment of post-stroke upper-extremity spasticity by focal neuronal 
or neuro-muscular blockade revealed the potential efficacy of such treatments in reducing 
hyperreflexia, muscle tone, and in improving passive range of joint motions [11], yet, 
functional benefits could not be convincingly demonstrated. Generally, functional effects of 
spasticity treatment seem to depend highly on a critical selection of subjects, individualized 
goal setting, and appropriate selection of outcome measures [12, 13]. Patients after severe 
stroke with a low potential for motor recovery in particular may profit from a pro-active 
treatment approach to prevent disabling spasticity and the functional consequences of 
secondary complications, such as muscles stiffness, contractures, and pain. Benefits can be 
achieved with regard to activities such as dressing, bathing and grooming, as well as with 
regard to limb positioning, cosmetic appearances, and comfort [12, 13]. Against this 
background, it seems clinically relevant to assess, besides the probability of motor recovery, 
the risk of developing spasticity in the individual patient early after stroke.  
However, although motor recovery can be predicted reasonably well by clinical assessment 
[14], early recognition of the risk of developing spasticity based on clinical characteristics is 
much more difficult and the literature does not really support clinical reasoning. Because the 
clinical assessment of spasticity measures resistance against passive stretch (hypertonia), it 
cannot distinguish between the neural (reflexive) mechanisms, and the secondary (intrinsic) 
changes in muscle properties. Studies on the risk factors for post-stroke hypertonia are also 
scarce. Besides a recently published cohort study by Leathly et al. [4], no other studies are 
available in (sub) acute stroke patients. In stroke survivors, Leathly et al. [4] found a 
moderate association of both muscle weakness and a low Barthel Index (BI) [15] on day 7 
after stroke with hypertonia at 12 months after stroke. Based on clinical experience, some 
authors have suggested the importance of sensory impairments, visuospatial deficits, and 
apraxia for developing hypertonia [16, 17]. However, these disorders were not identified as 
risk factors in the study by Leathly et al. [4], which might have been due to the relatively low 
number of cases with hypertonia (36%).  
Against this background, we conducted a cohort study including only patients with an initial 
paralysis of the upper extremity after supratentorial ischemic stroke to maximize the 
likelihood of observing hypertonia and, thus, to optimize the chance of identifying additional 
risk factors for post-stroke upper-extremity hypertonia. As a secondary goal, we studied the 
time course of upper-extremity hypertonia by assessing its prevalence at 6 consecutive 
moments after stroke during a follow-up period of 26 weeks.  
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Materials and Methods 
Patients 
As part of a larger study on the value of motor-evoked potentials (MEPs) in predicting motor 
and functional outcome after stroke [18], 43 consecutive acute patients with an ischemic 
supratentorial stroke were recruited during a 1.5-years’ period. These patients were admitted 
to the Department of Neurology at the Radboud University Nijmegen, Medical Centre. The 
diagnosis of stroke was made clinically by a neurologist according to the World Health 
Organization (WHO) clinical criteria [19] and confirmed by computerized tomography (CT) 
scan.  
Only patients presenting with stage I of the upper extremity according to Brunnstrom [20] 
(i.e., no tone and no voluntary muscle activity at the elbow, wrist, or finger flexors) at day 1 
were included within 7 days after stroke. Patients with a poor prognosis for survival (loss of 
consciousness, severe CT abnormalities, and severe co-morbidity) as well as patients with 
severe pre-existing impairments of the upper extremity of any type (e.g., rheumatic 
deformities, contractures) were excluded. Because all patients had to undergo transcranial 
magnetic stimulation to record MEPs, those with a history of craniotomy, epilepsy, cardiac 
prosthetic valve or pacemaker implantation, or severe polyneuropathy were also excluded. 
The local ethics committee approved the study protocol and written informed consent was 
obtained from all patients before study entry.  
Each patient received ‘best medical treatment’ according to the guidelines of the Netherlands 
Society of Neurology, including a multi-disciplinary initial rehabilitation approach. This 
approach ensured that each patient received physiotherapy to maintain optimal passive and 
active range of motion of all upper-extremity joints from day 1 after stroke. However, for the 
first 3 weeks after stroke, no specific therapy was initiated aimed at facilitation of hand 
function recovery. 
Potential risk factors 
Within the first 24 hours after stroke the treating neurologist assessed all patients with regard 
to initial motor functions, muscle tone, and level of consciousness. All consecutive clinical 
assessments of motor, sensory, and cognitive functions were performed at weeks 1, 2, 3, 6, 
12, and 26 after stroke by a rehabilitation physician (HH). Motor functions were assessed 
according to the upper-limb subset of the Fugl-Meyer Motor Assessment (FMA) [20]. A 
selected hand motor score was derived from the FMA, which consisted of the 7 original hand 
items of the FMA with a maximum score of 14 points. Early hand motor function recovery 
was defined as any change in the FMA hand score within the first 3 weeks after stroke. 
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Sensory deficits were assessed by clinical examination of light touch, pinprick, and vibration 
sense of the hemiparetic arm. Proprioception was assessed by the ‘thumb-finding test’ [21]. 
Sensory deficit was ultimately recorded on a binary scale as either ‘absent’ or ‘present’ 
based on reproducible differences in at least 2 sensory modalities compared with the non-
paretic arm. Biceps and triceps tendon reflexes were quantified according to the Mayo Clinic 
scale for tendon reflex assessment (range -4 to +4) [22]. Hyperreflexia was considered 
present if the tendon reflex on the paretic side was ≥ +1. 
Neglect was defined as the inability to detect, attend to, or respond to stimuli located on the 
contra-lesional side of body or action space [23]. Apraxia was defined as the inability to 
perform previously learned skilled acts, despite sufficient comprehension, motor capacity, 
and sensation. Both the existence of neglect and apraxia were based on clinical observations 
of the patient’s ADL performances by the nursing staff, the treating neurologist, and the 
consulting rehabilitation physician within the first 3 weeks after stroke. Neglect and apraxia 
were considered present if symptoms were witnessed by at least 2 of these 3 observers.  
Finally, ADL performances were assessed with the Barthel Index (BI) [15]. Consistent with 
Leathly et al. [4], the BI score at the first week after stroke was considered as a potential risk 
factor. 
Outcome assessment 
Hypertonia was clinically assessed by grading muscle tone through the Ashworth scale (AS) 
[24]. Muscle tone was assessed within the first 24 hours after stroke and consecutively at 
weeks 1, 2, 3, 6, 12, and 26 after stroke under standardized test conditions by a rehabilitation 
physician (HH). The patients lay supine or sat in a comfortable sitting position with their 
forearms supinated and resting on a horizontal plane. Patients were instructed to completely 
relax while their affected elbows and wrists were passively moved throughout the maximal 
range in both flexion and extension directions. Passive extension of the patient’s elbow was 
performed during approximately one second by counting “one thousand and one” while the 
forearm was held just proximal to the wrist. When the elbow was extended, the upper arm 
was stabilized just proximal to the elbow. Passive extension of the patient’s wrist was also 
performed during approximately one second while the hand was held just proximal to the 
metacarpo-phalangeal joints and the forearm just proximal to the wrist. Muscle tone was 
quantified according to the criteria outlined by Ashworth [24] (grades 0-4). Clinically relevant 






From 2x2 contingency tables, positive and negative predictive values for each of the potential 
risk factors with their 95% confidence interval were calculated. In addition, to test the 
association of gender with hypertonia, Pearson’s chi-square analysis was performed. The 
required 2-tailed significance level was set at 0.05. For the ordinal outcome measure BI at 
week 1 after stroke, the Mann- Whitney U test was performed to assess the association 
between the BI and hypertonia. Again, the required 2-tailed significance level was set at 
0.05.  
In case of positive outcome of the univariate analysis, multiple backwards logistic regression 
was planned to determine the explained variance by each characteristic with regard to 
hypertonia, independent of its possible association with other characteristics. 




Patients characteristics and time course of post-stroke hypertonia 
Two patients died within the first 2 weeks after stroke. Both continued to have a flaccid 
paralysis of the upper extremity from clinical presentation. Another patient was excluded from 
the study at week 13 because of a poor prognosis for survival after he had a recurrent stroke. 
Thus, 40 patients, 20 women and 20 men, completed the study. The clinical characteristics 
of these 40 patients are shown in Table 1. Sixteen (40%) patients had had a previous stroke, 
whereas 24 (60%) patients had had a first-ever stroke.  
The highest estimated AS scores in our patients were 0 (n=9), 1 (n=6), 2 (n=8), 3 (n=12), and 
4 (n=5). If clinical hypertonia was defined as AS equal to or more than 2, 25 (63%) patients 
developed hypertonia at any time after stroke. In 20 patients hypertonia developed within the 
first 6 weeks after stroke, and in 10 (25%) patients even within the first 3 weeks after stroke. 
This ‘early’ (within 3 weeks) hypertonia was not correlated with previous stroke (Fisher’s 
exact p = 0.48). We identified 16 hypertonic patients at 6 months who were not initially 
hypertonic, as well as 3 patients with normal muscle tone at 6 months who were initially 
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In 12 patients, recovery of hand motor function was present at week 26 after stroke. In the 
group with persistent hypertonia, 7 (33%) patients showed any recovery of hand motor 
function, whereas in the group without hypertonia 5 patients showed such recovery (26%). 
Figure 2 illustrates the FMA-hand scores at week 26 after stroke in both the patients with and 
those without persistent hypertonia. 
Table 1. Characteristics of the 40 patients 
        number 
Gender     Female     20 
    Male     20 
Stroke history     First ever     24 
    Previous     16 
Lesion side     Left     22 
    Right     18 
Median age, years (interquartile range)    68 (59‐77)     
Median Barthel Index on admission 
(interquatile range) 
  0 (0)     
 
7 7 6 6 6 6
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Potential risk-factors for post-stroke hypertonia 
Because, from a clinical point of view, we were most interested in predicting persistent 
hypertonia, we considered hypertonia at week 26 after stroke as the primary outcome. In 
univariate analyses, all associations between hypertonia at week 26 and the potential risk 
factors were low and statistically not significant. Table 2 shows the positive and negative 
predictive values with their 95% confidence intervals for all factors. Positive predictive values 
varied from 0.52 to 0.68 and the negative values from 0.33 to 0.62.  
In addition, 10 females and 12 men suffered from hypertonia at 26 weeks after stroke. In 
both patients with and those without hypertonia the median BI at week 1 after stroke was 2 
(inter-quartile range 0 to 4). There was no association between gender and hypertonia (χ2 
0.404; p = 0.525) and neither between the BI at week 1 and hypertonia (p = 0.93). Changing 
the definition of persistent hypertonia into AS equal to or more than 2 at week 12 or week 6 
after stroke yielded similar results. Even if clinically relevant hypertonia was defined as AS 
equal to or more than 1, or if hypertonia at any time after stroke was used as the primary 







































































































































































































































































































































































































































































In this study a sample of patients with initial paralysis of the upper extremity caused by 
ischemic supratentorial stroke was included to optimize the chance of identifying risk factors, 
additional to muscle weakness, for early, persistent hypertonia. The observed overall 
incidence of hypertonia within 6 months after stroke in this group was 63%. In comparison, 
Sommerfeld et al. [5] found a 24% overall incidence of hypertonia within 3 months in a 
hospital-based cohort of patients with an acute, first-ever, ischemic stroke. Other studies on 
stroke-related hypertonia mainly reported prevalences instead of incidences, varying from 19 
to 39% of the hospitalized stroke population at large [4-6]. Hence, our patient sample was 
clearly different from those in previous studies. It was restricted to a homogeneous subgroup 
of the most severely affected survivors from ischemic, supratentorial stroke, i.e., those with 
an initial paralysis of the upper extremity. The severity of stroke is also evident from the 
finding that all patients had an initial BI of 0. Based on the observed incidence in this study, 
this subgroup of stroke patients with initial paralysis of the upper extremity apparently has a 
substantial chance of developing hypertonia within 6 months after stroke. 
Yet, even in this severely affected group, we could not identify any of the selected clinical 
characteristics as a significant risk factor for early or persistent hypertonia. Even 
hyperreflexia, which is regarded by many clinicians as a sign of “spasticity”, was not 
significantly associated with the AS in this study. This finding is corroborated by several 
electrophysiological studies that have shown dissociations between hyperreflexia and 
hypertonia, indicating that phasic and tonic stretch reflexes are controlled differently by the 
central nervous system [2, 5]. However, it might also reflect the fact that the AS is unable to 
distinguish between neural mechanisms (hyperreflexia) and secondary intrinsic changes of 
muscle properties (contracture). As for sensory or cognitive deficits, our data do not 
underscore the clinical notion that loss of sensibility, neglect, or apraxia may increase the risk 
of developing post-stroke upper-extremity hypertonia. These findings are consistent with 
those of Patano et al. [25], who could not find any differences in sensory disturbances, 
aphasia, or visuospatial neglect between patients with prolonged muscular flaccidity and 
those with hypertonia in the sub-acute phase (2 to 6 months) after stroke. Hence, as yet, only 
a modest association between early muscle weakness and chronic hypertonia has been 
found by Leathly et al. [4]. 
The secondary goal of this study was to explore the time course of upper-extremity 
hypertonia during the first 26 weeks after stroke in patients with initial paralysis. Although it is 
generally assumed that muscle tone increases from flaccidity in the acute phase of stroke to 
various degrees of hypertonia in the long term [1, 2, 26], the patients with early (25% within 3 
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weeks after stroke), transient (10%), or late (15%) hypertonia in our cohort did not fit within 
this general idea. Sommerfeld et al. [5] reported hypertonia within the first week after stroke 
in 21% of their acute hospitalized patients as well. In contrast to the opinion of others [27], in 
our study early hypertonia was not correlated with previous stroke. In 3 patients who 
developed hypertonia within 6 weeks after stroke, muscle tone had normalized at 26 weeks, 
perhaps related to neural plasticity. At 26 weeks we identified another 6 patients in which 
hypertonia developed only after the third month post-stroke. It seems likely that secondary 
intrinsic changes of muscle properties contributed to this late hypertonia [28]. 
At 26 weeks after stroke, we did not find any difference in motor or functional recovery 
between patients with and those without hypertonia, which may be due to the fact that the 
majority of our patients ended up with a non-functional paralytic arm and hand. The unique 
influence of hypertonia on motor impairments and ADL performances is, no doubt, difficult to 
assess in a subgroup of patients with initial paralysis with such a poor chance of motor 
recovery. In addition, specifically patients with severe stroke may suffer from various other 
problems of, for example, mood, cognition, vision, and sensation, which may contribute to 
their overall disability. Lastly, the BI is probably not the best measure to assess ADL 
performances related to arm and hand function. When, for instance, hypertonia causes pain 
or discomfort or problems with arm positioning, dressing, or hygiene control, treatment that 
reduces hypertonia and prevents secondary complications may greatly benefit the patient on 
a functional level [12, 13], although such benefit does not need to be reflected in a change in 
the BI score. 
One of the possible limitations of this study is that upper-extremity hypertonia was clinically 
assessed using the AS, whereas instrumented analysis of electromyographic (EMG) and 
force signals from the upper-extremity muscles on passive stretching might have allowed 
better discrimination between active (i.e., contractions) and passive (i.e., stiffness) 
contributions to muscular resistance [3, 29]. However, instrumented tests are not yet 
available for routine clinical application, which is the reason that the AS and modified AS are 
still the most commonly used measures of adult spasticity in clinical practice. The AS is most 
frequently used as the primary outcome measure in intervention studies as well, and other 
scales, such as the tone assessment scale, can be regarded as modifications of the AS. All 
these measures are equally reliable regarding muscle tone assessment of the upper 
extremity [30]. Overall, there is a reasonable association between the (modified) AS and 
EMG responses in patients with hemiparetic stroke [31], which does not preclude a 
significant contribution of passive muscle properties to (particularly late) hypertonia. 
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Another limitation of our study may have been a lack of power to identify risk factors for 
upper-extremity hypertonia due to the still limited number of patients. We included merely 
patients with initial paralysis to optimize the risk of post-stroke hypertonia. This subgroup 
comprises only 19 to 30% of the stroke population at large and has a high risk of post-stroke 
death (62%) [32]. As a result, the inclusion rate was relatively low in just one academic 
hospital. However, 40 patients would have been sufficient to discriminate a moderate from an 
‘absent’ association between hypertonia and any clinical determinant (setting alpha at 0.05 
and 1-beta at 0.80). Hence, larger studies of high-risk patients will be needed to include the 
number of subjects to identify “weak” but significant associations. 
 
Conclusion 
The present study showed that a subgroup of patients with an initial paralysis of the upper 
extremity apparently has a substantial chance of developing hypertonia at any time after 
stroke. The observed incidence over the 26-week follow-up period was 63%. The prevalence 
of upper-extremity hypertonia during the first 26 weeks after stroke followed a rather dynamic 
course, with cases of early, transient, and late hypertonia. Even in this selected study sample 
with a high incidence of hypertonia, we could not identify any of the selected clinical 
characteristics as a risk factor for transient or persistent hypertonia. Unlike the stroke 
population in general, in patients with severe stroke and initial upper-extremity paralysis, 















































































Are neuroradiological or neurophysiological 
characteristics associated with upper- extremity hypertonia 
in severe ischemic supratentorial stroke? 
 








Objective: The primary aim of this study was to identify the neuroradiological and 
neurophysiological risk factors for upper-extremity hypertonia in patients with severe, 
ischemic, supratentorial stroke. 
Methods: Inception cohort of forty-three consecutive patients with an acute, ischemic, 
supratentorial stroke and an initial upper-extremity paralysis. Primary outcome: Upper-
extremity hypertonia was assessed by the Ashworth scale and clinically relevant hypertonia 
was defined as an Ashworth score equal to or more than 2. Any association of (clinically 
relevant) hypertonia with neuroradiological (lesion side, extent of lesion, and stroke history), 
and neurophysiological (motor-evoked potential and silent period) characteristics was 
investigated. 
Results: Associations between hypertonia and the selected neuroradiological and 
neurophysiological risk factors were generally low. Univariate analyses yielded none of the 
selected neuroradiological or neurophysiological characteristics as significantly associated 
with hypertonia.  
Conclusions: Despite the high incidence of hypertonia in these patients, we could not identify 




Spasticity is a characteristic component of the upper motor neuron syndrome in the post-
acute and chronic phases of stroke. The precise relationship between spasticity elicited by 
passive tendon or muscle stretch and the active movement capacity, however, remains 
unclear. In the upper extremity, spasticity may cause difficulty with basic arm and hand 
abilities, such as reaching and grasping, as well as with many more complex activities of 
daily living [1-5]. Functional effects of spasticity treatment seem to depend highly on a critical 
selection of subjects, individualized goal setting, and appropriate selection of outcome 
measures [6-9]. In particular, patients after severe stroke with a low potential for motor 
recovery may profit from a pro-active treatment approach to prevent disabling spasticity and 
the functional consequences of secondary complications, such as muscles stiffness, 
contractures, and pain. Against this background, it seems clinically relevant to assess, 
besides the probability of motor recovery, also the risk of developing spasticity in these 
patients early after stroke.  
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Studies on risk factors for post-stroke spasticity are, however, scarce and complicated by the 
inability of clinical measures to distinguish between the neural mechanisms and the 
secondary intrinsic changes of muscle properties. Indeed, the clinical assessment of 
spasticity incorporates both neural and non-neural mechanisms by grading resistance 
against passive stretch (hypertonia). As for clinical risk factors, as yet, only modest 
associations of early muscle weakness and a low initial Barthel Index (BI) with chronic 
hypertonia have been found [10]. In a companion paper describing the same selected study 
population of patients after stroke with an initial paralysis of the upper extremity and a BI of 0, 
we were unable to identify any clinical characteristic as an additional risk factor for early or 
persistent hypertonia, despite the high incidence of hypertonia observed in these patients 
[11]. In this perspective, it is a logical step to investigate whether specific neuroradiological or 
neurophysiological characteristics might be associated with early or persistent hypertonia.  
Neuroradiological assessments (magnetic resonance imaging or computerized tomography 
(CT) scan) in patients after acute stroke are performed on a routine basis to confirm 
diagnosis and differentiate lesion type. Some neuroradiological characteristics (lesion type, 
size, and site) have been associated with motor recovery and functional outcome, however, 
as yet, there remains much debate on whether stroke location or size are associated with 
hypertonia [12-15]. Clinical heterogeneity with regard to both patient-groups and time post-
stroke may be an important factor contributing to these inconsistencies in the literature. 
Transcranial magnetic stimulation (TMS) has also become appreciated as a diagnostic and 
prognostic tool in patients after stroke [16]. In tonically pre-activated muscles, TMS of the 
primary motor cortex induces a short-latency motor-evoked potential (MEP) in the 
electromyogram as an excitatory effect, followed by a transitory suppression of the 
electromyographic activity, the silent period (SP), as an inhibitory effect. Although motor 
recovery can be predicted reasonably well by TMS [17,18], early prediction of hypertonia 
based on TMS is much more difficult. In patients with sub-acute and chronic strokes due to 
focal vascular brain lesions an association has been found between shortening of the SP and 
hypertonia as assessed by the Ashworth scale (AS) [19-21]. Studies regarding these 
neurophysiological characteristics as potential risk factors for hypertonia in patients with 
acute stroke are, however, lacking. 
Against this background, we conducted a prospective cohort study including only acute 
stroke patients with an initial paralysis of the upper extremity to maximize the likelihood of 
observing hypertonia and, thus, to optimize the chance of identifying additional risk factors 
for post-stroke upper-extremity hypertonia. We investigated the association of 
neuroradiological (lesion side and extent) and neurophysiological characteristics (MEP and 
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SP) with early and late hypertonia, since these laboratory measures can be easily obtained 
in most hospitals with an acute stroke unit.  
 
Materials and Methods 
Patients 
As part of a larger study on the value of MEP in predicting motor and functional outcome 
after stroke [18], 43 consecutive acute patients with an ischemic supratentorial stroke were 
recruited during a 1.5-years’ period. These patients were admitted to the Department of 
Neurology at the Radboud University Nijmegen, Medical Centre. The diagnosis of stroke was 
made clinically by a neurologist according to the World Health Organization (WHO) clinical 
criteria [22] and confirmed by CT scan.  
Only patients presenting at day 1 after stroke with no voluntary muscle activity and no 
muscle tone at the elbow, wrist, or finger flexors (Brunnstrom stage I [23]) were included 
within the first 7 days after stroke. Patients with a poor prognosis for survival (loss of 
consciousness, severe CT abnormalities, and severe co-morbidity) as well as patients with 
severe pre-existing impairments of the upper extremity of any type (e.g., rheumatic 
deformities, contractures) were excluded. Patients with a history of craniotomy, epilepsy, 
cardiac prosthetic valve or pacemaker implantation, or severe polyneuropathy were also 
excluded. The local ethics committee approved the study protocol and written informed 
consent was obtained from all patients before study entry.  
Each patient received ‘best medical treatment’ according to the guidelines of the Netherlands 
Society of Neurology, ensuring that each patient received physiotherapy to maintain optimal 
passive and active range of motion of all upper extremity joints from day 1 after stroke. 
However, for the first 3 weeks after stroke, no specific therapy was initiated aimed at 
facilitation of hand function recovery. 
Potential risk factors 
Neuroradiological assessment 
In each patient, a CT scan of the brain was made twice; the first time on the day of admission 
and, the second time, at week 1 after stroke to delineate the structural lesion. Both an 
independent neuroradiologist and a neurologist assessed the CT scans of all patients, 
independently of one another. Evidence of previous stroke (‘present’ or ‘absent’) as well as 
the extent of the (structural) vascular lesions (‘extensive’ or ‘focal’) were recorded. Extensive 
stroke was defined as lesions with a diameter equal to or more than 5 cm and / or located in 
both subcortical and cortical areas. Stroke lesions with a diameter less than 5 cm and 
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restricted to the subcortical areas (subcortical white matter, or basal ganglia, or internal 
capsule) were regarded as focal. Both assessors were blinded with regard to the 
neurophysiological and clinical assessments. In the case of disagreement between the 
assessors, consensus was established afterwards. 
Neurophysiological assessment 
TMS of the motor cortex was performed twice in each patient; at first, within 1 week after 
stroke (t1) and, secondly, at 3 weeks after stroke (t2) by the same experienced clinical 
neurophysiologist. This clinical neurophysiologist was blinded with regard to the results of the 
clinical and neuroradiological assessments. Patients were positioned comfortably in a supine 
position. TMS was performed through a 90 mm circular coil placed in a tangential plane 
above the vertex and powered by a Magstim 200 magnetic stimulator. The stimulus intensity 
was set at maximum stimulator output (100% = 2 Tesla). To obtain a preferential activation of 
each hemisphere, a clockwise inducing current flow was used for the right hemisphere and a 
counter-clockwise current for the left hemisphere. MEPs were recorded at t1 and t2 from the 
biceps brachii muscle (BB) and the abductor digiti minimi muscle (ADM) on both the affected 
and the unaffected side. SPs were recorded at t1 and t2 from the ADM, as a representative 
muscle for distal motor function of the upper extremity. Recordings were made using an 
Oxford Synergy electromyograph with filter settings of 20 Hz and 3 kHz (amplifier range 100 
mV and recording sensitivity of 0.5 mV / bit). A 500-ms post-stimulus period was analysed. 
The MEPs and SPs were preferably recorded when facilitated by a slight voluntary ADM 
contraction. When patients could not elicit a contraction of the affected hand muscle, they 
were asked to activate the non-paretic ADM [24]. At least two responses were obtained to 
assess the reproducibility. The presence of a MEP was defined as any reproducible 
response with minimal peak-to-peak amplitude of 200 µV. The absence of a positive MEP at 
3 weeks after stroke was regarded as a potential risk factor for post-stroke hypertonia. 
Responses with the highest MEP amplitude were used for analysis. The SP length was 
measured from ADM-MEP onset until the return of uninterrupted voluntary electromyography 
activity. Responses with the shortest SP length were used for analysis. Data from the non-
paretic arm were compared with normative data and used as a reference. Finally, the BB and 
ADM responses (mean MEP amplitude and SP duration) were studied separately for both 
the paretic and the non-paretic side. 
Outcome assessment 
Hypertonia was clinically assessed by grading muscle tone through the AS [25]. Muscle tone 
(grade 0 to 4) was assessed within the first 24 hours and consecutively at weeks 1, 2, 3, 6, 
12, and 26 after stroke under standardized test conditions by a rehabilitation physician. The 
precise technique of assessment has been described in a companion paper [11]. Clinically 
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relevant hypertonia was operationally defined as an AS score equal to or greater than 2 in at 
least one joint. 
Data analysis  
The MEP amplitude and SP duration obtained from the ADM and the BB on the paretic side 
were compared with the corresponding values obtained from the non-paretic side using 
Student’s t-test. 
In addition, from 2x2 contingency tables, positive and negative predictive values for each of 
the potential risk factors with their 95% confidence intervals were calculated. In case of 
positive outcome of the univariate analysis, multiple backwards logistic regression was 
planned to determine the explained variance by each characteristic with regard to hypertonia, 
independent of its possible association with other characteristics. 
 
Results 
Neuroradiological and TMS characteristics  
Three patients were excluded from the study; 2 patients died within the first two weeks after 
stroke and another patient suffered from a recurrent stroke at week 13 resulting in a poor 
prognosis for survival. All 3 patients continued to have a flaccid paralysis of the upper 
extremity from clinical presentation. Thus, 40 patients, 20 women and 20 men, completed the 
study. The median age was 68 years (interquartile range 59 to 77 years). The 
neuroradiological characteristics of these 40 patients are shown in Table 1. Sixteen (40%) 
patients had had previous stroke, whereas 24 (60%) patients had had a first-ever stroke. 
Twenty-nine patients had extensive lesions that were located in the territory of the middle 
cerebral artery, involving cortical (n=2), subcortical (n=1), or both cortical and subcortical 
areas (n=26). Eleven patients had a focal, subcortically located lesion. In 4 of these patients 
the lesion was restricted to the basal ganglia.  
TMS of the motor cortex was performed in all patients, however, 4 patients refused the 
second MEP assessment. Two of these patients developed hypertonia, 1 patient within the 
first week after stroke. In the other patient, hypertonia was observed from the 6th week after 
stroke. Thus, the complete MEP dataset was available for only 36 patients. The quantitative 
aspects of the TMS recordings are summarized in Table 2 for the subgroups of patients in 
which a positive MEP was obtained at t1 and t2. At both times, the MEP amplitudes in the BB 
and the ADM were significantly lower on the paretic than on the non-paretic side.  
 




      Number (n) 
       
Stroke history  First ever    24 
  Previous    16 
       
Lesion side  Left    22 
  Right    18 
       
Infarct size   Small (<2cm)    1 
  Moderate (2‐5 cm)    16 
  Extensive (>5 cm    23 
       
Infarct localisation  Cortical    2 
  Subcortical    12 
  Cortical/subcortical    26 
       
Extent of stroke lesion  Focal    11 
  Extensive    29 
       
 
TMS of the motor cortex was performed in all patients, however, 4 patients refused the 
second MEP assessment. Two of these patients developed hypertonia, 1 patient within the 
first week after stroke. In the other patient, hypertonia was observed from the 6th week after 
stroke. Thus, the complete MEP dataset was available for only 36 patients. The quantitative 
aspects of the TMS recordings are summarized in Table 2 for the subgroups of patients in 
which a positive MEP was obtained at t1 and t2. At both times, the MEP amplitudes in the BB 
and the ADM were significantly lower on the paretic than on the non-paretic side.  
Potential risk-factors for post-stroke hypertonia 
From a clinical point of view, we were most interested in predicting persistent hypertonia. 
Therefore, we considered hypertonia at the 26th week after stroke as the primary outcome. 
Both at t1 and at t2 no differences in MEP amplitude on the paretic side could be found 
between patients with and those without hypertonia (Table 3). At t1 no SP could be elicited at 
the paretic side in any of our patients, whereas at t2 only in 4 patients a SP could be 
determined: 2 patients with and 2 without hypertonia. No difference in SP duration between 
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In univariate analyses, all associations between hypertonia at week 26 and the selected 
potential risk factors were low and statistically not significant (Table 4). Table 4 shows the 
positive and negative predictive values with their 95% confidence intervals for all factors. The 
positive predictive values varied from 0.52 to 0.68 and the negative values from 0.36 to 0.61. 
Changing the definition of persistent hypertonia into AS equal to or more than 2 at the 12th 
week or at the 6th week after stroke yielded similar results. Even if clinically relevant 
hypertonia was defined as AS equal to or more than 1, or if hypertonia at any time after 
stroke was used as the primary outcome, no association with the selected potential risk 
factors could be demonstrated.  
 
Discussion 
This study aimed to investigate to what extent selected neuroradiological and 
neurophysiological characteristics can be considered as risk factors for developing upper-
extremity hypertonia in patients with severe, ischemic, supratentorial stroke. With regard to 
the neuroradiological assessments, the observed lack of association between the extent of 
the vascular lesion and hypertonia is consistent with the study of Patano et al. [12], who also 
found no correlation between lesion volume and muscle tone. Having had a previous stroke 
or the side of the lesion was also not significantly associated with hypertonia. In general, the 
lack of association between stroke location and hypertonia in our study may have been 
influenced by the fact that the majority of our patients suffered from extensive lesions on CT 
involving both the cortical and subcortical areas. In the literature, there also remains much 
debate on the influence of stroke location on the occurrence of hypertonia [12-15], which 
may well be related to the fact that the applied methods to localize and measure the lesions 
lack sufficient sensitivity.  
The selected neurophysiological measures obtained by TMS did not show a significant 
association with the occurrence of hypertonia either. Although it has been shown that muscle 
weakness is a clinical risk factor for post-stroke hypertonia, the absence of an ADM-MEP at 
the third week after stroke was not associated with hypertonia. This negative result can be 
explained by the fact that hypertonia may not directly result from damage to the corticospinal 
pathways, but from concomitant damage to the para-pyramidal pathways [26].  
At the cerebral level, there may be a loss of the cortical drive to several inhibitory centres in 
the brainstem, e.g., the origin of the lateral reticulospinal tract, resulting in disinhibition of 
bulbar and spinal reflexes [26-28]. This loss of cortical drive may be due to lesions within 
areas projecting to the primary motor cortex, such as the primary somatosensory area, 
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supplementary motor area, the premotor area, basal ganglia, thalamus, and cerebellum. 
These brain areas provide important modulatory inputs to the primary motor cortex and 
lesions within these areas might, therefore, lead to a subsequent change in the balance 
between excitatory and inhibitory influences on the intra-cortical motor neurons that project to 
inhibitory centres at the level of the brainstem. Although these para-pyramidal pathways 
cannot be directly assessed, they might be indirectly assessed by TMS. Nevertheless, the 
results of this study do not support this clinical reasoning. 
In chronic stroke patients, Uozumi et al. [19] and Cruz-Martinez et al. [20] found a possible 
association between TMS-induced inhibitory phenomena (SP) and hypertonia. The authors 
hypothesized that in the course of the development of hypertonia, cortical inhibition 
decreases and, subsequently, the SP shortens. In patients with a subacute stroke (within 2 
weeks post-stroke) with a focal ischemic lesion in the territory of the middle cerebral artery, 
Catano et al. [21] observed a decrease in SP duration with increasing muscle contraction. 
This contraction-induced reduction of the SP was associated with hypertonia. Although this 
(relative) inefficacy of the inhibitory mechanisms might be a risk factor for hypertonia, the 
phenomenon of contraction-induced reduction of the SP could not be assessed in our study. 
The voluntary contraction of the hand muscles in the majority of our patients was so severely 
impaired that often no SP could be recorded. Even patients in whom a SP could be elicited 
lacked the ability to elicit different degrees of voluntary contraction. As a result, in only 4 out 
of 40 patients (10%) a SP could be determined at 3 weeks after stroke. The mean duration of 
the SP in 2 patients with hypertonia did not differ from the mean SP duration in 2 other 
patients without hypertonia. However, due to these small numbers of patients, the finding 
that the SP was not related to hypertonia in this acute-phase study must be interpreted with 
care. 
It is important to note that this study was restricted to a homogeneous group of patients with 
acute stroke with initial paralysis of the upper extremity and a BI of 0. Predicting hypertonia 
using neuroradiological and neurophysiological characteristics as potential risk factors in 
such a severe subgroup restricts generalization of the outcomes to less severely affected 
patients. Moreover, this severe subgroup is probably not the most appropriate group to study 
the value of TMS-induced inhibitory phenomena.  
These patients lack the ability to move their affected limb voluntarily and selectively, which is 
necessary to generate a MEP and a subsequent SP. 















































































































































































































































































































































































Another possible limitation of this study may still be a lack of power due to the limited number 
of patients. We included merely patients with initial paralysis to optimize the risk of post-
stroke hypertonia (approximately 62%). This subgroup comprises however, only 19 to 30% of 
the stroke population at large [29]. As a result, the inclusion rate was relatively low in just one 
academic hospital. Still, 40 patients should be a sufficient number to distinguish a ‘moderate’ 
from an ‘absent’ association between hypertonia and any clinical determinant (setting alpha 
at 0.05 and 1-beta at 0.80). Larger studies of high-risk patients are needed to identify 
“weaker”, but significant, associations. 
 
Conclusion 
As yet, the association of neuroradiological stroke characteristics as well as TMS-induced 
excitatory and inhibitory phenomena with hypertonia seems to be weak, even in patients with 
severe stroke and an upper-extremity paralysis. In addition, TMS characteristics, such as the 
contraction-induced inhibition of the SP, are not applicable in these patients during the acute 
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Objective: The primary aim of this study was to identify secondary functional changes in the 
peripheral motor units of the paretic upper extremity in patients with severe ischemic stroke 
and to determine how these changes develop during the first weeks. 
Methods: An inception cohort of 27 consecutive patients with an acute ischemic 
supratentorial stroke and an initial upper-extremity paralysis was compared to 10 healthy 
control subjects. The ulnar nerve was electrically stimulated proximal to the wrist and 
electromyographic recordings were obtained from the abductor digiti minimi (ADM) muscle. 
Hemiparetic side mean values of the compound muscle action potential (CMAP) at 1 and at 
3 weeks after stroke were compared with the non-paretic side and with CMAP values 
obtained from healthy controls. 
Results: The mean CMAP amplitude in patients was significantly lower on the paretic side 
compared with both the non-paretic side and with controls. Decrease in CMAP amplitude 
was observed in more than half of the stroke patients, sometimes as early as 4 days after 
stroke, and persisted in most cases. Whenever present, it was accompanied by absence of 
motor recovery at that specific time after stroke. 
Conclusions: Decreased CMAP amplitude in the ADM muscle can be seen already in the 
very acute phases after stroke unrelated to peripheral neuropathy, radiculopathy, or 
plexopathy, and it is accompanied by absence of upper motor neuron recovery. This 
knowledge is important for interpreting electrophysiological data in stroke patients. 
 
Introduction 
In stroke patients, transcranial magnetic stimulation (TMS) is enjoying increased use as a 
tool for studying cortical plasticity and subsequent reorganization processes in the case of 
paresis or paralysis after stroke. In TMS studies focusing on plasticity after upper motor 
neuron (UMN) lesions, it is assumed that the lower motor neuron (LMN) has not been 
affected and hence, no attention has been directed to nerve function distal to the level of the 
brain lesion. However, it is well known that injuries to the peripheral nerves lead to changes 
in the functional organization of the sensori-motor cortices [1-4]. From animal studies, we 
know that this cortical plasticity already occurs within hours after the primary lesion of the 
peripheral nervous system [2, 4]. Given this strong relationship between the central and 
peripheral nervous system, it seems possible that UMN lesions lead to functional changes in 
the LMN as well.  
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In UMN lesions, the LMN may become functionally depressed or undergo transsynaptic 
degeneration through loss of synaptic input and lack of activation. Hara and associates [5, 6] 
observed a decreased number of functional motor units already in the second week after 
stroke by F-wave motor unit number estimation (MUNE). This decrease was related to the 
severity of paresis; in general the loss was greater and more prolonged in patients with 
severe than in those with mild paresis. Because Hara et al. [6] included patients who had a 
supratentorial stroke at least 9 days (on average 19 days) after stroke, it remains unclear if 
these LMN changes already occur in the very acute phase after stroke. 
The motor unit decrease secondary to UMN lesions in the acute phase after stroke might be 
a confounding factor in studying cortical plasticity by TMS because the induced motor 
evoked potential (MEP) depends on the conductivity of the peripheral structures as well. 
Peripheral dysfunction may prevent axons from responding appropriately after TMS. To 
validly study neuronal plasticity in the acute and subacute phases after stroke, we should 
understand the underlying mechanisms of both UMN and LMN changes and their time 
course. In addition, and probably more clinically relevant, motor unit decrease secondary to 
UMN lesions might be a confounding factor in interpreting electrophysiological data in (sub) 
acute stroke patients as well. EMG or nerve conduction studies in acute stroke patients with 
considerable muscle weakness may lead to diagnostic errors, suggesting a peripheral 
neuropathy when none might exist. 
Hence, the primary aim of this study was to determine whether secondary changes in 
peripheral motor units are present in the very acute (< 1 week) and in the subacute (≥3 
weeks) phases after stroke. Against this background, we conducted a cohort study including 
only patients with an initial paralysis of the upper extremity after a supratentorial stroke to 
maximize the likelihood of changes in LMN function. Changes in LMN function were studied 
through recording compound motor action potential (CMAP) characteristics in the abductor 
digiti minimi (ADM) muscle after distal stimulation of the ulnar nerve in both the paretic and 
nonparetic arms of stroke patients and by comparing these results with CMAP characteristics 







Materials and Methods 
Patients  
As part of a larger study on the value of MEP in predicting motor and functional outcome 
after stroke [7], 27 consecutive acute patients with an ischemic supratentorial stroke in whom 
electromyographic (EMG) recordings were made using an Oxford Synergy electromyograph 
were included in this study. These patients were admitted to the department of neurology at 
the Radboud University Nijmegen, Medical Centre. The diagnosis of stroke was made 
clinically on admission by a neurologist according to the WHO clinical criteria [8] and 
confirmed by computed tomography scanning. 
Only patients presenting with stage I of the upper extremity according to Brunnstrom (i.e., no 
tone and no voluntary muscle activity at the elbow, wrist, or finger flexors) [9] at day 1 were 
included within 7 days after stroke. Patients with a poor prognosis for survival (loss of 
consciousness, severe CT abnormalities, and severe co-morbidity) as well as patients with 
severe pre-existing impairments of the upper extremity of any type (e.g., rheumatic 
deformities, contractures) were excluded. Patients were screened to ensure that they had no 
contraindication for TMS (e.g., history of craniotomy, epilepsy, cardiac prosthetic valve or 
pacemaker implantation, or severe polyneuropathy). From day 1 after stroke, each patient 
received a standard medical treatment according to the guidelines of the Dutch Society of 
Neurology, including a multidisciplinary team approach. Each patient received physiotherapy 
treatment to maintain optimal range of (joint) motion and to regulate muscle tone of the upper 
extremity; however, no specific therapy was initiated to improve hand motor recovery. 
A total of 10 healthy volunteers were similarly investigated to establish reference values. 
Volunteers were recruited among the relatives of patients participating in an amyotrophic 
lateral sclerosis study [10]. All control subjects were free from central and peripheral nervous 
system diseases and did not use any medications with possible effects on the nervous 
system.  
After a detailed explanation, all subjects gave written informed consent to participate in this 
study, which was approved by the local ethics committee. 
Clinical assessment 
Within the first 24 hours after stroke, the treating neurologist assessed all 27 patients with 
regard to their initial motor functions, muscle tone, and level of consciousness. All 
consecutive clinical assessments of motor and sensory functions, muscle tone, and stretch 
reflexes were performed at weeks 1, 2, 3, 6, 12, and 26 after stroke by a rehabilitation 
physician. Motor functions were assessed according to the upper-limb subset of the Fugl-
Meyer Motor Assessment (FMA) [9]. Sensory deficits were assessed by clinical examination 
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of light touch and pinprick of the hemiparetic arm. Biceps and triceps tendon reflexes were 
quantified according to the Mayo Clinic scale for tendon reflex assessment (range, -4 to +4) 
[11]. Hyperreflexia was considered present if the tendon reflex on the paretic side was ≥ +1.  
Hypertonia was clinically assessed by grading muscle tone through the Ashworth scale (AS) 
under standardized test conditions [12]. Clinically relevant hypertonia was operationally 
defined as an AS score equal to or greater than 2 in at least one joint [13]. 
The diagnostic criteria following physical examination of Kingery et al. [14] were used to 
diagnose plexopathy, radiculopathy, or neuropathy. All three of the following criteria had to 
be observed: 
1. A focal weakness in the distribution of the suspected nerve injury greater than the 
weakness observed in the rest of the paretic upper extremity. 
2. At least one of the following findings present only in the distribution of the suspected 
nerve injury:  
a. Diminished stretch reflexes relative to the rest of the hemiparetic upper extremity. 
b. Objective sensory loss. 
c. Muscle atrophy on visual inspection. 
3. An absence of hyperreflexia or rigidity in the distribution of the suspected nerve. 
 
Electrophysiological assessment 
In 27 patients, electrophysiological assessment of the ADM CMAP was performed twice, at 
first within 1 week (mean, 6.8, median, 7 days) after stroke (t1) and second, at 3 weeks 
(mean, 28.7, median, 25 days) after stroke (t2) by the same experienced clinical 
neurophysiologist. In addition, in the 10 healthy control subjects electrophysiological 
assessment of the ADM CMAP was performed once, using the same technique as in stroke 
patients.  
The ADM muscle was selected for this study because it was regarded as representative of 
distal motor functions of the upper extremity. CMAPs were recorded at t1 and t2 from the 
ADM on both the paretic and nonparetic side. CMAPs were recorded using surface 
electrodes placed in a tendon belly montage. EMG electrodes had parallel detection surfaces 
(1 cm in diameter) and were located 3 cm apart. The active electrode was positioned over 
the belly of the ADM. The inactive electrode was positioned on the tendon of the ADM. The 
ground electrode was positioned between the recording and the stimulus sites at the wrist 
over the head of the ulna. Electromyographic recordings were made using an Oxford 
Synergy electromyograph with filter settings of 20 Hz and 3 kHz (amplifier range 100 mV and 
recording sensitivity of 0.5 mV / bit). The ulnar nerve was stimulated just proximal to the wrist 
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both on the paretic and on the nonparetic side. CMAPs were evoked with supra-maximal 
stimulation using single square electrical pulses of 0.2-ms duration. Amplitude of CMAPs as 
well as distal motor latencies were determined over a standardized distance of 80 mm. The 
ADM responses were studied separately for both the paretic and the nonparetic side, and 
both responses were related to the ADM responses in healthy control subjects. Responses 
with the highest CMAP were used for analysis. Finally, CMAP amplitude ratios (CMAP-
amplitude paretic / nonparetic side) were determined in stroke patients and related to the 
amplitude ratios in healthy control subjects (CMAP-amplitude nondominant / dominant side). 
Statistical analysis 
Shapiro-Wilks tests of normality ensured the appropriateness of applying parametric 
statistics. Paired-sample t-tests were used to determine whether differences in CMAP 
characteristics were evident between the paretic and nonparetic side in stroke patients and 
between the dominant and nondominant side in the healthy control subjects. Paired-sample 
t-tests were also used to determine whether CMAP characteristics at both the paretic and 
nonparetic side differed between the first and the second electrophysiological assessment. 
Independent-sample t-tests were used to determine if these differences were significant 
between stroke patients and healthy control subjects. The Mann-Whitney test was used to 
compare amplitude ratios between stroke patients and healthy control subjects. The required 
2-tailed significance level was set at 0.05. All analyses were performed using the Statistical 




Twenty-seven stroke patients, 12 women and 15 men, were enrolled in the study. Although 
none of our patients had any pre-existing impairments of the upper extremity, radiological 
assessment showed a previous stroke in 12 patients (44%), whereas 15 patients (56%) had 
had a first-ever stroke. Seventeen patients had stroke lesions located in the left hemisphere, 
whereas 10 patients had lesions located in the right hemisphere. Twenty-one patients had 
extensive lesions that were located in the territory of the middle cerebral artery involving 
cortical (n=2), or both cortical and subcortical areas (n=19). Six patients had a focal, 






















The mean age of the stroke patients was 69.5 years (standard deviation, 10.0; range, 46 to 
84 years). Clinical assessment failed to identify stroke patients who met the diagnostic 
criteria for a brachial plexus injury, radiculopathy, or neuropathy both in the initial and in the 
follow-up examinations. None of our patients showed evident proximal or distal muscle 
atrophy or edema within the first week after stroke. If present, areflexia, flaccidity, sensory 
loss, and muscle weakness were not limited to, or more profound in the distribution of a 
specific nerve, root, trunk, or cord. Results of the clinical assessments are summarized in 
Table 1.  
The control group consisted of 9 women and 1 man. The mean age of the control group was 
61.8 years (standard deviation, 10.9; range, 38 to 80 years). 
The electrophysiological assessment was performed in all patients and control subjects, 
however, 2 patients refused the second assessment and 2 other patients died in the first 
weeks after their stroke. Thus, the electrophysiological assessment at 3 weeks after stroke 
was available for only 23 patients.  
Electrophysiological outcomes 
In the healthy control subjects, no significant differences in CMAP characteristics between 
the dominant and nondominant upper extremity were found. Therefore, these data were 
pooled for comparison with the stroke patients. 
The quantitative aspects of the CMAP recordings are summarized in Table 2 for all 
participants. The CMAP amplitude was significantly smaller on the paretic side compared to 
the nonparetic side of the stroke patients (t = -7.72, p = 0.000 at t1, and t = -7.80, p = 0.000 
at t2) and compared with healthy control subjects (t = -4.862, p = 0.000 at t1, and t = -6.13, p 







  Paretic side    Non‐paretic side    (Healthy) Control 
subjects 
CMAP amplitude                 
week 1    27    8.75 ± 2.76 mV    12.00 ± 2.77 mV*     12.53 ± 2.33 mV**  
week 3    23    7.62 ± 2.77 mV    11.05 ± 2.68 mV*     12.53 ± 2.33 mV** 
             
CMAP latency                 
week 1    27    2.59 ± 0.51 ms    2.48 ± 0.46 ms    2.63 ± 0.32 ms 
week 3    23    2.78 ± 0.40 ms    2.77 ± 0.45 ms    2.63 ± 0.32 ms 







    Number (n)    Stroke patients    Healthy control subjects    P value* 
           
CMAP ratio                 










           
Values are mean ± SD; * Mann Whitney test 
Overall, there was no statistical difference between the mean CMAP values of the control 
subjects and those obtained from the nonparetic arm of the stroke patients, neither at t1 nor 
at t2. Overall, the CMAP amplitude at t1 did not differ from the amplitude at t2 at the 
nonparetic side (t = 1.76, p = 0.92) and at the paretic side (t = 1.94, p = 0.70). As for distal 
motor latencies, no statistical differences were found between the paretic and nonparetic 
sides, or between the stroke patients and the healthy control subjects. CMAP amplitude 
ratios in stroke patients were significantly different from those in healthy control subjects both 
at t1 and at t2 (Table 3). Correcting the analysis for motor recovery by excluding the patients 
with some degree of motor recovery at either t1 or t2 yielded similar results. 
 
More than half of the stroke patients showed an abnormally decreased CMAP amplitude ratio 
at t1, lying outside the range of amplitude ratios found in healthy control subjects. In 3 
patients decreased CMAP amplitude ratios were seen as early as 4 days after stroke (Figure 
1). Three patients showed upper-extremity motor recovery already one week after stroke 
onset at which time their CMAP amplitude ratio fell within the range of amplitude ratios found 
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in healthy control subjects. One of these 3 patients refused the second assessment. Two 
other patients without motor recovery at week 1 showed motor recovery 3 weeks after stroke. 
 
Hence, a decreased CMAP amplitude ratio was always accompanied by absence of motor 
recovery at that specific time after stroke (Figure 1). During the follow-up period, the 
individual amplitude ratios followed a rather variable course with cases showing a decrease, 
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Discussion 
In this longitudinal study, a homogeneous sample of patients with initial paralysis of the 
upper extremity caused by ischemic supratentorial stroke was included to identify secondary 
functional changes in LMN. Decreased CMAP amplitudes in the ADM muscle on the paretic 
side were present in the majority of patients who had no signs of motor recovery on average 
1 week after stroke and persisted in the subacute phase (after the third week post stroke) in 
patients without motor recovery. Hara [5, 6] and Lukacs [15] and their associates have 
reported decreased CMAP amplitudes in the ADM muscle on the paretic side at least 9 days 
after stroke onset in a more heterogeneous sample of patients who had various degrees of 
paresis. This is the first longitudinal study reporting decreased CMAP amplitudes as early as 
4 days after stroke in paralytic patients without clinical signs of peripheral neuropathy. 
Some authors have suggested that the decrease in CMAP amplitude in the paretic upper 
extremity reflects a reduction in functional motor units, i.e., the number of units that can be 
excited by electrical stimulation [15, 16]. Hara et al. [5, 6] demonstrated a decrease in 
functional motor units by the F-wave MUNE. This decrease in functional motor units was 
accompanied by fibrillation potentials and positive sharp waves in the needle EMG observed 
at least 9 days after stroke. Other studies have recorded a high incidence of fibrillation 
potentials and positive sharp waves in the needle EMG from the second week after stroke as 
well [5, 6, 14, 15, 17, 18], remaining on a nearly constant level up to 3 to 4 months thereafter 
[6, 14]. Fibrillation potentials and positive sharp waves were never observed before 9 days 
after the initial stroke. Because these fibrillation potentials and positive sharp waves did not 
depend on denervation of the LMN, Spaans and Wilts [18] introduced the term pathologic 
spontaneous muscle fiber potentials (SMFP). In general, the incidence of SMFP was closely 
related to the severity of the paresis with greater and more prolonged occurrence in patients 
with severe than in those with mild paresis [6, 14, 15, 19].  
Considering the data available in the literature and those provided by the present study, the 
functional changes in the LMN after stroke might take place in a specific sequence. 
McComas et al. [16] first reported the concept of “dying back” neuropathy of the LMN as a 
result of UMN lesions. UMN lesions may cause loss of synaptic input and lack of activation of 
the spinal alpha motor neurons, which become functionally inactive or undergo transsynaptic 
degeneration [16, 17]. Dysfunction of these anterior horn cells results in a disturbance of the 
axonal flow, leading to axonal degeneration which starts proximally and extents to distal 
(Wallerian degeneration). Impaired axonal transport secondary to functional disturbance of 
spinal alpha motor neurons may then lead to a dysfunction of the neuromuscular 
transmission at the motor end plate and a subsequent decrease in the CMAP amplitude [19, 
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20] and pathological SMFP. Maintaining a sufficient axonal flow in a long neuron seems to 
require more energy from the anterior horn cells than maintaining sufficient flow in a short 
neuron [17]. Therefore, the distal upper-extremity muscles show the most prominent 
functional changes [17]. The SMFP found in the subacute phase after stroke tended to 
disappear after 6 weeks; however, motor unit loss neither progressed nor improved [6, 15, 
17, 18]. Apparently, once it occurs, motor unit loss persists for a long time. In the chronic 
phase of stroke, a slight enlargement of active motor units can be seen that can be explained 
by restoration of axonal function or by collateral reinnervation. Both mechanisms of recovery 
may lead to an increased number of muscle fibers that can be activated and may explain the 
recovery of the CMAP seen in the chronic stage after stroke [15]. 
From this point of view, it is important to realize that one should be informed about both UMN 
and LMN changes when using TMS to study neuronal plasticity in the acute and subacute 
phases in severe stroke patients. Motor unit decrease secondary to UMN lesions might be a 
confounding factor because the observed MEP depends on the conductivity of the peripheral 
structures as well. In future studies it is necessary to look at changes in motor unit structure 
and function over a longer time period to determine how these changes in LMN function 
influence motor recovery following stroke. 
Perhaps the most important clinical implication of this study, however, is that a decrease in 
CMAP amplitude and SMFP both may be caused by an UMN lesion and need not be related 
to an associated neuropathy, radiculopathy, or plexopathy of the paretic limb. Hence, studies 
relying solely on electrophysiological data to identify plexopathy, radiculopathy, or 
neuropathy in stroke patients may lead to diagnostic errors because of the high incidence of 
EMG abnormalities, which could mimic a plexopathy, radiculopathy, or neuropathy [14, 18]. 
Because of these EMG abnormalities, EMG has limited validity in diagnosing concomitant 
peripheral neuropathy in case of stroke, unless physical examination fails to demonstrate 
UMN symptoms in the paretic extremity. In that case, measuring the conduction latencies 
across the plexus and determining the CMAP amplitudes in the distribution of the suspected 
injury are recommended [14, 18]. 
 
Conclusion 
As a direct consequence of the stroke lesion and subsequent loss of central drive, 
adjustment of peripheral structures takes place. Spinal alpha motor neurons may become 
functionally depressed but may still survive after stroke. A decreased CMAP amplitude in the 
ADM muscle can be seen already in the very acute phases after stroke unrelated to 
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peripheral neuropathy, radiculopathy, or plexopathy. Whenever present, it was accompanied 
by absence of motor recovery at that specific time after stroke. This knowledge is important 
for interpreting electrophysiological data in stroke patients. Longitudinal studies are needed 
that look at these changes in motor unit structure and function over a longer time period to 
determine how these changes in LMN function develop and how they influence motor 
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Objective: The primary aim of this study was to compare stimulus-response characteristics of 
both motor evoked potentials (MEPs) and silent periods (SPs) induced by transcranial 
magnetic stimulation (TMS) in proximal and distal upper-extremity muscles. 
Methods: Stimulus-response curves of MEPs and SPs were obtained from the biceps brachii 
(BB) and abductor digiti minimi (ADM) muscles in 15 healthy participants. A non-linear mixed 
model was used to fit the stimulus-response curves to a sigmoid Boltzmann function.  
Results: Small residuals of the function were found for MEPs and SPs in both muscles. 
Higher maximal MEP amplitudes were found for the BB compared to the ADM (p < 0.01). 
The active motor threshold to obtain a SP was less for the ADM compared to the BB (p < 
0.01). The slope parameter of the function of the SP duration was steeper and more variable 
in the ADM than in the BB (p < 0.01). For the MEP amplitude no difference in active motor 
threshold and slope of the function was found between both muscles.  
Conclusions: Excitatory (MEP) and inhibitory (SP) effects of TMS differ between proximal 
arm and distal hand muscles in healthy participants. The adequate fit of our model suggests 
that this model can be used to study between and within subject changes in future studies.  
 
Introduction 
Transcranial magnetic stimulation (TMS) of the human motor cortex is a noninvasive 
technique to assess the integrity of the corticospinal motor pathways. TMS elicits a short-
latency motor evoked potential (MEP) as an excitatory effect that can be recorded by surface 
electromyography (EMG) in the target muscles. In pre-activated muscles, TMS of the primary 
motor cortex also induces a transitory suppression of the EMG-activity after the short-latency 
MEP as an inhibitory effect, referred to as the silent period (SP) [1-4]. The SP has been 
proposed as a measure of the excitability of the cortical inhibitory circuits, whereas the MEP 
has been proposed as a measure of the excitability of the facilitatory circuits [2].  
Both the MEP amplitude and the SP duration depend on the stimulus intensity. With 
increasing stimulus intensities both the MEP amplitude and the SP duration increase until 
they reach plateau values [2, 5-8]. The plateau phase of the MEP amplitude, however, 
seems to be achieved at lower stimulus intensities compared to the plateau phase of the SP 
duration [8]. The MEP and the SP differ in their response to muscle (pre)activation as well. 
TMS performed during voluntary muscle contraction evokes MEPs with a shorter latency and 
a higher amplitude than when the muscle is at rest [5], whereas the SP duration is relatively 
unaffected by the level of muscle pre-activation [2, 3, 5]. Partly because of these differences, 
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it has been suggested that the facilitatory mechanisms involved in the MEP are 
physiologically different from the inhibitory mechanisms contributing to the SP [1, 2,  4, 5, 9].  
Both the MEP and the SP have been used to predict post-stroke motor recovery [10-16]. In 
stroke patients with an initial paralysis of the upper extremity, the presence of an early MEP 
within the first weeks after stroke showed good positive predictive value (PPV = 1, 35 
patients) for regaining hand motor function at 6 months after stroke. The negative predictive 
value, however, was substantially lower (NPV = 0.88, 35 patients). Not all patients with hand 
motor recovery could be identified by the presence of an early MEP [17]. With regard to the 
SP, Traversa et al. [18] discovered that in stroke patients with a moderate paresis of the 
upper extremity the SP shortened during recovery and that the amount of shortening 
correlated with the degree of hand function recovery [18, 19]. However, a review on the role 
of the SP in predicting post-stroke motor recovery showed rather inconclusive results, which 
may be due to methodological differences between the studies [20].  
TMS studies on post-stroke motor recovery show considerable heterogeneity in patient 
characteristics, time of evaluation after stroke, stimulation procedures, and methodology, 
which could all be responsible for the differences between studies [20, 21]. MEP and SP are 
usually elicited at stimulus intensities corresponding to a certain percentage of the 
corticomotor threshold or the stimulator output. Due to their dependency on the stimulus 
intensity, changes in motor threshold have implications for the interpretation of MEP and SP 
characteristics. And it should be noted that an altered motor threshold (e.g., as observed 
during the subacute phases of stroke) might itself indicate an abnormality.  
With regard to the upper extremity, several TMS studies revealed differences in corticomotor 
thresholds for eliciting MEPs and the SPs between proximal and distal upper-extremity 
muscles [5, 7, 22]. In addition, distal muscles seem to be more sensitive to TMS-induced 
inhibitory phenomena compared to proximal muscles, probably due to their larger cortical 
representation and greater dependency on corticospinal tracts [5, 23]. As a consequence, it 
is necessary to have knowledge of the TMS characteristics in both proximal and distal upper-
extremity muscles.  
Stimulus-response curves have been constructed to study MEP amplitude and SP duration 
independently from their corticomotor threshold [6-9, 24-26]. Only few studies, however, 
have been conducted that have focused on the MEP amplitude or SP duration in both distal 
and proximal upper-extremity muscles over a wide range of stimulus intensities [7, 25]. Ray 
et al. [25] performed stimulus response-curves of the MEP amplitude exclusively from the 
biceps brachii and the abductor pollicis brevis muscles at rest in 8 healthy volunteers. Taylor 
et al. [7] constructed stimulus-response curves of MEP area and SP in both the biceps 
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brachii and adductor pollicis muscles in only 4 healthy volunteers at different levels of 
voluntary muscle contraction. Comparison of the results of these studies is difficult due to 
their variability in methodology (e.g., degree of muscle pre-activation used) and technical 
aspects (e.g., figure of eight versus round coil). Moreover, both studies did not apply stimuli 
over the full range of stimulus intensities from threshold to 100% stimulator output.  
The primary aim of this study was to explore the differences between proximal arm and distal 
hand muscles in stimulus-response characteristics of both MEP and SP in healthy 
volunteers. To construct reliable stimulus-response curves for both the MEP amplitude and 
the SP, these curves will be constructed over the full range of stimulus intensities ranging 
from threshold to 100% stimulator output.  
 
Materials and Methods 
Subjects 
Eighteen healthy individuals participated in this study. Because it has been reported that the 
threshold for eliciting both MEP and SP in the BB and ADM muscles at the dominant side is 
lower than at the non-dominant side [27], and because left handed subjects show larger MEP 
amplitudes compared to right handed subjects [28, 29], only right-handed subjects were 
included. Handedness was tested with the Edinburgh Handedness Inventory [30]. Subjects 
with a history of epilepsy, cardiac disorders, pacemaker implantation, craniotomy, psychiatric 
or neurological diseases were excluded. Pregnant women or individuals using medications 
with possible effects on the nervous system were excluded as well. Approval of the local 
ethics committee was obtained and all participants gave written informed consent. 
General Procedure  
Participants were comfortably seated in a chair with their right forearm and hand pronated 
and supported by a custom built device. The elbow was positioned in 90 degrees of flexion. 
The device restricted movement of the upper arm, forearm, wrist, and fingers, but allowed 
right isometric forearm flexion and digit V abduction. Bipolar EMG-recordings were obtained 
using 2 pairs of self-adhesive surface electrodes placed in a standard tendon belly montage. 
EMG-signals were recorded using a CED data acquisition and amplifier system (Cambridge 
Electronic Design Ltd) with a bandpass filter of 20 to 3000 Hz at a recording sensitivity of 0.5 
microVolt/bit (amplifier range 100 mV), using a recording time of 150 ms before and 850 ms 
after each stimulus. The EMG data were collected using Spike2 laboratory software 
(Cambridge Electronic Design Ltd). 
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First, EMG-activity was recorded from the abductor digiti minimi muscle (ADM). To obtain 
isometric muscle contractions, right digit V abduction was performed against a fixed frame, 
while digits II-IV were immobilized by Velcro straps. Secondly, the forearm and hand were 
supinated and EMG-activity in the biceps brachii muscle (BB) was recorded while 
participants performed elbow flexion against a fixed frame. For measurements in both 
proximal and distal muscles, participants were instructed to exert maximum force for 3 
seconds during 3 trials. Visual feedback of rectified EMG-activity was provided through a 
computer screen placed 1 meter in front of the participants. The EMG target level was 
presented as a vertical line.  
The maximal voluntary EMG-activity was taken as the mean EMG-amplitude achieved during 
these 3 trials. The 50% maximal voluntary EMG-activity, being the target level during the 
trials, was calculated from the maximal voluntary EMG-activity. 
Transcranial Magnetic Stimulation 
TMS of the motor cortex was performed through a 90 mm circular coil powered by a Magstim 
200 magnetic stimulator (Magstim Company Limited). The circular coil was used, because 
this type of coil evokes larger MEPs compared to a figure of eight coil during strong 
contractions [7]. The vertex was located and marked directly on the scalp. The coil was 
positioned in a tangential plane near the vertex at approximately 45 degrees to the sagittal 
line (Mid-central - Cz according to the international 10-20 system of electrode placement) 
and fixed in this position through a mechanical arm. A counterclockwise inducing current flow 
was used to activate the left hemisphere. 
During the TMS sessions, the participants performed constant isometric muscle contractions 
at 50% of their maximal voluntary EMG-activity to ensure maximal facilitation of motoneurons 
[7, 31]. The computer monitor displayed this target level. The participants were instructed to 
increase muscle activity to the target level, and to maintain muscle activity as close as 
possible to this level, until they were instructed to relax. TMS was delivered 2 seconds after 
the target level was obtained.  
TMS was applied with increasing intensities ranging from 20% to 100% (in 5% increments) 
maximum stimulator output (100% = 2 Tesla). To avoid serial order effects, the different 
stimulus intensities were applied in random order. At each stimulus intensity, 5 consecutive 
trials were performed with an inter-stimulus interval of approximately 5 seconds. Within such 
a single session, participants were instructed to relax for 2 seconds after each stimulus was 
delivered. The MEP amplitudes and SP durations in the BB and ADM were recorded. To 
avoid the occurrence of fatigue, consecutive sessions of different stimulus intensities were 




The baseline (BL) EMG-activity was calculated as the mean value of the rectified and filtered 
EMG-activity over the 150 ms time-segment prior to stimulus delivery. At each stimulus 
intensity, the mean MEP amplitude and SP duration were determined from the average of 
five trials. The active motor threshold was defined as the minimum stimulus intensity needed 
to elicit a recordable MEP (≥100 microVolts) from the target muscle in at least 3 out of 5 
trials. The MEP amplitude was calculated by subtracting the baseline activity from its 
maximum. The SP duration was defined as the latency between MEP onset and SP offset in 
the rectified EMG-data. The SP offset was determined as the return of continuous EMG-
activity to baseline values. If no SP could be detected in the averaged data, a duration of 0 
seconds was assigned.  
Next, the mean MEP amplitude and SP duration were plotted against stimulation intensity for 
each participant. Visual inspection of the stimulus-response curves revealed that the relation 
between these variables could have a sigmoid shape. Hence, the data were fitted with the 
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Where the three parameters of the function are: 
1) ai ,reflecting the plateau phase of participant i,  
2) b1i ,reflecting the active motor threshold of participant i, and 
3) b2i ,reflecting the slope parameter (steepness) of participant i,  
and where 
yij is the MEP amplitude or the SP duration of participant i at stimulus intensity j,  
Sj  is the stimulus intensity j, and εij is the normal distributed residual with mean zero and 
variance σ2  of participant i at stimulation intensity j.  
 
Statistical methods 
A non-linear mixed model was used to fit the individual data to this regression model. The 
dependent variables were the MEP amplitude and the SP duration of the ADM and BB 
muscles (y), respectively, and the independent (regression) variable was the stimulus 
intensity (S). The plateau phase (a) and the active motor threshold (b1) of the function were 
treated as random effects, to allow subject-specific regression coefficients. The “slope”- 
parameter (b2) was treated as a fixed (here: subject independent)  regression coefficient. The 
differences between the models with random effects  and  models with fixed effects were 
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tested for statistical significance, using the likelihood ratio test. Note that this test is based on 
the full likelihood function of the hierarchical models [32]. All parameters are estimated 
simultaneously, using maximum likelihood methods of the model used.  
The fit of the data to the final model was visualized in the observed and estimated stimulus-
response curves of the MEP amplitude and SP duration of the ADM muscle in two typical 
participants. Moreover R-square statistics have been performed. 
The estimated regression variables with standard error are presented. Paired-sample t-tests 
were used to determine whether differences in stimulus-response characteristics were 
evident between the ADM muscle and the BB muscle for MEP and SP. The required 2-tailed 
significance level was set at 0.05. All analyses were performed using the Statistical Package 
SAS version 8.2. 
 
Results 
Seven men and eleven women between 23 and 49 years of age (mean 32 years, standard 
deviation 9 years) were included. Three subjects failed to complete the experiment due to 
severe discomfort during the TMS assessment. These 3 individuals were excluded from the 
data analysis. The MEP and SP data of the remaining 15 right handed participants were 
used to construct the stimulus-response curves.  
 
Motor Evoked Potentials 
Figure 1 (a, b) shows the individual stimulus-response curves for the MEP amplitude of the 
BB and ADM muscles. The amplitudes in both muscles increased with increasing stimulus 
intensity until they reached a plateau. This figure also revealed that there was considerable 
inter-individual variation in both the active motor threshold and the maximum MEP amplitude. 
The variability in maximum MEP amplitude was largest for the BB muscle. These inter-
individual variations had to be taken into account when modeling the stimulus-response 
curves. Figure 2 visualized the fit of the data to the model. The upper part of this figure (a, b) 
shows the observed and the estimated stimulus-response curves of the MEP amplitude of 
the ADM muscle in two typical participants. The goodness of fit (R-square) for the BB was 
0.97 and for the ADM 0.93 (Table 1). 
 
Table 1 shows the estimated parameters with standard error (SE) of the Boltzmann function 
for both the BB and ADM muscles of an average participant of our population, as well as the 







The larger SE of the maximal amplitude (a) of the BB compared to the ADM reflects the 
larger inter-individual variability of the maximal amplitude in the BB (p < 0.01). Figure 2 (a, b) 
shows the observed and the estimated stimulus-response curves of the MEP amplitude of 
the ADM muscle in two typical subjects. Because the individual curves were simultaneously 
estimated in our model, we were able to estimate the percentage of participants having 
reached their plateau values. Table 2 shows the number of subjects that are closer than 1 
SE near the estimated plateau of the function at different stimulation intensities. As can be 
observed from table 2, all participants were near the plateau value at a stimulus intensity of 
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In the BB small bursts of EMG-activity occurred before the resumption of continuous EMG-
activity, especially at higher stimulation intensities. These burst were not observed in the 
ADM, not even at maximum stimulator output. Figure 1 (c, d) shows the individual stimulus-
response curves of the SP duration of the BB and ADM muscles. The SP durations in both 
ADM and BB muscle increased with increasing stimulus intensities. The individual stimulus-
response curves of the SP did not reach a plateau before maximum stimulator output (Figure 
1 and Table 2). The relation between stimulus intensity and the SP duration in both muscles 
could also be described by a sigmoid function as given by the Boltzmann equation. The fit of 
the data to the model is visualized in figure 2 and table 1. The lower part of this figure (c, d) 
shows the observed and the estimated stimulus-response curves of the SP duration of the 
ADM muscle in two typical participants.  
Table 1 shows the estimated parameters with standard error (SE) of the Boltzmann function 
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for both the BB and ADM muscles of an average participant of our population. The residuals 
of the function were small for both the BB and the ADM muscles. The active motor threshold 
of the function was less for the ADM compared to the BB (p < 0.01). The SE of the slope 
parameter of the function was larger for the ADM compared to the BB muscle (p < 0.01). 
Table 2 shows the number of subjects that are closer than 1 SE near the estimated plateau 
of the function at different stimulation intensities. As can be observed from table 2, none of 
the participants reached their plateau value before 100% stimulator output. 
 
Discussion 
The aim of this study was to explore the differences in stimulus-response characteristics of 
the MEP amplitude and SP duration between proximal and distal upper-extremity muscles. 
Overall, the form of the stimulus-response curves of the MEP and SP did not differ between 
proximal and distal muscles. Above active motor threshold, the MEP amplitude increased 
until it reached a plateau, whereas the SP duration in most participants did not reach a 
plateau value in the Boltzmann function before maximum stimulator output. As previously 
reported [6, 8], both curves could be quantitatively described by a sigmoid Boltzmann 
function.  
 
MEP amplitudes and SP durations, shown as a function of the stimulus intensity, varied 
substantially between individual participants. Across subjects there was considerable 
variability in active motor threshold of both the MEP and the SP in proximal and distal upper-
extremity muscles as well. Because both MEP and SP are related to the intensity of 
stimulation [2, 33], the inter-individual variability in active motor threshold makes it hard to 
compare the stimulus-response characteristics such as the maximum MEP or SP at a given 
stimulus intensity. Therefore, the stimulus-response curves had to be adjusted to the inter-
individual variability in motor threshold using a non-linear mixed model. The Boltzmann 
function described the data accurately when considering both the plateau of the function (a) 
and the active motor threshold (b1) as random effects, allowing subject specific regression 
coefficients. This is best illustrated by figure 2, which shows the observed and estimated 
stimulus response curves of 2 typical participants of our study. It is also illustrated by the 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































Motor evoked potential 
Although there was considerable variability in active motor threshold between individuals, no 
systematic differences were seen between the BB and ADM muscles in the active motor 
threshold and the slope parameter of the function. The active motor threshold of the 
stimulus-response curve reflects the stimulus intensity required to activate the corticospinal 
cells and spinal alpha motor neurons [26] that are near their threshold. The slope of the 
stimulus-response curve provides a general estimate of the excitability of the corticospinal 
pathway [26]. The recruitment characteristics of both corticospinal cells and spinal alpha 
motor neurons will influence the steepness of the slope [34]. Our results suggest that at least 
during an isometric muscle contraction of 50% of the maximal voluntary EMG-activity, the 
corticospinal cells and spinal alpha motor neurons in proximal and distal upper-extremity 
muscles behave similar in response to TMS. This is in agreement with the study of Taylor et 
al. [7]. These authors hypothesized that isometric contraction levels of 50 % MVC resulted in 
the recruitment of almost all available motoneurons in both the distal hand and proximal arm 
muscles [7]. However, at these high contraction levels changes in cortical excitability may 
also have contributed to the facilitation of the MEP in both muscles [35, 36].  
 
A high inter-individual variability in the maximal MEP amplitude of the function in the BB was 
found, with individual cases of higher and lower plateau levels in the BB compared to the 
ADM. The plateau value of the stimulus-response curve represents the balance between 
excitatory and inhibitory components of the corticospinal volley [26]. The plateau level 
depends on the inherent recruitment and discharge properties of both the corticomotor 
neuron and the spinal alpha motor neurons [21, 26]. With high levels of muscle contraction, 
Wu et al. [3] discovered that the inherent recruitment and discharge properties of the spinal 
alpha motor neurons are more important for the differential excitatory effects of TMS on the 
proximal arm and distal hand muscles than the cortical mechanisms. The recruitment and 
discharge properties of the spinal alpha motor neurons are different for the small hand 
muscles compared to the proximal arm muscles [3, 22]. In distal hand muscles most 
motoneurons are recruited at voluntary contraction forces below 30% MVC and a further 
increase in muscle contraction results in an increase in the firing rate of the motoneurons. In 
contrast, in the BB additional motoneurons are recruited up to 90% MVC. Rate coding plays 
a more prominent role in force modulation in distal hand muscles, whereas recruitment plays  
a more dominant role in proximal arm muscles [3]. These differences in recruitment and 
discharge properties might be responsible for the differences in variability of the plateau 
values found between the ADM and BB muscles in our study. 
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Silent period 
The stimulus-response curves of the SP had similar forms in the ADM and BB muscles. The 
threshold intensity to obtain a SP, however, was less for the ADM than for the BB muscle. 
The active motor threshold of the stimulus-response curve reflects the stimulus intensity 
required to activate the corticospinal and spinal alpha motor neurons. Distal hand muscles 
seem to be more sensitive to the inhibitory effects of TMS compared to proximal arm 
muscles, probably due to their greater cortical representation [5]. The slope of the function 
was steeper and more variable in the ADM compared to the BB. The increase in SP duration 
with increasing stimulation intensities reflects the activity of a greater number of inhibitory 
neurons activated during voluntary contraction [7]. As a consequence, the recruitment of 
intracortical inhibitory neurons by TMS must be different for distal hand muscles compared to 
proximal arm muscles. The difference in the recruitment properties between distal and 
proximal upper-extremity muscles might be due to their task specificity. Small hand muscles 
are mainly involved in fine, controlled motor tasks, in which fast modulation of the force is 
required. A strong inhibitory control, therefore, is necessary for the small hand muscles [5, 
37]. 
 
Another difference between proximal and distal upper-extremity muscles observed in our 
study population was the small burst of EMG-activity interrupting the SP. These small bursts 
of EMG-activity before return to the mean pre-stimulus EMG-activity were most commonly 
seen in the BB. These EMG bursts may be due to fluctuations in contraction force in the 
period immediately after TMS, such that some responses might have been evoked when the 
contraction force produced was less than the target level [6]. Because inhibitory inputs to 
corticofugal neurons are stronger in the distal hand muscles compared to proximal muscles 
[7], these bursts may also be due to non-cortical sources of motoneuron excitation, 
interrupting the SP in proximal muscles.  
 
Stimulus-response curves most likely reflect the excitability of the cortical circuitry, the 
corticospinal cells, as well as of the spinal alpha motor neuron pool [26]. The sigmoid shape 
of these curves is most likely related to a combination of the way cortical elements are 
recruited by TMS, the multiple components of the corticospinal volley, the recruitment of 
spinal alpha motor neurons with progressively larger motor unit potentials [38], and perhaps 
a greater tendency for synchronization of motor units discharges with increasing stimulus  
intensities [26]. The facilitatory mechanisms involved in the MEP, however, seem to differ 
from the inhibitory mechanisms eliciting the SP. The differences in stimulus-response 




It has previously been assumed that the MEP reflects the excitability of corticospinal cells, as 
well as of the spinal alpha motor neuron pool. The SP mainly reflects the cortical circuitry [7], 
although the early part of the SP, up to approximately 50 ms, might be due to both cortical 
and spinal inhibitory phenomena [3-5, 23]. If the SP would be generated by segmental 
inhibitory phenomena due to muscle twitches, the form of the stimulus-response curves of 
the SP would mimic that of the MEP. However, in our study the MEP amplitude reached a 
plateau in both distal and proximal upper-extremity muscles at a stimulation intensity of 
approximately 70% of the maximum stimulator output, whereas the SP duration did not reach 
its plateau value before 100% stimulator output. Although recruitment of inhibition (SP) and 
excitation (MEP) might correlate, they are thought to represent different neurophysiological 
systems within the cortex [9].  
 
In some participants TMS at the higher stimulation intensities (90 to 100%) was not well 
tolerated. Although several authors have reported that the maximum values for both MEP 
amplitude and SP duration are obtained only at 100% stimulator output [5], our data indicate 
that it is not necessary to perform TMS at intensities above 70% of the maximum stimulator 
output to obtain a maximum MEP amplitude in healthy participants at a pre-activation level of 
50% of maximum EMG-activity. However, at 70% stimulator output a linear increase in SP 
duration was still observed in most patients. TMS at high stimulus intensities is therefore still 
necessary to obtain maximum values for the silent period. 
 
In our study isometric contraction levels of 50% of maximal voluntary EMG-activity have been 
used to ensure maximal facilitation of the MEP [7, 31]. Especially in the BB muscle, the 
strong muscle twitches associated with high stimulus intensities occasionally interfered with 
the subject’s effort to keep the force constant. This has been reported in previous TMS 
studies as well [8]. Moreover, 23% of the healthy participants experienced fatigue during the 
TMS assessment and almost all participants had difficulty maintaining the target EMG-level. 
In patients with upper motor neuron disorders it will be even more difficult to maintain this 
high level of muscle contraction due to paresis. Although it is well known that voluntary pre-
activation of the target muscles provides an optimal facilitation to obtain maximal MEP 
amplitudes with minimum stimulation intensities compared to muscles at rest, there is still 
controversy on the most effective level of pre-activation [39-42]. Hence, more research is 
needed to define this optimal pre-activation level in patients with upper motor neuron 
disorders. 
 
After constructing stimulus-response curves in healthy participants, the question arises if 
these stimulus response-characteristics differ for patients with upper motor neuron diseases. 
TMS-induced stimulus-response curves 
 145
For instance, changes in motor threshold due to restorative mechanisms will have 
implications for the interpretation of the TMS data. Knowledge of the stimulus-response 
relations in various stages after upper motor neuron lesions will give more insight in the 
(disease specific) changes in excitation or inhibition of the corticomotor neuron and 
corticospinal pathways.  
 
Conclusion 
Differences in central inhibitory (SP) and excitatory (MEP) mechanisms induced by TMS 
have been observed between proximal and distal muscles. Variations in discharge and 
recruitment properties at high levels of muscle contraction, as well as differences in the 
physiology of muscle control seem to be responsible for these differences. Knowledge of the 
stimulus-response relations in various upper-extremity muscles will give more insight in the 
(muscle specific) differences in excitation or inhibition of the corticomotor neuron and 
corticospinal pathways. The adequate fit of the non-linear Boltzmann function suggests that 




















































































































Adapted version of an invited review for “Brain hypoxia-ischemia research progress”, Océane 
M. Roux, eds. Nova science publishers, Inc 2008 entitled “Predicting hand motor recovery 
and spasticity in patients with an acute, severe, middle cerebral artery stroke. The role of 
early clinical assessment and transcranial magnetic stimulation”. Annette A van Kuijk, Gert 





A major goal of this thesis was to investigate the predictive value of transcranial magnetic 
stimulation (TMS) for functional prognostication of the upper extremity in patients with a 
severe, middle cerebral artery stroke. More specifically, the additional value of motor evoked 
potentials (MEPs) and silent periods (SPs) was compared with regard to both hand motor 
recovery and the development of spasticity in patients with an initial paralysis of the upper 
extremity due to supratentorial stroke. In this section we will elaborate on the current, as well 
as on the future clinical value of TMS with regard to predicting hand motor recovery and 
spasticity. The most important strengths and limitations of the studies included will be 
addressed, as well as implications for future studies. 
 
Current clinical value of TMS to predict upper-extremity motor recovery from stroke 
In stroke patients with an initial paralysis of the upper extremity, the presence or absence of 
a MEP or SP seems to have no additional predictive value compared to early clinical 
assessment with regard to long-term hand motor recovery and spasticity. Accurate prediction 
of long-term hand motor recovery in these patients can be made 3 weeks after stroke, using 
the Fugl-Meyer motor assessment (FMA) upper-extremity subscore to predict recovery and 
the lower-extremity subscore to predict the absence of recovery [1]. With regard to spasticity, 
as yet, only modest associations of early muscle weakness and a low initial Barthel index 
with long-term hypertonia have been found [2]. 
 
Predicting Motor Recovery 
In the cohort of severe stroke patients with an initial paralysis of the upper extremity 
presented in chapter 4, similar positive predictive values (PPV = 1) with regard to long-term 
hand motor recovery have been found for the presence of a MEP in the abductor digiti minimi 
muscle (ADM) and early clinical assessment of the upper-extremity, as assessed by the FMA 
upper-extremity subscore. Both the presence of a MEP in the biceps brachii muscle (BB) and 
any degree of early leg motor recovery, as assessed by the FMA lower-extremity subscore, 
were less accurate in identifying hand motor recovery (PPV = 0.70 and 0.71, respectively). 
The discrepancy between the PPVs for the presence of an ADM-MEP on the one hand, and 
the presence of a BB-MEP on the other hand, is probably due to differences in the 
physiology of motor control [3, 4]. In contrast to proximal muscles, the spinal alpha motor 
neurons that innervate muscles of the hand receive direct, unilateral, monosynaptic input 
from the primary motor cortex [5, 6]. The integrity of these monosynaptic inputs from the 
corticospinal pathway is considered a prerequisite for normal hand function. As for the BB-
MEP and lower-extremity motor function, these determinants most likely reflect stroke 
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severity in general and are less specific for recovery of hand motor function. 
 
Although both early motor recovery and the presence of an ADM-MEP were highly predictive 
with regard to hand motor function 6 months after stroke, less than half of the patients with 
hand function at 6 months could be identified within the first 3 weeks, implicating a poor 
negative predictive value (NPV) for both factors. Only if the absence of any motor recovery in 
the upper-limb was combined with an absent MEP in both the BB and the ADM muscle, a 
NPV of 1.0 was reached at 3 weeks after stroke. Still, the absence of a FMA lower-extremity 
subscore at 3 weeks post stroke approached this prediction rather well with a NPV of 0.95. 
This latter criterion is easier to apply in daily clinical practice.  
 
Apparently, critical residual sparing of corticospinal function cannot be detected by TMS in all 
cases during the acute and subacute phases post stroke. This might be the result of 
insufficient cortical stimulation of functionally depressed, but undamaged 
corticomotoneurons. Another explanation is that restoration of motor function may be due to 
cortical reorganization involving brain systems that cannot be recruited by TMS, because 
these are not directly connected to the corticospinal pathways [7, 8]. In these cases, neuro-
imaging studies might add valuable information about the residual function of the 
sensorimotor system [9].  
 
Besides the TMS-induced excitatory mechanisms (MEP), the inhibitory mechanisms (SP) 
have been proposed as parameters to predict hand motor recovery. The review in chapter 3 
showed that only few, well designed TMS-studies on the prognostic value of the SP with 
regard to post-stroke motor recovery have been performed, which yielded rather inconsistent 
results. Comparison of the results is difficult because of the variability in patients’ 
characteristics and time post-stroke, methodology (e.g., definition of SP offset and onset), 
and the technical methods used. In most studies, prolonged SPs have been found in the first 
hours, immediately after stroke. This may be due to a generalized decrease in intracortical 
inhibition in order to optimize the intracortical excitatory processes, thus, supporting the 
motor output [10-12]. As a consequence, intra-cortical inhibition of the inhibitory interneurons 
in the primary motor cortex (that mediate the SP) decreases as well, resulting in prolonged 
SPs. In focal lesions of the primary motor cortex, however, the inhibitory interneurons 
mediating the SP themselves may become selectively damaged, leading to a decreased or 
























In the (sub)acute phases thereafter, different patterns of SP duration have been found, i.e. 
normal, prolonged, as well as shortened SPs. These different patterns are thought to be 
related to stroke location (primary versus non primary motor cortex). Because in patients with 
mild to moderate middle cerebral artery strokes the degree of normalization of the SP seems 
to correlate with the amount of hand function recovery [10, 14, 15], recovery-related 
intracortical phenomena may also be responsible for these different patterns. To differentiate 
these recovery-related mechanisms in patients with mild to moderate strokes from the 
influence of stroke location, neuro-imaging studies might add valuable information to TMS. In 
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however, the SP seems to have no additional predictive value for post-stroke motor recovery 
when compared with TMS-induced excitatory phenomena (MEP).  
In the cohort of patients with a severe, middle cerebral artery stroke and an initial upper-
extremity paralysis, we observed an overall incidence of 63% for hypertonia within the first 6 
months (chapter 5). Moreover, in a substantial amount of these patients (25%) the presence 
of hypertonia was observed already within the first 3 weeks after stroke. Apparently, these 
patients have a substantial chance to develop hypertonia in an early phase post stroke as 
well. As a consequence, by studying this subgroup we were able to maximize the likelihood 
of observing post-stroke hypertonia and, thus, to optimize the chance of identifying risk 
factors for hypertonia.  
 
Even in this selected population of severe stroke patients, we were unable to identify any 
clinical or neuroradiological characteristic as a risk factor for early (onset ≤ 1 week post 
stroke) or long-term hypertonia (> 3 months post stroke) (chapters 5 and 6). Clinical 
characteristics such as hyperreflexia, sensory impairments, visuospatial deficits and apraxia, 
which are often associated with spasticity based on clinical experience, were not associated 
with hypertonia (chapter 5). These findings are consistent with the literature [16]. The lack of 
association between stroke location and hypertonia in our study may have been influenced 
by the fact that the majority of our patients suffered from extensive lesions on CT-scans 
involving both cortical and subcortical areas in the brain.  
 
Reviewing the role of the SP in predicting motor recovery in chapter 3, there was some 
evidence that TMS might also be of value in predicting the development of post-stroke 
spasticity. In both subacute (≤ 2 weeks post stroke) and chronic stroke patients with initially 
mild to moderate paresis and a focal ischemic lesion in the territory of the middle cerebral 
artery, the relative inefficacy of the inhibitory mechanisms as indicated by a contraction-
induced reduction in SP might have a positive predictive value with regard to spasticity [15]. 
In severe stroke patients with an initial upper-extremity paralysis, however, none of the 
neurophysiological characteristic (the presence of a MEP or SP) could be identified as a risk 
factor for early or long-term hypertonia (chapter 6). Yet, due to the small numbers of patients, 
the finding that the SP was not related to hypertonia must be interpreted with care. In 
addition, the voluntary contraction of the hand muscles was so severely impaired in the 
majority of the patients that often no SP could be recorded. Even patients in whom a SP 




To elaborate on the predictive value of neurophysiological characteristics and cortical 
inhibitory mechanisms, longitudinal studies in patients with mild to moderate paresis and 
focal brain lesions should be conducted. From a neurophysiological point of view, the 
proposed relationship between TMS-induced inhibitory mechanisms and spasticity is not 
evident. TMS primarily assesses the corticomotoneuron and the corticospinal tract. Selective 
damage to the corticomotoneuron or the corticospinal tract does, however, not primarily 
result in spasticity, but rather in muscle weakness and a loss of fine, manipulatory hand 
movements [17]. Spasticity is generally thought to result from concomitant (in)direct damage 
to para-pyramidal motor pathways, such as the reticulo- and vestibulospinal tracts [17]. 
Stroke lesions within areas projecting to both the primary motor cortex and the brainstem 
might lead to a subsequent change in the balance between excitatory and inhibitory 
influences on the intra-cortical motor neurons that project to both the bulbospinal and the 
corticospinal tracts [8]. As a result, there may be a loss of the cortical drive to several 
inhibitory centres in the brainstem, resulting in disinhibition of bulbar and spinal reflexes as 
well [17, 18]. Although the para-pyramidal pathways cannot be directly assessed, they might 
be indirectly assessed by TMS. Nevertheless, as yet, the literature and the current results of 
this thesis do not support this idea.  
 
TMS as a future tool to study and predict upper-extremity motor recovery from stroke 
TMS as a future tool to predict upper-extremity motor function 
The results of the prognostic studies in this thesis do, however, not preclude the future 
clinical value of TMS in individual patients. In severe stroke patients that are difficult to 
examine due to, for instance, cognitive deficits or loss of consciousness, TMS may still 
provide more reliable results than clinical examination. These patients lack the ability to 
move the arm and hands selectively, whereas clinical scores such as the FMA rely on the 
patients’ ability to voluntarily and selectively move their extremities. As a result, early motor 
assessment can be biased by severe cognitive deficits. Particularly in these patients, 
neurophysiological assessment might be of additional value to provide objective, reliable, 
and quantitative data on the integrity of the corticospinal pathways. This hypothesis, 
however, would require prognostic studies in an even more selected subgroup of severe 
stroke patients than included in the studies presented in this thesis. As a result, the inclusion 
rate and the incidence of motor recovery will both be very low in this population, which would 
require large, multi-centred studies to include a sufficient number of subjects to identify 
significant associations.  
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This thesis primarily focused on the question whether the intactness of the corticospinal tract 
is predictive of the occurrence of hand motor function. For this purpose, both TMS 
characteristics (presence or absence of a MEP) and hand function (FMA hand score greater 
than 3) have been dichotomized. Thus, we were able to minimize the time taken and effort 
needed to perform TMS measurements in the selected patients. Patients with severe stroke 
are, however, not the most appropriate group to study whether the level of corticospinal 
functioning is predictive for the degree of hand function recovery. These patients lack the 
ability to move their affected limb voluntarily, which is necessary to adequately facilitate the 
MEP response. To answer the question whether the level of corticospinal functioning is 
associated with the degree of hand motor recovery, patients with mild to moderate strokes 
should be studied. 
 
In these patients, stimulus-response curves that reflect the MEP amplitude or the SP 
duration for a range of stimulation intensities may give more insight in the (disease specific) 
changes in excitation and inhibition of the corticomotorneuron and corticospinal pathways 
than single conventional TMS characteristics [19-21]. MEP and SP are usually elicited at 
stimulus intensities corresponding to a certain percentage of the corticomotor threshold or 
the stimulator output [22, 23]. Due to their dependency on the stimulus intensity, changes in 
motor threshold e.g., as observed during the subacute phases of stroke, have implications 
for the interpretation of conventional MEP and SP characteristics [22, 23]. Stimulus-response 
curves have been constructed to study MEP amplitude and SP duration independently of 
their corticomotor threshold [19-22, 24]. These curves are considered to provide more 
sensitive and meaningful reflections of the function of the corticospinal pathways than single, 
conventional TMS characteristics [20, 21]. 
 
When constructing stimulus-response curves, recent neurophysiological studies on upper-
extremity motor function have demonstrated that it is worthwhile to study the extensor 
muscles as well [25, 26]. In addition, recent clinical studies have indicated that active finger 
extension seems to be a reliable early predictor of upper-extremity motor recovery. It may be 
that the function of the finger extensors is most closely related to the degree of sparing of the 
corticomotoneurons and corticospinal pathways [26]. To substantiate this hypothesis, 
however, further research is needed. 
 
TMS as a future tool to predict upper-extremity spasticity 
Although the severe stroke patients that were studied in this thesis have a substantial risk of 
post-stroke spasticity, it may not be the most appropriate group to investigate the predictive 
value of neuroradiological characteristics and TMS-induced inhibitory phenomena with 
Chapter 9 
 158
regard to spasticity. In general, these patients suffer from large, extensive stroke lesions, 
affecting multiple brain areas. The relation of a specific brain area with the development of 
spasticity is, therefore, difficult to assess. Moreover, patients with initial upper-extremity 
paralysis lack the ability to move their affected limb voluntarily, which is necessary to 
generate a SP. To reveal the prognostic value of neuroradiological and TMS-induced 
inhibitory phenomena with regard to spasticity, a cohort of patients with mild to moderate 
paresis and more restricted brain lesions should be studied. In these milder patients, 
however, spasticity will be less frequent, requiring a much larger study sample than included 
in the studies presented in this thesis.  
 
As for using the SP in spasticity prediction, the lack of uniformity regarding its definition may 
influence the observed duration, even if the SP is studied relative to the corticomotor 
threshold [27]. In this thesis, the SP has been assessed as the time period between the 
onset of the MEP and the resumption of continuous tonic voluntary EMG-activity to pre-
stimulus EMG-levels. Both reference points are consistent in proximal and distal upper-
extremity muscles and can readily be determined by a computer, independent of the 
assessor, and are hence less subject to inter-rater variability. In contrast, manually 
assessment of the data is subject to greater inter-rater variability. MEP and SP assessment 
tends to be more complex in stroke patients and inter-rater reliability may be of even greater 
concern in this population, suggesting a more critical need for (computerized) methods. 
 
As for predicting post-stroke spasticity, a limitation of the studies presented in this thesis is 
that upper-extremity hypertonia was clinically assessed using the Ashworth scale, whereas 
instrumented assessments including surface EMG and force registrations from the upper-
extremity muscles upon passive stretching would have provided better discrimination 
between active (i.e., contraction) and passive (i.e., muscle stiffness and shortening) 
contributions to muscular resistance [28]. However, instrumented tests are not yet available 
for routine clinical application, which is the reason that the (Modified) Ashworth Scale is still 
the most commonly used measures of adult spasticity. Other clinical scales can be regarded 
as modifications of the Ashworth scale. All such measures show equally and limited reliability 
and validity regarding muscle tone assessment [29, 30]. Future studies should, therefore, 
implement more advanced methods to quantify spasticity. 
 
TMS as a future tool to understand upper-extremity motor function and recovery 
Apart from clinical prognostication, TMS may be used to gain valuable information about the 
underlying mechanisms responsible for motor recovery after stroke. A better understanding 
of the factors that facilitate motor recovery as well as of the time window in which restorative 
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mechanisms are active is needed to optimize treatment strategies in individual patients. TMS 
can be used to assess relevant corticospinal reorganization in response to focal ischemic 
damage or subsequent (functional) recovery [7, 8, 22, 31, 32]. Stimulus-response curves of 
MEP amplitude and SP duration may give insight in the (disease specific) changes in 
excitation and inhibition of the corticomotorneurons and corticospinal pathways [19-22]. 
These curves reflect the excitability of all components of the corticospinal pathways, i.e. 
cortical circuitry, corticospinal tract, the spinal alpha motor neuron pool, and spinal 
interneuronal relays [19, 20]. 
In chapter 8 considerable variability in the active motor threshold of the stimulus-response 
curves in both proximal (arm) and distal (hand) muscles across healthy subjects is reported. 
Because both MEP and SP depend on the intensity of the stimulation [22, 23], the 
interindividual variability in active motor threshold made it difficult to compare the stimulus-
response characteristics such as the maximum MEP or SP duration at a given stimulus 
intensity. Therefore, the stimulus-response curves had to be adjusted to this inter-individual 
variability in motor threshold using a non-linear mixed model. A sigmoid Boltzmann function 
described the data accurately when considering both the plateau of the function and the 
active motor threshold as random effects, allowing subject specific regression coefficients. 
The adequate fit of this model suggests that the non-linear Boltzmann function can be used 
to study between and within subject changes due to cortical and corticospinal reorganization 
in future TMS studies. 
Even if the non-linear Boltzmann function was used, differences in the central facilitatory 
mechanisms induced by TMS (maximal MEP amplitude) were present between proximal and 
distal upper-extremity muscles. Variations in recruitment and discharge properties at high 
levels of muscle activation seem to be responsible for these differences [33, 34]. In proximal 
hand muscles, recruitment plays a dominant role in force modulation, whereas rate coding 
plays a prominent role in the force modulation of distal hand muscles [34]. With regard to the 
inhibitory mechanisms, differences in both the maximal SP duration and the slope of the 
input-output curve were found between proximal arm and distal hand muscles. Distal hand 
muscles seem to be more sensitive to TMS-induced inhibitory phenomena than the proximal 
arm muscles, probably due to their larger cortical representation [35, 36]. Moreover, small 
hand muscles are mainly involved in fine motor tasks in which sharp, sudden modulation of 
the force is required. A strong inhibitory control, therefore, is necessary for the small hand 
muscles [3, 34], whereas non-cortical sources of motoneuron excitation may be stronger in 
proximal muscles [37]. Yet, proximal and distal upper-extremity motor functions are equally 
important in providing an adequate understanding of upper limb functioning in stroke 
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patients. As a consequence, it is necessary to have muscle-specific knowledge of TMS 
characteristics. 
Although stimulus-response curves may be sensitive reflections of the function of the cortico-
spinal pathway, the exact contribution of each single element of this pathway cannot be 
retrieved. By adding modern imaging techniques such as diffusion and perfusion weighted 
magnetic resonance imaging (MRI) to the TMS-induced stimulus-response curves, we may 
be able to better distinguish the restorative intracortical mechanisms from those of the 
descending tracts [38]. These MRI techniques, however, cannot assess the precise brain 
location in relation to functionally important motor and sensory pathways [39]. Diffusion 
tensor imaging (DTI) and fiber tractography offer new perspectives to assess the location 
and extent of focal brain lesions, as they can visualize the main fiber bundles (e.g., the 
corticopsinal tract) and provide information on tissue integrity [39, 40]. DTI and fiber 
tractography may shed light on alterations in brain connectivity resulting from neuroplasticity, 
as well as on Wallerian degeneration after stroke. The latter process is important because, 
as a consequence of the stroke lesion and the subsequent loss of central drive, adaptation of 
peripheral neural structures takes place.  
Spinal alpha motor neurons may become functionally depressed, but may still survive after 
stroke. In the majority of the patients presented in chapter 7, who had no signs of motor 
recovery in the upper-extremity and no clinical signs of peripheral neuropathy, decreased 
compound motor action potentials (CMAPs) in the ADM muscle on the paretic side were 
present as early as 4 days post stroke on peripheral stimulation of the ulnar nerve. This 
decrease in CMAP amplitude in the affected upper extremity reflects a reduction in functional 
motor units, i.e., the number of spinal alpha motor neurons and their axons that can be 
excited by electrical stimulation [41-45]. In patients suffering from hand motor weakness, this 
reduction occurs already in the early phases post stroke [41]. UMN lesions may cause a 
sudden loss of synaptic input and lack of activation of the spinal alpha motor neurons, which 
then become functionally inactive or undergo trans-synaptic degeneration [41, 46, 47]. 
Dysfunction of the anterior horn cells results in a disturbance of the axonal flow, leading to 
axonal degeneration (Wallerian degeneration). Impaired axonal transport may then lead to a 
dysfunction of the neuromuscular transmission at the motor end plate with a subsequent 
decrease in the CMAP amplitude [46]. This concept is referred to as “dying back” neuropathy 
[41], and appears closely related to the severity of the paresis [42, 43, 45, 47]. Maintaining a 
sufficient axonal flow in a long neuron seems to require more energy from the anterior horn 
cells than maintaining sufficient flow in a short neuron [48]. Therefore, the distal upper-
extremity muscles show the most prominent functional changes [48].  
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In patients without motor recovery, motor unit loss neither progresses nor improves in the 
sub-acute phases [42, 45, 47, 48], remaining on a nearly constant level up to 3-4 months 
post stroke [45, 47]. Apparently, once it occurs, motor unit loss persists for a long time. In the 
chronic phase of stroke, a slight enlargement of active motor units can be seen that can be 
explained by restoration of axonal function or by collateral reinnervation. Both mechanisms of 
recovery may lead to an increased number of muscle fibers that can be activated and may 
explain the recovery of the CMAP seen in the chronic stages after stroke [42, 43]. The 
adaptive changes observed in the motor units might influence muscle structure and function. 
As yet, however, there are no longitudinal studies that look at these changes over a longer 
time-period to determine how they develop and how they are associated with motor recovery 
following stroke. In these cases DTI and fiber tractography may add valuable information to 
neurophysiological studies on the association of Wallerian degeneration and damage to both 
the cortical motoneuron and corticospinal tract. 
 
Coda 
To better understand motor and functional recovery after stroke, longitudinal studies are 
needed that assess and integrate neuroplasticity at all levels of the sensorimotor system, i.e., 
the upper motor neuron, the lower motor neuron, as well as the musculo-tendineous 
apparatus. Within the 2nd stimulation program for rehabilitation research in the Netherland 
(funded by the Netherlands Organization for Health Research and Development (ZonMw)), a 
new national research consortium has recently been instituted that will conduct, besides two 
early-phase multi-centre randomized intervention trials, several multi-centre cohort studies 
using functional MRI and, the above suggested neurophysiological techniques, as well as 
advanced kinesiological and biomechanical measurement tools to monitor and explain the 
plasticity of the upper-extremity sensorimotor system after stroke (“EXPLICIT”). Hopefully, 
this research will bring about promising new perspectives for understanding, predicting, and 
promoting motor recovery and spasticity after stroke, that will support the rehabilitation of 







































































































































Chapter 1 is a general introduction and provides information on stroke epidemiology, post-
stroke muscle weakness and spasticity, and the use of transcranial magnetic stimulation 
(TMS) for clinical prognostication. The introduction concludes by presenting the scope and 
structure of this thesis. The main goal of this thesis is to investigate the additional predictive 
value of TMS to early clinical examination with regard to long-term hand motor recovery and 
spasticity of the hemiplegic upper extremity. This issue is addressed in a homogeneous 
group of stroke survivors with a severe, supratentorial, ischemic stroke. After an introductory 
systematic review that provides an important rationale for studying and predicting post-stroke 
motor recovery and spasticity, four prognostic studies are presented that focus on the 
prediction of long-term hand motor recovery and hypertonia of the upper extremity in severe 
stroke patients. Next, two neurophysiological studies address some important 
methodological considerations for future studies. The last part of this thesis is the general 
discussion, which elaborates on the reported findings of the above-mentioned studies in a 
more comprehensive manner.  
Chapter 2 presents an introductory systematic review that evaluates the methodological 
quality of intervention studies on the clinical effectiveness of focal neuronal and 
neuromuscular blockade in post-stroke upper-extremity spasticity. Although 12 studies were 
included, only 2 randomized clinical trials met the predetermined criteria of minimal validity. 
The homogeneity of the patient groups with regard to diagnosis, time post-stroke, and their 
comparability with regard to functional prognosis and other sources of selection bias were 
generally poor. Yet, there was sufficient evidence for the effectiveness of BTX-A treatment 
for reducing muscle tone and improving passive range of motion at all arm-hand levels in 
chronic stroke patients lasting approximately 3 to 4 months. The effectiveness of BTX-A 
treatment for improving functional abilities could not be convincingly demonstrated, although 
two subgroups were identified that might specifically benefit at a functional level: (1) patients 
with mild hypertonia and a potential for voluntary extensor activity at the wrist and fingers, 
and (2) patients with severe hypertonia and no potential for motor recovery, but who suffered 
from problems with positioning, handling, and taking care of the affected arm and hand. 
Whereas in the first subgroup improvement of active motor function can be pursued, 
improvement of ‘passive’ abilities is a realistic goal in the second subgroup. We concluded 
that functional effects of spasticity treatment depend on a critical selection of subjects and 
individualized goal setting with appropriate selection of outcome measures. In order to 
adequately select subjects and set attainable individual goals, reliable clinical prognostication 
of motor recovery and the development of both spasticity and hypertonia is essential. 
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Chapters 3 and 4 both deal with the prediction of motor recovery of the upper extremity, 
whereas chapters 5 and 6 focus on the prediction of upper-extremity hypertonia in patients 
with severe stroke.  
Chapter 3 is a narrative review and a case series addressing the question whether the silent 
period (SP) can be of additional value to the motor evoked potential (MEP) in predicting post-
stroke motor recovery of the upper limb. Relevant studies showed rather inconsistent results 
and suffered from heterogeneity in technical methods, methodology, and patient 
characteristics. In most studies prolonged SPs have been observed immediately after stroke, 
whereas in the (sub)acute phases thereafter, different patterns of SP duration have been 
found. The majority of the patients included in the case series suffered from a severe, 
ischemic, middle cerebral artery stroke. As a result, the voluntary contraction of the hand 
muscles was so severely impaired that no SP could be recorded. It was concluded that in 
acute stroke patients with an initial severe paresis or paralysis, the SP seems to have no 
additional value to MEP for predicting post-stroke motor recovery. Still, in patients with mild 
to moderate strokes, (contraction-induced) reduction of the SP has been associated with 
spasticity. Although the relation between the SP, recovery-related intracortical phenomena, 
and spasticity remains as yet unclear, a neurophysiological model underlying the SP is 
discussed.  
In Chapter 4, the predictive values of the presence of an early MEP and of early clinical 
assessment have been compared with regard to long-term hand motor recovery. A 
prospective cohort study of 39 patients with a first-ever, ischemic, middle cerebral artery 
stroke and an initial upper extremity paralysis is presented. Hand motor recovery at 26 
weeks post onset was selected as the primary outcome and defined as a hand subscore of 
the Fugl-Meyer Motor Assessment (FMA) greater than 3 points. Motor functions as assessed 
by the FMA upper- and lower-extremity subscores, as well as the presence of a MEP in the 
abductor digiti minimi (ADM) and biceps brachii (BB) muscles at 1 and 3 weeks post stroke 
were considered relevant prognostic determinants. At 6 months after stroke, 12 patients 
(34%) had regained hand function. Both the presence of an ADM-MEP and any recovery in 
the FMA upper-extremity subscore (at week 1 and 3) showed a positive predictive value of 
1.0 with regard to hand motor recovery at 6 months post stroke. The FMA lower-extremity 
subscore showed the best negative predictive values (NPV = 0.90 at week 1; and 0.95 at 
week 3). It was concluded that in stroke patients with an initial paralysis of the upper 
extremity, the presence or absence of a MEP has no additional predictive value compared to 
early clinical assessment with regard to long-term hand motor recovery. Based on the FMA, 
accurate prediction of long-term hand function can be made 3 weeks after stroke using the 
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upper-extremity subscore to predict recovery, and the lower extremity subscore to predict 
absence of recovery.  
The primary goal of the study presented in Chapter 5 was to identify possible clinical risk 
factors, in addition to muscle weakness, for upper-extremity hypertonia in patients with a 
severe, ischemic, middle cerebral artery stroke. In addition, the prevalence and time-course 
of upper-extremity hypertonia was assessed at 6 consecutive moments during the first 26 
weeks after stroke. A prospective cohort of forty-three patients who had been consecutively 
admitted to an university hospital with an acute, ischemic, middle cerebral artery stroke and 
an initial upper-extremity paralysis was included. Clinically relevant hypertonia (defined as an 
Ashworth score ≥ 2) at 6 months after stoke was selected as the primary outcome. The 
following potential risk-factors were considered at week 1 post stroke: 1) motor functions as 
assessed by the upper-extremity subscore of the FMA, 2) Barthel Index, 3) consciousness, 
4) sensory disturbances, 5) apraxia, 6) neglect, and 7) hyperreflexia. Twenty-five patients 
(63%) developed hypertonia during the follow-up period of 26 weeks. During this period, the 
prevalence of hypertonia followed a rather dynamic course, with cases of early, transient, 
and late hypertonia. Despite the high incidence of hypertonia, none of the selected clinical 
characteristics could be identified as a risk factor.  
The primary goal of the study presented in Chapter 6 was to identify possible 
neuroradiological and neurophysiological risk factors for upper-extremity hypertonia in the 
same cohort of severe stroke patients as presented in chapter 5. Any association of 
hypertonia (Ashworth ≥ 2) with neuroradiological (lesion side, extent of lesion, and previous 
stroke), and neurophysiological (presence of a MEP or SP) characteristics was investigated. 
Associations between hypertonia and the selected neuroradiological and neurophysiological 
characteristics were generally low. Despite the high incidence of hypertonia in the study 
population, none of the selected neuroradiological or neurophysiological characteristics could 
be identified as a risk factor for upper-extremity hypertonia.  
In chapters 7 and 8, two studies are reported that further investigate the use of 
neurophysiological methods for understanding and predicting motor recovery and hypertonia 
in severe stroke patients. 
Chapter 7 presents a cohort study aimed at identifying secondary functional changes in the 
peripheral motor units of the affected upper extremity in patients with severe ischemic stroke. 
In addition, it is investigated how these peripheral functional changes develop during the first 
weeks after stroke. A prospective cohort of 27 consecutive patients with an acute ischemic 
supratentorial stroke and an initial upper-extremity paralysis was compared to 10 healthy 
control subjects. Clinical assessment at admission and at 1 and 3 weeks after stroke was 
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performed in all patients using the criteria of Kingery to diagnose plexopathy, radiculopathy, 
or neuropathy. The ulnar nerve was electrically stimulated proximal to the wrist and 
electromyographic recordings were obtained from the ADM muscle. Mean values of the 
compound muscle action potential (CMAP) on the affected side were compared with those 
obtained from the non-affected side at 1 and 3 weeks after stroke and with the CMAP values 
obtained from healthy controls. The mean CMAP amplitude in patients was significantly 
lower on the affected side compared with the non-affected side and with the controls. A 
decrease in CMAP amplitude was observed in more than half of the stroke patients, in some 
cases as early as 4 days after stroke. Whenever present in the (sub)acute phases, it was 
accompanied by absence of motor recovery at that specific time after stroke. Thereafter, 
recovery of CMAP amplitude was strongly associated with motor recovery. We concluded 
that a decreased CMAP amplitude in the ADM muscle can be seen already in the very acute 
phase after stroke, which is unrelated to peripheral neuropathy, radiculopathy, or plexopathy, 
but strongly related to absence of upper motor neuron recovery. This knowledge is important 
for the use of neurophysiological methods in stroke patients, including the interpretation of 
TMS results. 
In Chapter 8 stimulus-response characteristics of both MEP and SP induced by TMS were 
studied and compared between proximal and distal upper-extremity muscles. Stimulus-
response curves of MEPs and SPs were obtained from the BB and ADM muscles in 15 
healthy participants. A sigmoid Boltzmann function was used to fit the stimulus-response 
curves. The Boltzmann function described the stimulus-response curves of the MEP and the 
SP in both muscles adequately. The parameters of the stimulus-response curves of both the 
MEP and the SP differed between proximal arm and distal hand muscles in healthy 
participants. Higher maximal MEP amplitudes were found for the BB compared to the ADM, 
whereas for the MEP amplitude no difference in active motor threshold and slope of the 
function was found between both muscles. The active motor threshold to obtain a SP was 
less for the ADM compared to the BB. The slope parameter of the function of the SP duration 
was steeper and more variable in the ADM than in the BB. The differences between proximal 
arm and distal hand muscles might be due to differences in motor control of the upper-
extremity muscles. It was concluded that, in future research, a Boltzmann function can be 
used to fit stimulus-response curves of both MEP and SP in muscles of the upper extremity 
to study between and within subject differences. However, specific curves should be 
constructed for proximal and distal muscles. 
In Chapter 9, the general discussion, the main findings are summarized and discussed in 
view of the importance of the integrity of the corticospinal pathways for both upper-extremity 
motor recovery and spasticity after stroke. The current as well as the future value of TMS 
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with regard to predicting and understanding hand motor recovery and hypertonia is 
addressed. The need for new longitudinal recovery studies is stressed. These studies should 
assess and integrate neuroplasticity at all levels of the sensorimotor system, i.e. the upper 
motor neuron, the lower motor neuron, as well as the musculo-tendineous apparatus in order 
to better monitor, explain, and predict motor recovery and both spasticity and hypertonia of 










Hoofdstuk 1, de algemene inleiding, bespreekt de epidemiologie van het cerebrovasculair 
accident (CVA) en het daarbij optredende verlies aan spierkracht en spasticiteit. Daarnaast 
worden de basisprincipes van transcraniële magneetstimulatie (TMS) uitgelegd. De inleiding 
eindigt met de doelstelling en de opbouw van dit proefschrift. Een belangrijke doelstelling van 
dit proefschrift is het bepalen van de toegevoegde waarde van TMS ten opzichte van het 
vroege standaard klinisch onderzoek bij het voorspellen van herstel van handfunctie en het 
ontstaan van spasticiteit. Deze toegevoegde voorspellende waarde wordt onderzocht in een 
homogene groep patiënten met een supra-tentorieel gelokaliseerd, ernstig ischemisch CVA. 
Na een inleidende systematische literatuurstudie, die belangrijke argumenten geeft voor het 
bestuderen en het voorspellen van herstel van spierkracht en spasticiteit na CVA, worden 
vier prognostische studies gepresenteerd die zich richten op het voorspellen van het herstel 
van handkracht en het ontstaan van musculaire hypertonie op de lange termijn. Hierna 
volgen twee neurofysiologische studies die zich richten op enkele belangrijke 
methodologische overwegingen voor toekomstige TMS studies. Het laatste deel van dit 
proefschrift, de algemene beschouwing, plaatst de gerapporteerde bevindingen in een 
breder perspectief.  
In Hoofdstuk 2 wordt een systematische literatuurstudie besproken, waarin de 
methodologische kwaliteit wordt onderzocht van interventiestudies gericht op de effectiviteit 
van behandeling van spasticiteit in de bovenste extremiteit door middel van focale neurolyse 
of neuromusculaire blokkade bij CVA patiënten. Hoewel 12 studies werden geïncludeerd, 
voldeden slechts 2 gerandomiseerde studies aan de vooraf bepaalde criteria van minimale 
validiteit. De homogeniteit van de onderzochte patiëntgroepen met betrekking tot zowel de 
diagnose, het tijdstip na CVA, als hun functionele prognose en de controle voor andere 
mogelijke bronnen van vertekening was over het algemeen laag. Desondanks kon bij 
chronische CVA-patiënten voldoende bewijskracht gevonden worden voor de effectiviteit van 
de behandeling met botulinetoxine A voor het verminderen van musculaire hypertonie en het 
verbeteren van de passieve bewegingsuitslagen van de bovenste extremiteit. Deze effecten 
hielden tot 3 à 4 maanden na behandeling aan. De effectiviteit van de botulinetoxine A 
behandeling voor het verbeteren van de gebruiksmogelijkheden van de bovenste extremiteit 
kon niet overtuigend worden aangetoond, hoewel twee subgroepen werden geïdentificeerd 
die op functioneel niveau zouden kunnen profiteren van de behandeling: (1) patiënten met 
milde musculaire hypertonie en het vermogen tot actieve strekking van de pols en/of vingers, 
en (2) patiënten met forse musculaire hypertonie, zonder vooruitzicht op herstel van 
spierkracht of actief bewegingsvermogen, en met problemen bij het (passief) positioneren en 
verzorgen van de aangedane arm en hand. Daar waar in de eerste subgroep verbetering van 
het actieve bewegingsvermogen kan worden nagestreefd, is in de tweede subgroep 
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verbetering van de passieve verzorgingsmogelijkheden en contracturen een meer 
realistische doelstelling van behandeling. Geconcludeerd werd dat de functionele resultaten 
van spasticiteitsbehandeling afhangen van een kritische selectie van patiënten en van op het 
individu toegesneden doelstellingen met een juiste selectie van uitkomstmaten. Om tot een 
juiste selectie van patiënten te kunnen komen en haalbare, individuele, doelen te kunnen 
stellen, is een betrouwbare voorspelling van zowel het herstel van actief 
bewegingsvermogen, als van het ontstaan van spasticiteit en musculaire hypertonie 
noodzakelijk. 
In de Hoofdstukken 3 en 4 wordt het voorspellen van actief bewegingsvermogen 
besproken, terwijl in de hoofdstukken 5 en 6 de nadruk ligt op het voorspellen van 
musculaire hypertonie in de bovenste extremiteit bij patiënten met een ernstig CVA. 
Hoofdstuk 3 geeft een overzicht van de bestaande literatuur (narrative review) en bevat 
tevens een cohort studie. Beide richten zich op de vraag of de “silent period” (SP), naast de 
motore opgewekte potentialen (MEPs), van toegevoegde waarde is bij het voorspellen van 
herstel van actief bewegingsvermogen van de arm en hand na CVA. Relevante 
literatuurstudies toonden inconsistente resultaten. Er werd een grote verscheidenheid gezien 
aan gebruikte TMS technieken, methodologie, en aan patiëntkenmerken. Direct na het CVA 
werd in het meeste studies een verlenging van de SP duur waargenomen, terwijl in de 
subacute fase zowel verkorting, normalisatie, als verlenging van de SP duur werd vermeld. 
In de cohort studie kon bij de meeste patiënten met een ernstig, ischemisch CVA 
(gelokaliseerd in het stroomgebied van de arteria cerebri media) geen SP worden 
geregistreerd. Deze patiënten hadden een dusdanig ernstig verlies van spierkracht in de 
handspieren dat geen SP kon worden opgewekt. Geconcludeerd werd dat in de acute fase 
na CVA de SP geen toegevoegde waarde heeft ten opzichte van MEP bij het voorspellen 
van het herstel van actief bewegingsvermogen bij patiënten met een fors of volledig 
krachtsverlies van de bovenste extremiteit. Bij patiënten met een mild CVA werd een 
mogelijke associatie gevonden tussen de (door spiercontractie geïnduceerde) verkorting van 
de SP en spasticiteit. Hoewel de precieze relatie tussen de SP, cerebrale plasticiteit, en 
spasticiteit onduidelijk is, wordt een mogelijk neurofysiologisch verklaringsmodel voor de SP 
besproken.  
In Hoofdstuk 4 wordt de voorspellende waarde van (de aanwezigheid van) een MEP in de 
vroege fase voor het actief bewegingsvermogen van de hand 6 maanden na het CVA 
vergeleken met de voorspellende waarde van het vroege klinisch onderzoek. Dit werd 
onderzocht in een prospectief cohort van 39 patiënten met een eerste, ischemische CVA 
gelokaliseerd in het stroomgebied van de arteria cerebri media en een volledig krachtsverlies 
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van de bovenste extremiteit direct na het CVA. Herstel van handfunctie 26 weken na het 
ontstaan van het CVA werd beschouwd als de belangrijkste uitkomst maat. Herstel werd 
gedefinieerd als een score van meer dan 3 punten op de hand subschaal van de Fugl-Meyer 
Motor Assessment (FMA). Actief bewegingsvermogen van de bovenste en onderste 
extremiteit, beoordeeld middels de daarbij behorende subschalen van de FMA, en de 
aanwezigheid van een MEP in de abductor digiti minimi (ADM) en/of de biceps brachii (BB) 
werden beschouwd als relevante prognostische determinanten en geregistreerd in de eerste 
en derde week na het CVA. Zes maanden na CVA was er bij 12 patiënten (34%) sprake van 
herstel van handfunctie. Zowel de aanwezigheid van een ADM-MEP als een score groter 
dan 0 op de bovenste extremiteit subschaal van de FMA in de eerste en derde week na het 
CVA hadden een positief verspellende waarde van 1.0 voor het herstel van handfunctie op 
de lange termijn. Een score van tenminste 10 punten op de onderste extremiteit subschaal 
van de FMA had de beste negatief voorspellende waarde (week 1 NPV = 0.90, week 3 NPV 
= 0.95). Er werd geconcludeerd dat bij patiënten met een volledig krachtsverlies van de arm 
en hand direct na CVA de aan- of afwezigheid van een MEP geen toegevoegde 
voorspellende waarde heeft ten opzichte van vroege klinische beoordeling voor het herstel 
van handfunctie op de lange termijn. Gebruikmakend van de FMA bovenste extremiteit 
subschaal kan 3 weken na het CVA een accurate voorspelling van herstel worden gedaan 
van handfunctie op de lange termijn. De onderste extremiteit subschaal kan gebruikt worden 
om de afwezigheid van herstel te voorspellen.  
De belangrijkste doelstelling van de studie die gepresenteerd wordt in Hoofdstuk 5 was om 
bij patiënten met een ernstig, ischemisch CVA in het stroomgebied van de arteria cerebri 
media naast spierzwakte, mogelijke andere klinische risicofactoren te identificeren voor het 
ontstaan van musculaire hypertonie in de bovenste extremiteit. Ook werd gedurende 6 
opeenvolgende momenten tijdens de eerste 26 weken na het CVA de prevalentie van 
hypertonie in de bovenste extremiteit bestudeerd. Hiertoe werd een prospectief cohort 
bestaande uit 43 patiënten, verwezen naar een academisch ziekenhuis in verband met een 
acuut, ischemisch CVA en een volledig krachtsverlies van de bovenste extremiteit 
geïncludeerd. Als primaire uitkomstmaat werd de aanwezigheid van klinisch relevante 
musculaire hypertonie 6 maanden na CVA geselecteerd. Klinische relevante hypertonie werd 
daarbij gedefinieerd als een Ashworth score groter of gelijk aan 2. Als mogelijke 
risicofactoren werden beschouwd de aanwezigheid van één van de volgende determinanten 
1 week na het CVA: 1) gebrek aan bewegingsvermogen gemeten met de bovenste 
extremiteit subschaal van de FMA, 2) lage Barthel Index, 3) laag bewustzijn, 4) 
sensibiliteitsstoornissen, 5) apraxie, 6) neglect, en 7) hyperreflexie. Vijfentwintig patiënten 
(63%) ontwikkelden hypertonie gedurende de onderzoeksperiode van 26 weken. Gedurende 
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deze periode wisselde de prevalentie van musculaire hypertonie sterk, waarbij er sprake was 
van patiënten met vroeg, tijdelijk, en laat optredende hypertonie. Ondanks de hoge incidentie 
van musculaire hypertonie kon geen van de geselecteerde klinische determinanten worden 
geïdentificeerd als een risicofactor voor hypertonie.  
De doelstelling van de studie gepresenteerd in Hoofdstuk 6 was mogelijke 
neuroradiologische en neurofysiologische risicofactoren te identificeren voor het ontstaan 
van musculaire hypertonie in de bovenste extremiteit in hetzelfde cohort van patiënten als 
genoemd in hoofdstuk 5. Er werd gekeken naar mogelijke associaties tussen klinisch 
relevante hypertonie (Ashworth ≥ 2) van de bovenste extremiteit en neuroradiologische 
(infarctzijde, uitgebreidheid van het infarct, en een eventueel eerder infarct), en 
neurofysiologische (aanwezigheid van een MEP of SP) determinanten. De gevonden 
associaties tussen hypertonie en de geselecteerde neuroradiologische en neurofysiologische 
determinanten waren laag. Ondanks de hoge incidentie van musculaire hypertonie in deze 
patiëntengroep kon geen van de geselecteerde neuroradiologische of neurofysiologische 
karakteristieken worden geïdentificeerd als een risico factor voor musculaire hypertonie.  
In de Hoofdstukken 7 en 8 worden 2 studies besproken die een aantal methodologische 
aspecten onderzoeken van het gebruik van neurofysiologische methoden bij het verklaren en 
voorspellen van het herstel van actief bewegingsvermogen en musculaire hypertonie bij 
ernstige CVA patiënten. 
In Hoofdstuk 7 wordt een cohort studie gepresenteerd die zich richt op het vaststellen van 
secundaire veranderingen in de functie van de perifere motor units van de aangedane 
bovenste extremiteit bij patiënten met een ernstig, ischemisch CVA. Daarnaast wordt 
onderzocht hoe deze veranderingen zich gedurende de eerste weken na het CVA 
ontwikkelen. Een prospectief cohort bestaande uit 27 patiënten met een acuut, ischemisch, 
supratentorieel gelokaliseerd CVA en een initiële paralyse van de bovenste extremiteit werd 
vergeleken met een controlegroep van 10 gezonde personen. Bij opname en na 
respectievelijk 1 en 3 weken na het CVA vond bij alle patiënten een lichamelijk onderzoek 
plaats. De klinische criteria van Kingery werden toegepast om perifere neuropathie, 
radiculopathie, of plexopathie te diagnosticeren. Electromyografische reacties van de ADM 
werden verkregen door de nervus ulnaris proximaal van de pols elektrisch te stimuleren. In 
de eerste en derde week na CVA werden de aldus verkregen gemiddelde waarden van de 
spierreactie, de compound muscle action potential (CMAP), aan de aangedane zijde 
vergeleken met de waarden aan de niet aangedane zijde en met CMAP waarden van de 
controle groep. Bij patiënten was de gemiddelde CMAP amplitude significant lager aan de 
aangedane dan aan de niet aangedane zijde, en tevens ten opzichte van de controle groep. 
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In meer dan de helft van de CVA patiënten werd een verlaging van de CMAP amplitude 
gezien, soms al 4 dagen na het CVA. Wanneer in de (sub)acute fase sprake was van een 
verlaging van de CMAP, ging dit altijd gepaard met de afwezigheid van actief 
bewegingsvermogen op dat specifieke moment. Na de acute fase was het herstel van de 
CMAP amplitude sterk geassocieerd met het herstel van actief bewegingsvermogen. 
Geconcludeerd werd dat in de ADM een verlaging van de spierreactie (CMAP amplitude) al 
in een zeer vroege fase na CVA kan worden gezien. Deze verlaging is niet gerelateerd aan 
perifere neuropathie, radiculopathie, of plexopathie, maar is sterk gerelateerd aan de 
afwezigheid van herstel van het centrale motorische (corticospinale) neuron. Hiermee dient 
bij het gebruik van neurofysiologische methoden bij CVA patiënten rekening gehouden te 
worden. 
In Hoofdstuk 8 worden de stimulusrespons karakteristieken van de door TMS opgewekte 
MEP en SP bestudeerd. De stimulusrespons curven van zowel proximale armspieren (BB) 
als distale handspieren (ADM) van 15 gezonde vrijwilligers werden met elkaar vergeleken. 
De stimulusresponse curven werden beschreven door middel van een sigmoïdale Boltzmann 
functie. Deze Boltzmann functie bleek de stimulusrespons curven van zowel MEP als SP in 
beide spieren goed te beschrijven. Bij de gezonde vrijwilligers verschilden de parameters van 
de beschreven stimulusrespons curven van zowel MEP als SP tussen de proximale arm- en 
de distale handspieren. Bij de MEP werden in de BB in vergelijking met de ADM hogere 
maximale MEP amplitudo’s gevonden. Er werd geen verschil in de actieve drempelwaarde 
en de helling van de Boltzmann functie tussen beide spieren gevonden. Bij de SP was de 
actieve drempelwaarde in de ADM lager dan in BB, terwijl de helling steiler en meer variabel 
was. De geobserveerde verschillen in de parameters van de Boltzmann functie tussen de 
proximale arm- en de distale handspieren worden mogelijk veroorzaakt door verschillen in de 
centrale aansturing van de betreffende spieren. Er werd geconcludeerd dat de Boltzmann 
functie in toekomstig onderzoek gebruikt kan worden om de stimulusresponse curven van 
MEP en SP in spieren van de bovenste extremiteit te beschrijven. Wanneer bij de 
interpretatie van de parameters rekening gehouden wordt met de verschillen tussen 
proximale en distale spieren, kunnen met de Boltzmann functie verschillen binnen en tussen 
patiënten bestudeerd worden. 
In Hoofdstuk 9, de algemene discussie, worden de belangrijkste bevindingen samengevat 
en besproken in het licht van het belang van de integriteit van de corticospinale banen voor 
het herstel van actief bewegingsvermogen en voor het ontstaan van spasticiteit in de 
bovenste extremiteit na een CVA. De huidige en toekomstige waarde van TMS voor het 
voorspellen en het begrijpen van herstel van handfunctie en spasticiteit wordt 
bediscussieerd. Ook wordt de noodzaak voor verder longitudinaal onderzoek naar de 
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herstelmechanismen optredend na een CVA benadrukt. In toekomstige studies zou de 
plasticiteit op alle niveaus van het sensomotorische systeem, dat wil zeggen zowel in het 
centrale zenuwstelsel, als in het perifere zenuwstelsel en het spier-pees apparaat, 
meegenomen moeten worden om het herstel van actief bewegingsvermogen en het ontstaan 











Net als mijn werk in de kinderrevalidatie was ook dit onderzoek teamwork, en ik wil dan ook 
iedereen bedanken die betrokken was of zich betrokken voelde bij het tot stand komen van 
dit proefschrift. Een aantal mensen wil ik echter in het bijzonder bedanken: 
Sander, dank je voor het vertrouwen dat je in mij stelde bij het doen van dit onderzoek. 
Hoewel bij de start van het project het niet mijn bedoeling was om er een promotietraject van 
te maken, is het dat onder jouw begeleiding wel geworden. Je kritische blik, maar vooral de 
inspirerende discussies hebben ertoe geleid dat dit proefschrift voor mij een mijlpaal in mijn 
carrière geworden is. Ik verheug me bijzonder op de voortzetting van onze samenwerking in 
de EXPLICIT-studie, en ben blij met het vertrouwen dat jij daarbij opnieuw in mij stelt. 
Machiel, alweer een revalidatiearts die onderzoek doet op jouw vakgebied. Het is jouw 
verdienste dat dit onderzoek op het grensvlak van de klinische neurofysiologie en de 
revalidatie mogelijk is in Nijmegen. Dank je voor de waardevolle beoordelingen van mijn 
onderzoek vanuit klinisch neurofysiologisch perspectief.  
Jaco, zonder jou was dit proefschrift niet tot stand gekomen. Ik bewonder je niet aflatend 
enthousiasme voor “ons” TMS onderzoek. Jij hebt zonder enig tegengas alle TMS metingen 
verricht naast al je andere academische taken. Je vond altijd tijd om ons te bestoken met 
mailtjes over nieuwe TMS literatuur. Samen met jou studenten begeleiden bij hun 
onderzoeksstage werd een feest, met inspirerende discussie over de klinische 
uitvoerbaarheid van TMS metingen. Maar de beste herinneringen bewaar ik toch aan onze 
gezamenlijke gang naar de voor ons vreemde wereld van de biostatistiek.  
Henk, voor een aantal hoofdstukken heb ik gebruik mogen maken van jouw database. 
Zonder probleem kreeg ik de beschikking over al jouw data, waarvoor mijn dank. Wij zijn het 
bewijs dat het Serviam en ‘t College prima kunnen samengaan. 
Sander, Machiel, Jaco en Henk, onze samenwerking is nog niet voorbij, en ik verheug me op 
de volgende fase van het onderzoek en op de verdere verdieping in de wereld van de TMS.  
Dit project zou niet mogelijk zijn geweest zonder hulp van enthousiaste medewerkers. 
Allereerst wil ik alle medewerkers van de klinische neurofysiologie bedanken voor hun 
bijdrage. Ik heb me op jullie afdeling nooit een vreemde eend in de bijt gevoeld. Dank aan 
alle arts-assistenten revalidatie, die op de dagen dat ik werkzaam was in ’s-Hertogenbosch 
ervoor zorgden dat er toch patiënten geïncludeerd konden worden. Dank aan Linda Anker en 
Linda van Ooijen voor hun bijdrage aan het vergaren van de data bij de gezonde 
proefpersonen. Dick, dank je voor de waardevolle aanvullingen en discussies rondom de 
methodologische aspecten en je kennisoverdracht betreffende de neurofysiologie van het 
perifere motor neuron. Graag zou ik ook prof. dr. Kremer, en Jurgen Schelhaas, beide 
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neuroloog, Bas Bevaart revalidatiearts, en de epidemiologen Jan Hendriks en Jacques van 
Limbeek willen bedanken voor hun medewerking bij het tot stand komen van een aantal 
artikelen.  
Verder zou dit onderzoek niet mogelijk geweest zijn zonder de deelname van CVA-patiënten. 
Ik wil alle patiënten hiervoor bedanken, en wens hen, ondanks de zware tijd die zij gehad 
hebben en soms nog hebben, al het goede voor de toekomst. 
Onderzoek en klinische werkzaamheden kun je alleen maar combineren als je een leuke 
werkplek hebt en collega’s waar je op kunt bouwen. En die heb ik! Allereerst dank aan de 
beide secretariaten, die voor een groot deel van de randvoorwaarden zorgen. Karin, Desirée, 
Francien, dank voor de gezellige roddels en afdelingsetentjes. Ook dank aan Annette, mijn 
secretaresse op Tolbrug, die het steeds weer lukt om in mijn overvolle agenda gaatjes te 
vinden. Margreet, dank voor al het kopieer- en invoegwerk in de voorbereidingsfase, 
waardoor ook de conceptversie er strak uit ziet. 
Katinka en Jan-Willem, dank jullie voor het vertrouwen dat jullie in mijn werk stellen en jullie 
kritische blik op de samenvatting.  
Mijn collega’s Annemarie, Bas, Fred, Gery, Ineke, Mariëtte en Willy, wil ik bedanken voor de 
fijne samenwerking. Kim, Martin en Ellen, jullie als directe collega’s en kinderdokters hebben 
ervoor gezorgd dat ik mijn onderzoekswerk kan combineren met het werken in “onze” 
kinderrevalidatie. Samen timmeren we hard aan de weg, totdat deze tot aan het nieuwe 
gebouw van het kinderexpertise centrum is aangelegd. Ongetwijfeld volgen daarna weer 
nieuwe uitdagingen. Annette, mijn medemanager in de kinderrevalidatie, dank voor al het 
werk dat jij verzet als ik weer eens een dubbelplanning heb, en “ons huis komt heus wel op 
orde!” Tenslotte alle medewerkers van de kinderrevalidatie en van de mytylschool Gabriel, ik 
bof ontzettend met zo’n team van mensen die je eerder in ontwikkelen moet afremmen dan 
stimuleren, en ik verheug me op de verdere samenwerking met jullie op weg naar het 
kindercentrum. 
Tenslotte, had ik deze mijlpaal nooit kunnen bereiken zonder de steun van mijn ouders en 
familie. Dankzij hen heb ik mij kunnen ontwikkelen tot wie ik nu ben. Roger, dank je voor alle 
steun, medeleven en relativisme zowel bij mijn werk en als bij het onderzoek. En ja, mijn 
volgende leerdoel is meer tijd vrijmaken om samen leuke dingen te doen. 
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